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Abstract
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verrucae – a randomised controlled trial
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Objective: To compare the clinical effectiveness and cost-effectiveness of cryotherapy 
using liquid nitrogen versus patient daily self-treatment with 50% salicylic acid for the 
treatment of verrucae (plantar warts).
Design: A multicentre, pragmatic, open, two-armed randomised controlled trial with an 
economic evaluation. Randomisation was simple, with the allocation sequence generated 
by a computer in a 1 : 1 ratio.
Setting: Podiatry clinics, university podiatry schools and primary care in England, Scotland 
and Ireland.
Participants: Patients were eligible if they presented with a verruca which, in the opinion 
of the health-care professional, was suitable for treatment with both salicylic acid and 
cryotherapy, and were aged 12 years and over.
Interventions: Cryotherapy using liquid nitrogen delivered by a health-care professional 
compared with daily patient self-treatment with 50% salicylic acid (Verrugon, William 
Ransom & Son Plc, Hitchin, UK) for a maximum of 8 weeks.
Main outcome measures: The primary outcome was complete clearance of all verrucae 
at 12 weeks. Secondary outcomes were complete clearance of all verrucae at 12 weeks, 
controlling for age, whether or not the verrucae had been previously treated and type 
of verrucae, with a second model to explore the effect of patient preferences, time to 
clearance of verrucae, clearance of verrucae at 6 months, number of verrucae at 12 weeks 
and patient satisfaction with the treatment.
Results: In total, 240 eligible patients were recruited, with 117 patients allocated to 
the cryotherapy group and 123 to the salicylic acid group. There was no evidence of a 
difference in clearance rates between the treatment groups in the primary outcome [17/119 
(14.3%) in the salicylic acid group vs 15/110 (13.6%) in the cryotherapy group; p = 0.89]. 
The results of the study did not change when controlled for age, whether or not the 
verrucae had been previously treated and type of verrucae, or when patient preferences 
were explored. There was no evidence of a difference in time to clearance of verrucae 
iv Abstract
between the two groups [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.51 to 1.25; 
p = 0.33] or in the clearance of verrucae at 6 months (33.7% cryotherapy vs 30.5% salicylic 
acid). There was no evidence of a difference in the number of verrucae at 12 weeks 
between the two groups (incidence rate ratio 1.08, 95% CI 0.81 to 1.43; p = 0.62). Nineteen 
participants reported 28 adverse events, 14 in each group, with two treatment-related 
non-serious adverse events in the cryotherapy group. Cryotherapy was also associated 
with higher mean costs per additional healed patient (£101.17, 95% bias-corrected and 
accelerated CI £85.09 to £117.26). The probability of cryotherapy being cost-effective is 
40% for a range of willingness-to-pay thresholds of £15,000–30,000 per patient healed.
Conclusions: There is no evidence for a difference in terms of clearance of verrucae 
between cryotherapy and salicylic acid (at both 12 weeks and 6 months), number of 
verrucae at 12 weeks and time to clearance of verrucae. Cryotherapy was associated with 
higher mean costs per additional healed patient compared with salicylic acid.
Trial registration: Current Controlled Trials ISRCTN18994246.
Funding: This project was funded by the NIHR Health Technology Assessment programme 
and will be published in full in Health Technology Assessment; Vol. 15, No. 32. See the HTA 
programme website for further project information.
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Executive summary
Objective
To compare the clinical effectiveness and cost-effectiveness of cryotherapy using liquid nitrogen 
versus 50% salicylic acid for the treatment of verrucae (plantar warts).
Methods
Design
A multicentre, pragmatic, open, two-armed randomised controlled trial was undertaken with 
an economic evaluation. Participants were randomised using simple randomisation, with the 
allocation sequence generated by a computer in a 1 : 1 ratio. The sample size calculation was based 
on the difference in cure rates at 12 weeks between the two groups. In order to give 80% power 
to show a difference in cure rates of 70% versus 85% required 120 patients in each group or 133 
patients after allowing for 10% attrition, i.e. a total of 266.
Setting
Participants were recruited from 14 sites in England, Scotland and Ireland: two podiatry clinics, 
one of which was in Scotland, four university podiatry schools, one of which was in Ireland and 
eight general practitioner (GP) practices in five different regions of England.
Participants
Potential participants were identified by a health-care professional from the study site from GP 
referrals or self-referrals received by the podiatry or GP practice for the treatment of verrucae. 
Patients were eligible to participate in the trial if they presented with a verruca that, in the 
opinion of the health-care professional, was suitable for treatment with both salicylic acid and 
cryotherapy, and were aged 12 years and over.
Interventions
Participants randomised to cryotherapy using liquid nitrogen received a maximum of four 
treatments, 14–21 days apart, delivered by a health-care professional. The first treatment was a 
gentle freeze lasting approximately 10 seconds, with subsequent treatments undertaken according 
to the site’s usual practice. Debridement, masking and padding of the site were also undertaken 
according to the site’s usual practice. Participants randomised to patient self-treatment with 50% 
salicylic acid (Verrugon, William Ransom & Son Plc, Hitchin, UK) were instructed on how to 
use the acid by a health-care professional and instructed to apply it once daily for a maximum of 
8 weeks.
Main outcome measures
The primary outcome was complete clearance of all verrucae at 12 weeks. Secondary outcomes 
were complete clearance of all verrucae at 12 weeks, controlling for age, whether or not the 
verrucae had been previously treated and type of verrucae, with a second model to explore the 
effect of patient preferences, time to clearance of verrucae, clearance of verrucae at 6 months, 
number of verrucae at 12 weeks and patient satisfaction with the treatment.
x Executive summary
Results
A total of 240 participants (90% of the sample size) were recruited to the trial, with 117 patients 
allocated to the cryotherapy group and 123 to the salicylic acid group. There was no evidence of 
a difference between the proportions of participants with complete clearance of all verrucae at 
12 weeks between the salicylic acid and cryotherapy groups {14.3% vs 13.6%, chi-squared test 
statistic 0.02 [1 degrees of freedom (df)]; p = 0.89}. Cryotherapy was also associated with higher 
mean costs per additional healed patient [£101.17, 95% bias-corrected and accelerated confidence 
interval (CI) £85.09 to £117.26]. The probability of cryotherapy being cost-effective is 40% for a 
range of willingness-to-pay thresholds of £15,000–30,000 per patient healed. The results of the 
study did not change when the analysis was repeated but controlled for age, whether or not the 
verrucae had been previously treated and type of verrucae or patients’ preferences at baseline.
There was no evidence of a difference in the clearance of verrucae at 6 months between the 
salicylic acid and the cryotherapy groups [30.5% vs 33.7%, chi-squared test statistic 0.22 (1 df); 
p = 0.64] nor in time to clearance between the two groups [hazard ratio (HR) 0.80, 95% CI 0.51 
to 1.25; p = 0.33]. There was no evidence of a difference in the number of verrucae at 12 weeks 
between the two groups (incidence rate ratio 1.10, 95% CI 0.84 to 1.45; p = 0.47).
Conclusions
There was no evidence of a difference in clearance rates of verrucae between the 50% salicylic 
acid and the cryotherapy using liquid nitrogen groups. However, the results of this study are 
applicable only to verrucae or plantar warts and not to warts at other sites, such as the hands, 
which may respond differently to cryotherapy.
The findings of this study would not be generalisable to other freezing agents, such as nitrous 
oxide or over-the-counter (OTC) freezing treatments, as they freeze at a higher temperature than 
liquid nitrogen. Nor could the results be extrapolated to other concentrations of salicylic acid 
available as OTC preparations, which are usually of a lower concentration, or to the treatment 
being applied by a health-care professional.
Cryotherapy is associated with higher mean costs per patient healed compared to salicylic acid. 
Both higher mean costs and lack of evidence of a difference in effectiveness result in cryotherapy 
having a low probability of being cost-effective, even at high (> £15,000 per patient healed) cost-
effectiveness threshold values.
Implications for future research
There are other treatments available for cutaneous warts, but with very little good-quality evidence 
assessing their effectiveness. The effectiveness of these treatments is worthy of further study.
Trial registration
This trial is registered as ISRCTN18994246.
Funding
This project was funded by the NIHR Health Technology Assessment programme and will be 
published in full in Health Technology Assessment; Vol. 15, No. 32. See the HTA programme 
website for further project information.
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Chapter 1  
Background
What are verrucae?
Verrucae (or plantar warts) are caused by the human papillomavirus. They are extremely 
common, being experienced by most people at some time during their lives. Verrucae are 
infectious and can be painful, especially when affecting the soles of the feet or the nails. Although 
most verrucae will spontaneously disappear without treatment, many patients seek treatment 
because they are painful or because they are being prevented from doing sports and other 
activities of daily living.
Various studies have examined the prevalence of warts/verrucae and have produced a wide range 
of estimates. Three population-based studies reported point prevalence rates ranging from 0.84% 
(USA)1 to 3.3% (UK)2 and up to 12.9% (Russian Federation).3 Studies of school-age populations 
have reported prevalence of 12% in 4 to 6-year-olds, 3.9% to 4.7% in 11 to 16-year-olds4 and 24% 
in 16 to 18-year-olds.5 A recent cross-sectional study, including 1465 children in four primary 
schools in the Netherlands, reported prevalence rates in children aged 4–12 years of 33% (9% had 
hand warts, 20% had plantar warts and 4% had both).6
Estimates of the rate of natural resolution of warts vary widely. Massing7 found that two-thirds 
resolved within 2 years, but the resolution rates reported in the placebo arms of trials suggest 
that warts may resolve more rapidly. In a Cochrane systematic review8 of wart treatment, 21 
trials with placebo groups were reviewed. The average proportion that were clear of warts in 
the placebo groups in these trials was 27% (range 0 to 73%), after an average period of 15 weeks 
(range 4 to 24 weeks). This has led some to suggest that warts should not be treated at all.9,10 
However, some viral warts may persist for many years and there is no reliable means of predicting 
which ones will resolve spontaneously.
Verrucae are spread by direct skin-to-skin contact or indirectly via contact with contaminated 
surfaces (e.g. swimming pools or communal showers),11 although having a family member with 
a wart and having a high incidence of warts within a child’s class have been shown to be stronger 
risk factors than the use of swimming pools and shared bathing areas.6 If a verruca is scratched or 
knocked it can bleed, making it easier for the virus to infect another part of the body through a 
breach in the skin.12
What treatments are available?
Many treatments are available for the treatment of verrucae, including cryotherapy, topically 
applied treatments, surgical curettage, and complementary and alternative therapies. The most 
commonly prescribed treatments are cryotherapy with liquid nitrogen and topical salicylic acid.13
Side-effects are common with all verrucae treatments, and include pain, burning, blistering, 
bleeding and scarring. Pain and blistering are more commonly reported for cryotherapy 
treatments,14 and, for this reason, cryotherapy is not recommended for young children.10
2 Background
What evidence is there for the most commonly used treatments?
A Cochrane systematic review8 that assessed the effects of different local treatments of cutaneous, 
non-genital warts was updated in 2006 (search date March 2005). This review highlighted 
considerable uncertainty around the optimal treatment of verrucae.
The best available evidence was for topical treatments containing salicylic acid (of varied 
strengths). These preparations were significantly better than placebo. Data pooled from five 
placebo-controlled trials showed a cure rate of 117/160 (73%) compared with 78/162 (48%) in 
control subjects.8
Evidence for the effectiveness of cryotherapy was limited. The review found two trials comparing 
cryotherapy with salicylic acid and one comparing duct tape with cryotherapy. These trials 
showed no significant difference in efficacy for the compared treatments. More recently, a head-
to-head trial of salicylic acid compared with cryotherapy has been reported in a primary care 
setting in the Netherlands. This trial found that cryotherapy was significantly better than salicylic 
acid for the treatment of hand warts, but that there was no significant benefit of cryotherapy 
compared with salicylic acid in plantar warts.15 Cure rates for plantar warts were 29% for 
cryotherapy, 33% for salicylic acid and 23% for a no-treatment control group.
Why did we do the trial?
The treatment of warts and verrucae represents a considerable cost burden to both patients 
and the NHS. An economic decision model assessing the effectiveness and cost-effectiveness of 
salicylic acid and cryotherapy estimated that almost 2 million people in England and Wales see 
their general practitioner (GP) for the treatment of cutaneous warts each year, at a cost of at least 
£40M per annum.14
Despite this, the evidence base on which to inform clinical decision-making is poor. Of the 60 
trials identified in the 2006 Cochrane systematic review,8 46 (77%) were classified as low quality; 
in addition, heterogeneity between the trials was high and analyses were often inappropriate or 
misleading. A major conclusion from the Cochrane review8 was that a trial comparing topical 
salicylic acid with cryotherapy was urgently needed.
In response to an open call for trial proposals looking at medicines for children, the National 
Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme agreed 
to fund the EVerT (Effective Verruca Treatments) trial, with the aim of establishing the efficacy 
and cost-effectiveness of these two treatments.
Specific objectives of the trial
 ■ To assess the clinical effectiveness and acceptability of cryotherapy compared with salicylic 
acid for the treatment of verrucae.
 ■ To assess the cost-effectiveness of the compared treatments.
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Chapter 2  
Methods
Trial design
The EVerT trial was an open, pragmatic, multicentred, two-armed, randomised controlled 
trial (RCT) with equal randomisation. Participants with verrucae were randomised (1 : 1) to 
receive either:
 ■ cryotherapy using liquid nitrogen, delivered by a health-care professional (a podiatrist, 
practice nurse or GP) or
 ■ once-daily self-treatment with 50% salicylic acid (Verrugon, William Ransom & Son Plc, 
Hitchin, UK).
Approvals obtained
The Trent Multicentre Research Ethics Committee (MREC) approved the study and substantial 
amendment to address the NIHR HTA programme reviewers’ comments on 26 October 2004 
and 16 August 2006, respectively. Galway Research Ethics Committee approved the study on 
20 March 2009.
Salicylic acid was classified as a medicinal product, therefore, clinical trial authorisations 
(CTAs) were obtained from the competent authorities in the UK and Ireland: the Medicines 
and Healthcare products Regulatory Agency (MHRA) (CTA number 22803/0001/001-0001) on 
8 February 2005 and the Irish Medicines Board (clinical trial number CT 1552/1/1 Salicylic Acid/
Liquid Nitrogen) on 30 January 2009.
The details of MREC, local research ethics committees (LRECs), competent authorities and 
research and development department approvals are provided in Appendix 1.
The trial was assigned the International Standard Randomised Controlled Trial Number 
(ISRCTN) of ISRCTN18994246; EudraCT number 2004-000905-24; and National Research 
Register number N0484189151.
Trial sites
The study was conducted in 16 study sites: 15 in the UK and 1 in Ireland. Sites were recruited 
throughout the duration of the trial. The sites were podiatry schools, outpatient podiatry clinics, 
GP practices or, in one case, a primary care trust (PCT) podiatry service outpatient clinic. Details 
of the study sites are provided in Appendix 2.
Participant eligibility
People with one or more verrucae were recruited into this study.
4 Methods
Inclusion criteria
Potential participants were eligible for inclusion in the trial if they met the following criteria:
 ■ They had a verruca which, in the opinion of the health-care professional, was suitable for 
treatment with both salicylic acid and cryotherapy.
 ■ They were aged 12 years and over.
The study was funded via the NIHR HTA’s medicines for children call. Consequently, the initial 
inclusion criteria focused on children and young people between the ages of 12 and 24 years, 
inclusive. However, because of poor recruitment the upper age restriction was lifted.
Exclusion criteria
Potential participants were excluded if they met one or more of the following criteria:
 ■ They were currently in a trial evaluating other treatments for their verruca.
 ■ They had impaired healing, for example owing to diabetes, peripheral vascular disease or any 
other condition.
 ■ They were immunosuppressed, for example had agammaglobulinaemia or were taking 
immunosuppressant drugs such as oral corticosteroids.
 ■ They had neuropathy.
 ■ They were currently on renal dialysis.
 ■ They had cold intolerance, for example Raynaud syndrome or cold urticaria.
 ■ They had any of the following conditions: blood dyscrasias of unknown origin, 
cryoglobulinaemia, cryofibrinogenaemia or collagen or autoimmune disease.
 ■ They were unable to give informed consent.
Recruitment into the trial
Members of the research team participating in the study received ‘Good Clinical Practice’ 
training, as well as training in all aspects of the trial, including participant recruitment, eligibility 
criteria, trial protocol, adverse event reporting procedures and trial documentation. In order to 
standardise the study prior to commencement, each study site also received a trial handbook.
Potential participants for the trial were identified by a health-care professional at the study site 
from GP referrals, or self-referrals received by the podiatry clinic or GP practice for the treatment 
of verrucae. Participants were provided with an appointment for assessment/treatment and sent 
an invitation letter, information sheet about the trial, baseline questionnaire and consent form 
for the study (see Appendices 3 and 4). The flow of participants through the trial is presented in a 
CONSORT (Consolidated Standards of Reporting Trials) diagram (see Figure 2).
In order to aid recruitment, one or more of the following strategies were adopted at some sites to 
increase the number of people with verrucae presenting to the clinics:
 ■ GPs in the recruiting area were approached by either the York Trials Unit (YTU: University 
of York, UK) or the local Primary Care Research Network. They were requested to refer 
patients presenting with a verruca and who expressed an interest in taking part in the trial to 
the recruiting site.
 ■ The trial was promoted by means of a recruitment poster that was displayed in 41 libraries, 
15 pharmacies, 19 swimming pools, 8 supermarkets, 2 universities and 2 hospitals.
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 ■ Secondary schools were approached and asked to send out study information to their 
students. Fifteen schools in three different recruiting areas agreed to send out study 
information to 7410 students and displayed recruitment posters.
 ■ The trial was publicised in two local newspapers, in three university press releases, on three 
university websites and on two local radio stations. Potential participants were directed to the 
local recruiting site.
The documentation used to aid recruitment to the study is included in Appendix 5.
For individuals responding to an advert for trial participants, telephone screening by the study 
sites was recommended to ensure that the potential participants fulfilled the inclusion criteria.
Participants were given a minimum of 24 hours to read the information sheet and consider 
participation. In Ireland, where possible, there was a minimum of 6 days between the patient 
signing the consent form and the start of treatment in order to comply with local regulations. 
Participants who wished to take part in the study and who returned their baseline questionnaire 
were screened by the health-care professional using a randomisation form that listed the 
eligibility criteria (see Appendix 4). Eligible patients, and their parent/guardian for those under 
16 years of age, were able to discuss the study in more detail prior to providing written informed 
consent. Baseline data were then recorded and a digital photograph taken of the verruca(e). 
Participants’ GPs were notified of their involvement in the EVerT trial after recruitment.
Baseline assessment
After written informed consent had been obtained, baseline data were collected using the 
podiatrist treatment assessment form and the baseline questionnaire (see Appendix 4). The 
following data were collected.
Type and number of verruca(e)
The number and type of verruca(e) (mosaic or non-mosaic) were collected on the podiatrist 
treatment assessment form in order to examine whether or not mosaic verrucae respond less well 
to treatment than simple verrucae.
Duration and previous treatment of current verruca(e)
The duration of the current verruca(e) and type of any previous treatment received were recorded 
on the participant baseline questionnaire.
Reason for seeking treatment
The reasons for seeking treatment for the verrucae were recorded on the participant 
baseline questionnaire.
Level of pain
Participants were asked to rate how painful their current verruca was at baseline on a five-point 
Likert scale of 0–4, where 0 was not at all painful and 4 was extremely painful.
Number of previous verrucae and age at which they occurred
The number of previous verrucae and age at which they occurred were recorded on the 
participant baseline questionnaire.
6 Methods
Patient’s treatment preference
The patient’s treatment preference was recorded on the podiatrist treatment assessment form to 
allow us to explore the influence of the patient’s treatment preference on treatment outcomes.
Date of birth
Date of birth was recorded on the participant baseline questionnaire, allowing age at 
recruitment to be calculated and to allow us to explore the influence of the participant’s age on 
treatment outcomes.
Gender
The gender of participants was recorded on the participant baseline questionnaire.
Ineligible patients
The health-care professionals were asked to complete an ineligible patient form (see Appendix 4) 
for those participants who wished to take part in the trial, but were ineligible to do so. Data 
collected on this form were reasons why the patient was not eligible, date of birth, gender, type of 
wart and date of consideration for trial entry. Where the patient was willing, a completed baseline 
questionnaire was also collected.
Randomisation
Patients were randomised equally between the two treatment arms: cryotherapy using liquid 
nitrogen delivered by the health-care professional (podiatrist, practice nurse and GP) or daily 
self-treatment by the patient with 50% salicylic acid. The health-care professional at the recruiting 
site randomised the patient using the secure, remote, independent YTU telephone or web-based 
randomisation service. Randomisation was simple, i.e. it was not restricted in any way. Stratified 
randomisation was not used in order to reduce the risk of subversion, which can occur using 
forms of restricted randomisation. The allocation sequence was computer generated, with the 
treatment allocation being concealed from both the health-care professional and YTU until the 
moment of randomisation.
Sample size
The Cochrane systematic review8 found only one small trial directly comparing the effectiveness 
of a chemical treatment, salicylic acid, with cryotherapy in patients with warts on their feet 
alone. This poor-quality study found a 58% cure rate among the patients allocated to cryotherapy 
compared with 41% among those treated with salicylic acid. This difference of 17% was not 
statistically significant. The overall cure rates from this study are smaller than those observed 
in two placebo-controlled trials of salicylic acid, both of which reported cure rates of 85% for 
active treatment, possibly because more resistant verrucae were included in the study comparing 
cryotherapy with salicylic acid. The EVerT trial was powered to show a 15% difference in 
effectiveness. To give us 80% power (5% two-sided significance) to show a difference in cure rates 
of 70% versus 85% at 12 weeks, we required a sample size of 120 patients in each treatment group 
or 133 patients in each group after allowing for 10% attrition (i.e. 266 in total).
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
7 Health Technology Assessment 2011; Vol. 15: No. 32DOI: 10.3310/hta15320
Trial interventions
Participants were randomised to receive either cryotherapy using liquid nitrogen delivered by a 
health-care professional or daily self-treatment with 50% salicylic acid (Verrugon).
Cryotherapy using liquid nitrogen delivered by the health-care professional
Patients randomised to cryotherapy using liquid nitrogen received up to a maximum of four 
treatments 14–21 days apart. Treatment was delivered by the health-care professional according 
to the usual practice of each trial site. Most of the health-care professionals delivering the 
cryotherapy had several years’ experience in delivering cryotherapy using liquid nitrogen. If a 
patient presented with more than one verruca, the health-care professional was instructed to treat 
the verrucae as they would in normal practice.
Prior to treatment, if it was the site’s normal practice, the callus surrounding the verruca(e) was 
debrided (e.g. with a scalpel or file) with any haemorrhages stopped by digital pressure only. The 
tissue surrounding the verruca was either masked (e.g. with petroleum jelly) or left unmasked, as 
per usual practice. Liquid nitrogen was applied using a spray (method of choice if available) or 
probe until the health-care professional was satisfied that the tissue had been frozen adequately. 
On the advice from the Trial Steering Committee (TSC), clinicians were advised that the first 
treatment should be a gentle freeze (approximately 10 seconds’ duration) in order to ensure that 
the patient could tolerate the treatment. Silver nitrate was not applied to the verruca. If necessary, 
the health-care professional could pad the area surrounding the verruca after treatment, for 
example with 7 mm of felt-cavity padding. Patients were given a cryotherapy patient’s advice sheet 
(see Appendix 3). Patients were also advised to keep the area dry for 24 hours and that the area 
may blister and be uncomfortable. If required, patients were recommended to use painkillers, as 
they would for a headache, if the area was very painful.
Daily self-treatment by the patient with 50% salicylic acid
Patients randomised to self-treatment with 50% salicylic acid were instructed how to use the 
salicylic acid by the health-care professional and were provided with a salicylic acid patient’s 
advice sheet (see Appendix 3) at the first trial appointment. Thereafter, the salicylic acid was 
applied once daily by the patient (or parent/guardian if appropriate) for a maximum of 8 weeks as 
per the manufacturer’s instructions as follows:
 ■ The self-adhesive ring should be fixed with the hole over the verruca.
 ■ Squeeze a little Verrugon ointment into the hole and directly onto the verruca.
 ■ Remove backing paper from plaster.
 ■ Cover ring completely with plaster. Seal into position.
 ■ Repeat treatment daily after gently pumicing or filing off the dead part of the verruca.
All patients were given a follow-up appointment at 2 weeks as a safety check. Further supplies 
of felt pads, plasters and salicylic acid were provided to the patient when required. Patients were 
asked to return all of the tubes of salicylic acid they had received during the trial to the treating 
health-care professional at their 12-week appointment. The health-care professional weighed the 
tube(s) to determine how much salicylic acid had been used over the 8-week period.
8 Methods
Participant follow-up
Appendix 6 shows a summary of participant follow-up for the EVerT trial. Participants were 
given the option to complete participant questionnaires in either paper or web-based format 
according to their preference. In order to increase the response rate to the week-12 questionnaire, 
participants received an unconditional £5 (€5 for the site in Ireland) with their week-12 
questionnaire. The week-12 questionnaire was preceded by a letter notifying the participant that 
their week-12 questionnaire would arrive shortly and that it would be accompanied by a five 
pound (or five euro) note as an acknowledgement for their taking part in the trial and completing 
the questionnaires.
In order to minimise the difference in attendance between participants in the two groups, 
participants were reimbursed £20 for attending their week-12 outcome assessment appointment 
with the health-care professional. Information about this reimbursement was included in the 
patient information sheet.
Trial completion
Participants were deemed to have exited the trial when:
 ■ the participant had been in the trial for 6 months
 ■ the participant wished to exit the trial fully
 ■ the participant’s health-care professional withdrew him/her from the trial
 ■ the participant was lost to follow-up
 ■ the participant died.
Instead of withdrawing fully from the trial, participants had the option of:
 ■ withdrawing only from receiving the trial treatment
 ■ withdrawing only from postal or web-based questionnaires
 ■ withdrawing from the collection of data by the health-care professional
 ■ any combination of the above.
If the participant elected to withdraw from all three (trial treatment, questionnaires and data 
collection) then he or she was deemed as a full withdrawal (trial exit). Health-care professionals 
were able to indicate any change in the patient’s level of participation by completing the change of 
circumstances form (see Appendix 4). This ensured appropriate follow-up from the YTU.
Measurement of primary outcome
The primary outcome was complete clearance of all verrucae at 12 weeks after randomisation. 
Clearance of verrucae was defined as the restoration of normal skin on close inspection.
At the 12-week appointment the treating health-care professional or other member of the 
research team took a digital photograph of the participant’s foot. Participants who did not attend 
their 12-week outcome assessment appointment were asked to take a digital photograph of their 
foot and send it to the YTU. Two blinded assessors independently assessed the photographs for 
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each participant from all the sites to determine whether or not the verrucae had cleared, and 
whether or not they could tell which treatment the patient had received. The assessors discussed 
any discrepancies with referral to a third assessor for a final decision if required.
Previous studies co-ordinated by the YTU had found that using cameras to obtain blinded 
outcome assessments was not without its challenges. We therefore undertook an additional 
blinded outcome assessment at the recruiting site at the participant’s 12-week appointment. This 
assessment would then be used in cases in which assessment of the digital photograph was not 
possible, for example when the photograph was not interpretable or was missing. The blinded 
outcome assessment at the site was undertaken by another member of the research team who 
was unaware of the treatment the participant had received. The health-care professional recorded 
whether or not the verruca(e) had completely cleared on the podiatrist outcome assessment form 
(see Appendix 4). Participants were reminded not to tell the person undertaking the blinded 
assessment which treatment they received and participants allocated to the salicylic acid group 
were asked not to return any used or unused Verrugon tubes to them. If the outcome assessment 
was not blinded, this was recorded on the podiatrist outcome assessment form.
The primary outcome was then calculated using whether or not the verrucae had cleared, as 
decided by the blinded assessors from the photographs. However, if no photographs were 
available for a participant, or if the photograph was not interpretable, then the outcome from the 
blinded assessment at 12 weeks was taken. If neither of these were available for a participant then 
the patient’s self-reported outcome recorded in the week-12 questionnaire or on the ‘verrucae 
gone’ form (see Appendix 4) were used.
Measurement of secondary outcomes
Self-reported time to clearance of verrucae
Participants were asked to report if their verruca(e) had cleared on their week-3, week-12 and 
6-month questionnaires (see Appendix 4) and, if it had cleared, on what date it cleared. In 
addition to this, participants were asked to return their ‘verruca gone form’ if their verrucae 
cleared at any other time points. If there was any discrepancy between the dates reported by the 
participant then the longest date to clearance was used.
Clearance of verrucae at 6 months
Clearance of verrucae at 6 months was recorded on the participant’s 6-month questionnaire. If 
the participant had verrucae at 6 months then the position of the verrucae (either in the original 
or in a new position) was recorded.
Number of verrucae remaining at the 12-week appointment
The number of verrucae remaining at 12 weeks was recorded on the podiatrist outcome 
assessment form to summarise the effects of the two regimens.
Additional data collected
Recurrence of verrucae at 6 months
Participants were asked whether or not they had a verruca at 6 months on the participant’s 
6-month questionnaire. If a verruca was present they were asked to record whether or not it was 
in the original or in a different place.
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Patient satisfaction with treatment
Patient satisfaction with treatment (on a five-point scale, from ‘very unhappy’ to ‘very happy’) 
was reported on the participant week-1, week-3 and week-12 questionnaires.
Pain associated with first treatment
Pain associated with the first treatment (on a scale of 0–10, where 0 is no pain and 10 is the 
worst pain imaginable) was recorded on the patient pain questionnaire (see Appendix 4). This 
questionnaire was designed for participants to complete after their first treatment and return to 
the YTU using a reply-paid envelope.
Pain associated with verrucae and use of painkillers
Participants were asked to rate how painful their verrucae were on a five-point Likert scale of 
0–4, where 0 was not at all painful and 4 was extremely painful. They were also asked to record 
if they needed to take a painkiller because of their verruca treatment during the first 3 weeks 
following entry into the study and, if yes, the number of days they took painkillers. Data were 
collected on the week-1 and week-3 questionnaires.
Treatment details
The number of appointments attended by each participant, excluding the week-12 outcome 
assessment appointment, were recorded by the health-care professional on the podiatrist 
treatment assessment form. Details of the cryotherapy delivered at each appointment were 
recorded by the health-care professional on the same form, including the number of freezes 
performed, the duration of the first freeze on that visit, whether or not the health-care 
professional considered that sufficient freezing took place and whether or not the patient asked 
for the freeze(s) to be stopped, and, if so, why. As a means of assessing adherence, the weight 
of salicylic acid ointment used over the treatment period was recorded by the health-care 
professional on the podiatrist treatment assessment form by weighing the tubes of salicylic acid at 
the start and end of treatment. In addition, the number of times salicylic acid was applied within 
the past 7 days was reported on the participants’ week-1 and week-3 questionnaires.
Adverse events
An adverse event was defined as ‘any untoward medical occurrence in a subject to whom a 
medicinal product has been administered, including occurrences which are not necessarily 
caused by or related to that product’.
Health-care professionals were asked to report any adverse events occurring in participants in 
both groups to the trial office using either the ‘serious adverse event form’ or the ‘non-serious 
adverse event form’ (see Appendix 4). The reporting health-care professional was asked to 
indicate whether or not, in his or her opinion, the event was related to the treatment. Serious 
adverse events were defined as an event that resulted in death, was life-threatening, required 
hospitalisation or prolongation of existing hospitalisation, resulted in a persistent or significant 
disability or incapacity, or resulted in a congenital anomaly or birth defect. When appropriate an 
assessment of intensity and expectedness was also undertaken.
A list of possible treatment-related adverse events was established, a priori, based on reports in 
the literature. These were pain, blistering, irritation to the skin, infection, burning sensation, 
bleeding, scarring and allergic contact reaction.
Health-care professionals were asked to report any serious adverse events within 24 hours of 
becoming aware of the event and provide a follow-up report if necessary.
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Reasons for stopping treatment and any new treatments
Whether or not the participant found it necessary to stop the treatment to which they had 
been allocated and, if so, the reasons for this were recorded on the participant’s week-12 
questionnaires. Whether or not they started another treatment, and, if so, what was the new 
treatment, was also recorded on the week-12 questionnaire.
Statistical analysis
All analyses were conducted on an intention-to-treat basis, including all randomised patients 
in the groups to which they were randomised. All of the analyses were conducted using Stata 
statistic and data analysis software version 10.1 (StataCorp LP, College Station, TX, USA), except 
the logistic regression model accounting for centre clustering effects, which was undertaken 
using Sas version 9.2 (SAS Institute Inc., Cary, NC, USA) and two-sided significance tests at the 
5% significance level for the primary outcome measure and 1% significance level for secondary 
outcome measures. Multiple imputation methods were used to handle missing data. The 
statistician conducting the analysis remained blind to treatment group and data were unblinded 
only once all data summaries and analyses were completed.
Trial completion
The flow of participants through the trial is presented in a CONSORT diagram. The numbers of 
participants withdrawing from treatment and/or the trial were summarised together with the 
reasons where available.
Baseline data
All baseline data were summarised by treatment group and described descriptively. No formal 
statistical comparisons were undertaken. Continuous measures were reported as means and 
standard deviations (SDs), whereas categorical data were reported as counts and percentages.
Primary analysis
The primary outcome was complete clearance of all verrucae at 12 weeks. This was a dichotomous 
outcome (presence or absence of verruca). We compared the proportions of participants with 
complete clearance of all verrucae using a chi-squared test.
The Cohen’s kappa measure of inter-rater agreement was used to assess the agreement between 
the two assessors of the blinded photographs whether or not the verrucae had cleared.
Secondary analysis
Clearance of verrucae at 12 weeks
A logistic regression model was used to adjust the primary analysis for important prognostic 
variables (age, whether or not the verrucae have been previously treated and type of verruca). 
Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were obtained from 
this model.
Time to clearance of verrucae
Time to clearance was derived as the number of days from randomisation until the date of 
clearance as detailed from the participant’s self-reported questionnaire. Participants’ verrucae 
that had not cleared were treated as censored and their date of trial exit, or date of last available 
assessment, or 183 days/trial cessation, as appropriate, was used to calculate their duration in 
the trial.
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A Cox proportional hazards model was used to compare the time to clearance of the verrucae 
between the two groups, adjusting for the same covariates as for the primary outcome.
Clearance of verrucae at 6 months
The complete clearance of all verrucae at 6 months was analysed in the same way as the primary 
outcome, with adjustments for the same covariates.
Number of verrucae at 12 weeks
Negative binomial regression was used to compare the number of verrucae at 12 weeks between 
the two treatment groups, with adjustment for the number of verrucae at baseline. These models 
are used to estimate the number of occurrences of an event when the event has Poisson variation 
with overdispersion.
Patient’s treatment preference
As patients and health-care professionals were not blinded to treatments, we carried out an 
analysis to assess the influence of participant’s treatment preference on treatment outcomes. 
A logistic regression model was developed using the primary outcome and included patient 
preference and an interaction term between randomised treatment and preferred treatment in 
the model.
Missing data
We investigated the sensitivity of the results to missing data with multiple imputation analysis. 
Five imputations were created using a set of appropriate imputation models constructed using 
variables that were predictive of the missing data. Multiple imputation analysis was performed 
using the multiple imputation procedure in Sas.
Additional data collected
The following additional data were collected:
 ■ recurrence of verrucae at 6 months
 ■ patient satisfaction with treatment
 ■ pain associated with the first treatment
 ■ pain associated with verrucae and use of painkillers
 ■ treatment details for the cryotherapy delivered and adherence data for the salicylic acid arm
 ■ adverse events
 ■ reasons for stopping treatment and any new treatments
 ■ if patients had verrucae at 6 months were they in the original or a different place?
All additional data were summarised by treatment group (where appropriate), but no statistical 
analyses were performed.
Economic analysis
Aim of the economic analysis
Economic evaluation of health interventions is a tool used to assist decision-makers in 
prioritising and allocating resources in the health-care sector, by assessing the value for money 
(cost-effectiveness) of alternative interventions.
The aim of the economic analysis was to assess the relative costs and effectiveness of cryotherapy 
and salicylic acid for the treatment of verrucae. Data on both costs and effectiveness of the two 
comparators were synthesised to assess the additional cost required for an additional unit of 
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
13 Health Technology Assessment 2011; Vol. 15: No. 32DOI: 10.3310/hta15320
outcome. For this analysis, a cost-effectiveness approach was taken, where the outcome was 
defined as complete clearance of verrucae at 12 weeks.
The analysis was conducted on an ‘intention-to-treat’ basis. Hence, the analysis compared the 
treatment groups based on their original random allocation, regardless of protocol deviations and 
participants’ compliance or withdrawal. The NHS perspective was taken for the analysis where 
only costs directly linked to the NHS budget (GP or nurse visits, podiatrist time and cost of 
equipment and medications) were included.
Data
Resource use data
During the participant’s treatment period within the study, data on the resource use component of 
the economic analysis were collected from both participants’ self-completed questionnaires and the 
relevant form (podiatrist treatment assessment form) completed by the health-care professionals.
The number of visits to the podiatrist, nurse or GP for treatment was recorded by the health-care 
professional who treated the trial participant. In particular, details on the number of cryotherapy 
sessions administered and the number of tubes of salicylic acid provided to the patients 
were collected.
In addition, data on other resource usage were collected at 12 weeks after randomisation on a 
patient self-reported questionnaire. The questionnaire was designed for participant completion 
and was returned to the trial office using a reply-paid envelope. Participants were asked to 
complete the questionnaire about the number of visits to the clinic for treatment of their verruca 
and health service use (e.g. if they had seen a GP, practice nurse or attended an emergency visit 
with a GP because of their verruca).
Outcome data
The outcome data used for the economic analysis were the complete clearance of verrucae 
at 12 weeks. The data on outcome were extracted primarily by two independent assessors 
from digital photographs taken at 12 weeks. In cases where the digital photograph was not 
interpretable, the data were extracted from the podiatrist outcome assessment form and, 
finally, the patient self-reported questionnaire at 12 weeks. This has been described above (see 
Measurement of primary outcome).
Methods for calculation of costs
Cost of the cryotherapy treatment
The cost of cryotherapy treatment comprised two components: the cost of the equipment and the 
opportunity cost of the health-care professional’s time for attending the patients.
The list of equipment required for cryotherapy was compiled by a combination of interviewing 
podiatrists who run podiatric clinics and the equipment that was bought as part of setting up a 
trial centre. The equipment list included:
1. cryogenic gloves
2. safety glasses
3. aluminium Dewar
4. tipping trolley for Dewar
5. withdrawal device
6. cryosurgery applicator
7. slim probe
8. apron.
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In the economic analysis, annuitisation of the equipment cost was performed (see Equation 1). 
For this procedure, the cost of the equipment (K), which was incurred on its purchase, is spread 
over the lifetime of the equipment to obtain an equivalent annual cost (E).16 An interest rate (r) 
of 3.5% and a lifespan (n) for the cryogenic equipment of approximately 5 years were used in the 
calculations of the annuity factor.
K E r
r
n
=
− + −1 1( )
 [Equation 1]
To assign an equipment cost per treatment, the annual cost (E) was divided by the maximum 
number of the treatments that can be provided by a GP or podiatrist. The maximum number of 
treatments was calculated based on an average appointment time of 20 minutes and assuming 
full capacity of the clinics for the total number of working days per year (i.e. 253 excluding bank 
holidays in the UK). The average appointment time of 20 minutes was based on the experience of 
podiatrists and practice nurses.
In addition to the equipment cost, the cost of liquid nitrogen, which was the freezing agent 
for the cryotherapy, was calculated. Liquid nitrogen is nitrogen in a liquid state at a very low 
temperature.17 Hence, the Dewars are refilled frequently, approximately every 4–6 weeks, even 
though the liquid nitrogen is not being used fully for patient treatments. It is, therefore, difficult 
to assess the quantity of liquid nitrogen that is required for a single treatment. However, from 
the trial data, it was noticed that in one trial centre (Galway, Ireland) that exclusively treated trial 
participants, four refills of a 25-litre Dewar were ordered in a time frame of 3 months. The cost of 
liquid nitrogen per treatment was calculated by dividing the cost of four refills of a 25-l Dewar by 
the total number of treatments performed in that centre.
The clinician’s time was calculated based on an average appointment time of 20 minutes. The 
treatments were administered to the trial participants by either a GP, nurse or podiatrist. The unit 
costs for these health-care professionals were retrieved from the Unit costs of health and social 
care 2009.18
Cost of the salicylic acid treatment
The cost of the salicylic acid treatment comprised two components: the cost of the medication 
and the health professional’s time spent for each treatment assessment visit.
The cost of the medication included the:
 ■ Verrugon ointment tubes
 ■ felt pads
 ■ plasters.
The cost of Verrugon tubes was calculated based on the number of tubes used by the patients, 
irrespective of whether or not the patient had used up the entire content of the last tube received. 
For example, if the patient did not finish the second tube, the total of the two tubes was used for 
cost calculations. It should be noted that the maximum number of tubes used per participant in 
the trial was two.
The total numbers of felt pads and plasters were calculated based on the total number of 
applications, which, in turn, was based on the number of Verrugon tubes that a patient used. 
Hence, if the patient used only one tube of Verrugon then he or she needed pads and plasters 
sufficient for 28 applications. This is half of the total number of applications possible during 
the 8-week treatment period of the trial. Similarly, if the patients used two tubes then pads and 
plasters were required for 56 applications.
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The total number of felt pads boxes used per patient was calculated by dividing the number of 
applications by 36 (this is the total number of felt pads in a box: www.nu-careproducts.co.uk/
chiropody.htm#feltpads, product PPD12619) and rounded up to a whole number. Similarly, 
for the plasters, a box of 10 fabric strips sold by a national pharmacy chain,20 equivalent to 20 
applications, was used as a reference. The total number of boxes needed for the treatment was 
calculated by dividing the number of applications by 20 and rounding up to a whole number.
The cost of the health-care professional’s time for the administration of treatment was calculated 
based on an average appointment time of 20 minutes.
Unit costs of the treatments
The unit costs for the cryotherapy equipment were retrieved either from the supplier’s website 
or from a catalogue that was sent to the different trial centres. When more than one type of the 
same item was available, the average unit cost was calculated. The unit costs for the cryotherapy 
equipment are presented in Table 1.
The cost data that were used for calculating the cost of liquid nitrogen per treatment were 
retrieved from the purchases of liquid nitrogen of a single centre. The costs included the cost of 
the liquid nitrogen and the cost of delivery. The average cost over four purchases was calculated. 
Details are provided in Table 2.
For the salicylic acid treatment, the unit costs for the medication, pads and plasters are presented 
in Table 3.
TABLE 1 Unit cost of cryotherapy equipment
Item Source Size/type Pricea,b
Average 
price Price (£)c
Price including 
VAT (£)d
Cryogenic gloves Catalogue sent to 
Galway
€35.00 €35.00 28.88 33.94
Safety glasses BOC Products21 £4.42 £4.42 4.42 5.19
Dewar Catalogue sent to 
Galway
25 l aluminium €833.00 €868.00 716.30 841.65
25 l stainless steel €903.00
Tipping trolley for 
Dewar
Catalogue sent to 
Galway
€433.00 €433.00 357.33 419.86
Withdrawal device Catalogue sent to 
Galway
€708.00 €708.00 584.26 686.51
Cryosurgery applicator Catalogue sent to 
Galway
330 ml capacity 
applicator
€630.40 €642.10 529.88 622.61
450 ml capacity 
applicator
€653.80
Slim probe Catalogue sent to 
Galway
1 mm €99.40 €99.40 82.03 96.38
2 mm €99.40
3 mm €99.40
Cryogenic apron BOC Products21 Small £137.28 £163.02 163.02 191.55
Medium £154.44
Large £171.60
Extra large £188.76
a Different prices are provided for different sizes/types of equipment. The average price was calculated.
b All of the prices reported in euros refer to 2009–10 prices.
c Exchange rate: 1€ = 0.825232749 GBP (source: google.co.uk, date 10 June 2010).
d VAT was applied at 17.5%.
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Unit costs of the health-care professionals’ time
The unit costs of the health-care professional’s time were retrieved from the Unit costs of health 
and social care 200918 document published by the Personal Social Services Research Unit 
(PSSRU) of Kent University. Unit costs for health-care professionals with the lowest qualifications 
were chosen. These are presented in Table 4.
Data analysis
The analysis of data was mainly dictated by the level of missing data for the primary outcome. 
The base-case analysis was conducted as a ‘complete case analysis’, where only patients with 
available primary outcome data were included. Where resource use data were missing, mean 
values were imputed based on the response group of the patients.
An additional analysis was conducted by including all the patients and performing multiple 
imputations on both the primary outcome and the missing total costs.
For both analyses, the mean differences in costs and effects and the 95% CIs around those were 
calculated by using bias-corrected and -accelerated (BCA) bootstrap methods. For the mean 
difference in costs, a linear regression was used, whereas logistic regression was used for the 
difference in primary outcome, given the binary nature of the data.
All the analyses were conducted using Stata statistic and data analysis software, version 10.1.
TABLE 2 Cost of liquid nitrogen
Item Source Price (€)a Average (€) Price (£)b
Price including 
VAT (£)c
Liquid nitrogen (calculated 
for 25-l Dewar)
Galway 
invoice
Invoice 1 2.79/l 65.88
Invoice 2 2.79/l
Invoice 3 2.48/l
Invoice 4 2.48/l
Delivery charges Galway 
invoice
Invoice 1 38/delivery 27.43
Invoice 2 38/delivery
Invoice 3 16.86/delivery
Invoice 4 16.86/delivery
Total for liquid nitrogen and 
delivery
93.31 77.00 90.47
a All of the prices reported in euros refer to 2009–10 prices.
b Exchange rate: 1€ = 0.825232749 GBP (source: google.co.uk, 10 June 2010).
c VAT was applied at 17.5%.
TABLE 3 Unit costs for the salicylic acid treatment
Item Source Price including VAT (£)a
Verrugon 6 g BNF 5922 3.00
Fabric plasters Boots the Chemist 1.49
Pads www.nu-careproducts.co.uk/chiropody.htm#feltpads, product PPD126 2.30
BNF, British National Formulary.
a VAT was applied at 17.5%.
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Cost-effectiveness analysis
The cost-effectiveness of cryotherapy versus salicylic acid was assessed by comparing the 
incremental costs between the two arms of the trial with the incremental benefit, which is 
expressed as the difference in the proportion of patients with completely cleared verrucae at 
12 weeks.
When two options are compared, one is said to ‘dominate’ the other, and thereby is considered 
to be the more cost-effective option, if it is associated with a mean cost saving (a negative 
incremental cost) and positive mean incremental effect. Where one intervention does not 
dominate the other it is usual practice to calculate the incremental cost-effectiveness ratio (ICER) 
associated with each intervention group, relative to the next best alternative.
The ICER was calculated by dividing the mean incremental cost (ΔC) by the mean incremental 
effect (ΔE) (ICER = ΔC/ΔE), where E is the difference in effectiveness and C is the cost. 
Subsequently, the decision-makers can assess whether or not the additional benefit is worth the 
additional cost. Hence, a treatment strategy can be considered cost-effective only if the decision-
maker’s willingness to pay for an additional unit of outcome, i.e. the cost per additional patient 
cured at 12 weeks, is greater than (or equal to) the ICER. Cost-effectiveness acceptances curves 
(CEACs) were plotted. CEACs express the probability that a treatment is more cost-effective 
than its comparator for different thresholds the decision-makers may be willing to pay for an 
additional unit of outcome.
TABLE 4 Unit costs for health-care professionals’ time
Health-care professional Source Unit of measurement Unit cost (£) Used for
Nurse (GP practice) PSSRU Per hour (minute) in clinic 28.00 (0.47) Administration of cryotherapy/salicylic acid
Nurse (GP practice) PSSRU Per surgery consultation 10 Additional nurse visits
GP PSSRU Per surgery/clinic minute 2.70 Administration of cryotherapy/salicylic acid
GP PSSRU Per surgery consultation lasting 
11.7 minutes 
31 Additional GP visits
Community chiropodist/
podiatrist
PSSRU Per clinic visit 11.00 Administration of cryotherapy/salicylic acid
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Chapter 3  
Protocol changes
Inclusion and exclusion criteria
This study was funded via the NIHR HTA’s ‘medicines for children’ call, so the initial inclusion 
criteria focused on participants aged between 12 and 24 years of age. However, owing to poor 
recruitment, the possibility of opening up the inclusion criteria to participants over the age 
of 24 years was considered. The study investigators, TSC and Data Monitoring and Ethics 
Committee (DMEC) could see no reason why participants over the age of 24 years should not be 
included in the study. It was felt that including these patients would improve the generalisability 
of the study’s findings, making the results of the study of greater interest to health-care 
practitioners. Therefore, it was decided to include patients over the age of 24 years, and although 
there was no known reason why results from participants from older patients should not be 
applicable to younger patients, it was decided to undertake an analysis looking for an interaction 
with age.
Following advice from the TSC (20 September 2006 and 19 July 2007), it was decided to exclude 
the following patients from the study in order to enhance patient safety:
 ■ patients who were currently on renal dialysis
 ■ patients who had cold intolerance, for example Raynaud syndrome or cold urticaria
 ■ patients who had any of the following conditions: blood dyscrasias of unknown origin; 
cryoglobulinaemia; cryofibrinogenaemia; collagen and autoimmune disease
 ■ patients who were immunosuppressed, for example had agammaglobulinaemia or were 
currently taking immunosuppressant drugs such as oral corticosteroids
 ■ patients with neuropathy.
Treatment regimens
In order to increase the generalisability of the study’s results it was decided that debridement 
prior to treatment with cryotherapy was no longer a requirement, but could be performed if 
it was the site’s usual practice. Following advice from the TSC (20 September 2006), further 
clarifications to the cryotherapy regimen and the treatment of patients with more than 
one verruca were made (see Chapter 2, Cyrotherapy using liquid nitrogen delivered by the 
health-care professional).
Clarification of secondary outcomes and analysis
Following advice from the TSC (20 September 2006) it was decided to clarify the secondary 
outcomes, the adverse event reporting procedure and the economic analysis plan, and it was 
decided that the influence of prognostic variables on the primary outcome should be investigated.
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Questionnaire response rates
The response rate to the 12-week questionnaire was initially lower than anticipated. Results of 
a systematic review23 identified the use of financial incentives as a means of increasing response 
rates to postal questionnaires. The YTU had also identified that participant questionnaire return 
rates in previous NIHR HTA trials24 could be improved if participants were sent an unconditional 
£5 as a token ‘thank you’ reimbursement at the end of the trial.
We therefore applied to the regulatory authorities for permission to send participants £5 or €5 
with their week-12 questionnaire, i.e. the primary outcome data point. This was not mentioned 
in the patient information sheet, so that any possibility that it would be interpreted as a financial 
incentive to taking part in the trial was minimised. The week-12 questionnaire was preceded by 
a letter notifying the participant that their week-12 questionnaire was due to arrive shortly. This 
letter also stated that the questionnaire would be accompanied by a £5 (or €5) note as a thank you 
for their taking part in the trial and completing the questionnaires.
Recruitment
The original proposal contained five recruiting sites that planned to recruit three participants per 
month over an 18-month period. As the trial progressed, recruitment fell below expected levels 
despite the recruitment of extra study sites. Details regarding the recruitment of each site can be 
found in Appendix 1. An extension in time and funding was obtained from the funder and the 
recruitment period was extended to 39 months (November 2006 to January 2010).
In order to increase the number of eligible patients presenting to the recruiting sites, a variety of 
recruitment strategies were introduced. Details regarding the recruitment strategies can be found 
in Appendix 5.
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Chapter 4  
Clinical results section
Trial recruitment
Over the course of the trial there was a total of 16 participating sites: 15 in the UK and one in 
Ireland. These were the podiatry schools at the University of Northampton, the University of 
Huddersfield, the University of Brighton (at Leaf Hospital, Eastbourne), Glasgow Caledonian 
University (at Southern General Hospital) and the National University of Ireland, Galway (NUI 
Galway); Brownlow Group Practice, Liverpool; Springfield Surgery, Bingley; Sheffield PCT 
podiatry clinic; Sacriston Surgery, Sacriston; The Haven Surgery, Burnhope; Peaseway Medical 
Centre, Newton Aycliffe; Arlington Road Medical Practice, Eastbourne; Claughton Medical 
Centre, Birkenhead; Harbinson House Surgery, Sedgefield; Annfield Plain Surgery, Stanley; and 
Islington PCT podiatry service.
Recruitment of at least one trial participant took place in 14 out of the 16 sites. Recruitment was 
staggered, with sites joining and leaving the trial over its course. The two sites that did not recruit 
any patients were Annfield Plain Surgery, because of the short time period between the site 
initiation visit and the end of the recruitment period, and Islington PCT podiatry services, which 
withdrew from the study before it had recruited any patients.
Recruitment began in November 2006 and ceased in January 2010. In total, 284 individuals were 
screened as potential participants and, of these, 242 (85.2%) were randomised. The overall rate 
of recruitment is shown in Figure 1. The number of participants recruited per site ranged from 2 
to 58 (Table 5). Figure 2 shows the CONSORT flow chart of participants through the trial. Two 
ineligible participants with hand warts rather than verrucae on their feet were randomised in 
error, one to each treatment group. These two patients have been excluded from all tables, figures, 
summaries and analyses (for exceptions, see Table 5 and Figures 1 and 2).
Baseline participant characteristics
In total, 240 eligible participants were recruited to the study: 117 in the cryotherapy group 
and 123 in the salicylic acid group. We received a completed baseline questionnaire for 237 
participants (114 and 123 individuals in the cryotherapy group and salicylic acid groups, 
respectively). Three patients did not return their baseline questionnaires. The baseline 
characteristics are summarised by treatment group in Tables 6 and 7. Data collected on 
participants’ previous verrucae are summarised by treatment group in Table 8.
The majority of patients in the study were female (n = 157, 66%) and the median age of patients 
was 24 years, with the youngest person in the study being 12.0 and the oldest person being 
75.3 years. The majority (n = 185, 78%) of participants had received previous treatment for 
their verrucae. In most cases this included self-treatment using an over-the-counter (OTC) 
preparation. Preparations previously used included salicylic acid preparations (Bazuka Gel, 
Bazuka Extra-Strength Gel, Verrugon, Salactol and Boots own-brand gel) and cryotherapy 
self-treatments (Wartner, Scholl Freeze and Bazuka Sub-Zero). In both groups, a small number 
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of individuals (six in the cryotherapy arm and eight in the salicylic acid arm) reported they had 
tried other treatments, including tea tree oil (four participants).
Just under 60% (n = 139) of participants reported that they were seeking treatment for their 
verrucae because it was painful; however, when patients were asked how painful their verrucae 
were, only 34 (14%) reported that they were in quite a lot or extreme pain. A large number of 
TABLE 5 Number of participants randomised by group and site
Site
Cryotherapy 
(N = 118)
Salicylic acid  
(N = 124)
Total  
(N = 242)
n (%) n (%) n (%)
University of Northampton 25 (21.2) 33 (26.6) 58 (24.0)
University of Huddersfield 24 (20.3) 21 (16.9) 45 (18.6)
Glasgow Caledonian University 15 (12.7) 21 (16.9) 36 (14.9)
Arlington Road Medical Practice 14 (11.9) 5 (4.0) 19 (7.9)
Brownlow Group Practice 8 (6.8) 9 (7.3) 17 (7.0)
NUI Galway 5 (4.2) 8 (6.5) 13 (5.4)
Sacriston Surgery 6 (5.1) 7 (5.6) 13 (5.4)
University of Brighton 6 (5.1) 7 (5.6) 13 (5.4)
Sheffield PCT 4 (3.4) 5 (4.0) 9 (3.7)
Claughton Medical Centre 3 (2.5) 3 (2.4) 6 (2.5)
Peaseway Medical Centre 4 (3.4) 1 (0.8) 5 (2.1)
Harbinson House Surgery 2 (1.7) 2 (1.6) 4 (1.7)
Springfield Surgery 1 (0.8) 1 (0.8) 2 (0.8)
The Haven Surgery 1 (0.8) 1 (0.8) 2 (0.8)
FIGURE 1 Trial recruitment rate.
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FIGURE 2 EVerT CONSORT diagram. a, More than one category could be checked for each patient. HCP, health-care 
professional.
 Assessed for eligibility (n = 284)
Excluded (n = 44)a
Not eligible for both treatments (n = 12) 
Under 12 years of age (n = 2)
Unable to give informed consent (n = 1)
Impaired healing (n = 6)
Taking immunosuppressant drugs (n = 3)
Involved in another trial (n = 3)
Other reasons (n = 25)
Randomised (n = 242)
Randomised in error 
Cryotherapy (n = 1) and salicylic 
acid (n = 1)
Allocated to cryotherapy (n = 117) Allocated to salicylic acid (n = 123)
Lost to questionnaire follow-up  (n = 10)
Week 1 (n =  5)
Week 3 (n = 0)
Week 12 (n = 5)
Withdrawn from study (n = 3) HCP 
on sick leave
Primary outcome analysis  (n = 110)
Missing data (n = 4)
Analysed at 6 months (n = 98)
Missing data (n = 6)
Primary outcome analysis  (n = 119)
Missing data (n = 4)
Analysed at 6 months (n = 95)
Missing data (n =  12)
Lost to questionnaire follow-up (n = 16)
Week 1 (n = 8)
Week 3 (n = 3)
Week 12 (n = 5)
TABLE 6 Baseline characteristics
Characteristics Cryotherapy (N = 114) Salicylic acid (N = 123)
Gender
Female n (%) 84 (73.7) 73 (59.3)
Male n (%) 30 (26.3) 50 (40.7)
Age (years)
Mean (SD) 30.1 (15.7) 30.2 (16.4)
Median (minimum, maximum) 24.3 (12.2, 75.3) 23.2 (12.0, 70.6)
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individuals reported ‘other’ reasons for seeking treatment as a free-text comment. The most 
frequently reported reasons included the unfavourable appearance of the verrucae, risk of 
infecting other individuals, the verrucae were annoying or embarrassing, the verrucae had been 
present for a long time and that the participants just wished to get rid of them. A large number 
of participants previously had verrucae and the median number of previous verrucae was two, 
occurring at 5–74 years of age.
TABLE 7 Baseline verrucae characteristics
Characteristics Cryotherapy Salicylic acid
No. of verrucae at baselinea
N 106 119
Mean (SD) 4.0 (6.6) 3.4 (3.6)
Median (minimum, maximum) 2.0 (1.0, 55.0) 2.0 (1.0, 20.0)
Duration of verrucae in months
N 108 119
Mean (SD) 25.0 (24.9) 26.9 (24.5)
Median (minimum, maximum) 14.5 (0.9, 144.0) 20 (1.5, 130.0)
Type of verrucae
Mosaic, n (%) 29 (26.9) 21 (17.5)
Non-mosaic, n (%) 79 (73.1) 99 (82.5)
Previous treatment
Yes, n (%) 89 (78.1) 96 (78.0)
No, n (%) 25 (21.9) 27 (22.0)
Type of previous treatmenta
N 89 96
Self-treatment, n (%) 81 (91.0) 82 (85.4)
Podiatrist/chiropodist, n (%) 24 (27.0) 29 (30.2)
GP, n (%) 30 (33.7) 43 (44.8)
Trial investigating verruca treatments, n (%) 0 (0.0) 2 (2.1)
Other, n (%) 6 (6.7) 8 (8.3)
Reasons for seeking verruca treatmentb
N 114 123
Painful, n (%) 68 (59.6) 71 (57.7)
Unable to go swimming, n (%) 29 (25.4) 41 (33.3)
Unable to participate in other sports, n (%) 18 (15.8) 28 (22.8)
Other, n (%) 46 (40.4) 59 (48.0)
Pain intensity
Not at all, n (%) 44 (38.9) 44 (36.1)
A little bit, n (%) 37 (32.7) 34 (27.9)
Moderately, n (%) 20 (17.7) 22 (18.0)
Quite a lot, n (%) 10 (8.8) 18 (14.8)
Extremely, n (%) 2 (1.8) 4 (3.3)
a Data were not received for 15 patients.
b More than one category could be checked so the total for all categories may total more than 100%.
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In general, the two groups were well balanced at baseline; however, there were slight imbalances 
in gender and the type of verrucae. The proportion of women was greater in the cryotherapy 
group than in the salicylic acid group. However, as there is no evidence that gender is a 
prognostic factor for verrucae clearance, this imbalance is unlikely to affect clearance outcomes 
and gender was not included in any analyses. The proportion of participants with a mosaic 
verruca was greater in the cryotherapy group than in the salicylic acid group.
Primary outcome: complete clearance of verrucae at 12 weeks
In total, 229 participants had a response for whether or not there was complete clearance of 
all verrucae at 12 weeks after randomisation, with 206 (90.0%) having a blinded outcome 
assessment: 159 (69.4%) had a blinded outcome assessment from a digital photograph with 31 
photographs deemed to be of insufficient quality to allow an assessment to be undertaken (The 
two assessors agreed that they were unable to assess 28 photographs. However, they disagreed 
on a further 51 photographs. When these 51 photographs were sent to the third assessor she was 
unable to assess three of these photographs, making a total of 31 photographs which could not be 
assessed.) Forty-seven (20.5%) had a blinded outcome assessment from a health-care professional 
assessment; four (1.7%) had an unblinded outcome assessment from a health-care professional 
assessment; and 19 (8.3%) had patient self-reported data. Overall, 32 of the 229 (14.0%) had 
complete clearance of all verrucae at 12 weeks: 17 out of the 119 (14.3%) patients in salicylic acid 
group and 15 of the 110 (13.6%) patients in the cryotherapy group. We compared the proportions 
of participants with complete clearance of all verrucae and there was no evidence of a difference 
between the salicylic acid and the cryotherapy groups (14.3% vs 13.6%, difference = 0.6%, 95% CI 
–9.6% to 8.3%; p = 0.89).
Determination of primary outcome
Table 9 shows the data comparing the outcomes from two independent assessors for photographs 
from 190 patients. Of these, 106 patients were deemed by both assessors to have verrucae, 
although both agreed that five patients’ verrucae had all cleared. The assessors disagreed in 51 
cases: Assessor 1 classified that two patients had no verrucae, whereas Assessor 2 classified these 
patients as having verrucae. Similarly, Assessor 2 classified that one patient had no verrucae, 
TABLE 8 Previous verrucae characteristics
Characteristics Cryotherapy Salicylic acid
Previous verrucae
Yes, n (%) 72 (63.7) 81 (65.9)
No, n (%) 34 (30.1) 36 (29.3)
Don’t know, n (%) 7 (6.2) 6 (4.9)
No. of previous verrucae
N 69 76
Mean (SD) 3.7 (3.5) 4.0 (4.01)
Median (minimum, maximum) 2.0 (1, 15) 2.0 (1, 25)
Age at which previous verrucae occurred (years)
N 72 77
Mean (SD) 18.9 (14.9) 17.9 (12.8)
Median (minimum, maximum) 13.5 (7.0, 74.0) 13.0 (5.0, 60.0)
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whereas Assessor 1 classified them as still present. There were five cases in which Assessor 1 
classified the verrucae as cleared, but Assessor 2 was unable to assess whether or not the verrucae 
had cleared. In the remaining 43 cases, the disagreement was between ‘not cleared’ and ‘unable to 
assess’ classifications. To quantify the strength of this association the kappa measure of agreement 
was estimated as 0.45 [standard error (SE) 0.05, 95% CI 0.35 to 0.55]. This indicates a moderate 
level of agreement.
Secondary outcomes
Complete clearance of verrucae at 12 weeks adjusted analysis
The primary analysis was repeated but controlled for age, whether or not the verrucae had been 
previously treated (yes/no) and the type of verrucae (mosaic/non-mosaic). The results from the 
logistic regression highlighted that there was no evidence of a difference between the salicylic 
acid and the cryotherapy groups (OR 0.96, 95% CI 0.44 to 2.11; p = 0.92).
Age was categorised into three groups (< 18 years, > 18 but < 25 years, and over 25 years). There 
was a non-significant effect of age (< 18 years vs > 25 years, OR 0.66, 95% CI 0.22 to 1.98; and 
> 18 years but < 25 years vs > 25 years, OR 0.80, 95% CI 0.35 to 1.82).
After adjusting for clustering of healing rates within a centre there was still no evidence of a 
difference between the salicylic acid and the cryotherapy groups (OR 1.04, 95% CI 0.43 to 2.50; 
p = 0.92). The resultant intraclass correlation was almost zero (2.74 × 10–10; p = 1.00).
Self-reported time to clearance of verrucae
We compared the time to clearance of the verrucae between the two groups, adjusting for the 
same covariates as above (age, previous treatment and type of verrucae). There was no evidence 
of a difference in the time to clearance between the two groups when compared in the Cox 
proportional hazards model [hazard ratio (HR) 0.80, 95% CI 0.51 to 1.25; p = 0.33].
Clearance of verrucae at 6 months
We received data on presence/absence of verrucae at 6 months from 193 participants. Overall, 
62 of the 193 (32.1%) had complete clearance of all verrucae at 6 months: 29 of the 95 (30.5%) 
patients in the salicylic acid group and 33 out of the 98 (33.7%) patients in the cryotherapy group. 
There was no evidence of a difference between the salicylic acid and the cryotherapy groups 
(30.5% vs 33.7%, difference = –3.1%, 95% CI –10.0% to 16.3%; p = 0.64). The findings from the 
adjusted analysis were similar to the unadjusted analysis (OR 1.17, 95% CI 0.62 to 2.21; p = 0.62).
TABLE 9 Results of the blinded classification of clearance of verrucae using photographs by the two 
independent assessors
Assessor 1
Assessor 2
TotalCleared Not cleared Unable to assess
Cleared 5 1 5 11
Not cleared 2 106 41 149
Unable to assess 0 2 28 30
Total 7 109 74 190
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Number of verrucae remaining at 12 weeks
The median number of verrucae at 12 weeks in the salicylic acid group was 2 (minimum to 
maximum = 0–20) and in the cryotherapy group was 1 (minimum to maximum = 0–40). There 
was no evidence of a difference in the number of verrucae at 12 weeks between the two groups 
[incidence rate ratio (IRR) 1.08, 95% CI 0.8 to 1.43; p = 0.62].
Patient’s treatment preference
Twenty-eight (11.7%) and 86 (35.8%) participants expressed a preference at baseline for salicylic 
acid and cryotherapy, respectively, whereas 104 (43.3%) did not have a preference and 22 
people did not respond to this question. When we extended the primary analysis to include an 
interaction term between randomised treatment and preferred treatment we found no evidence 
to suggest that patients’ preferences at baseline influenced the outcome.
Missing data
We investigated the sensitivity of the results to missing data with multiple imputation analysis. 
There was little difference in the estimates obtained from the complete case analysis and the 
multiple imputation analysis. The summary of the sensitivity of results to missing data is 
presented in Table 10.
Patients’ willingness to have the same treatment allocation
There was an association between willingness to have the same allocation and treatment 
randomised {chi-squared test statistic 17.90 [2 degrees of freedom (df)]; p = 0.0001}. More 
patients were willing to have cryotherapy again and fewer patients were willing to have salicylic 
acid again than expected under independent association.
Additional data collected
Recurrence of verrucae at 6 months
Thirty-two patients had clearance of verrucae at 12 weeks. At 6 months, 22 of these 32 patients 
had reported their verrucae as gone, six had missing data and four (two patients in each group) 
reported that their verrucae had returned in its original place.
Patient satisfaction with treatment
Table 11 summarises patient satisfaction with treatment, reported on a five-point scale (from 
‘very unhappy’ to ‘very happy’) on the participant week-1, week-3 and week-12 questionnaires.
At week 1, the majority of participants in both groups were happy with their treatment, with 
68 individuals (67%) and 69 individuals (65%) in the cryotherapy and salicylic acid treatment 
groups, respectively, answering that they were either ‘happy’ or ‘very happy’. Only a small 
TABLE 10 Summary of the sensitivity of results to missing data
Outcome Complete cases estimate (95% CI) Multiple imputation estimate (95% CI)
Clearance at 12 weeks (unadjusted) 0.95 (0.45 to 2.00) 1.01 (0.49 to 2.08)
Clearance at 12 weeks (adjusted) 0.96 (0.44 to 2.11) 0.99 (0.47 to 2.07)
Clearance at 6 months 1.17 (0.62 to 2.21) 1.18 (0.68 to 2.08)
No. of verrucae 1.08 (0.81 to 1.43) 1.06 (0.82 to 1.38)
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proportion of individuals (7% in the cryotherapy group and 6% in the salicylic acid group) were 
unhappy (answered ‘unhappy’ or ‘very unhappy’) with their treatment. At week 3, participants in 
both groups reported a similar level of satisfaction with their treatment to week 1. The majority 
(73% in the cryotherapy group and 61% in the salicylic acid group) reported that they were 
happy, and only 10% and 12% in the cryotherapy and salicylic acid treatment groups, respectively, 
reported that they were unhappy. At week 12, once again the majority (62%) of participants in 
the cryotherapy group reported that they were happy with their treatment and only 13% reported 
that they were unhappy. However, in the salicylic acid group individuals were less happy with 
their treatment than they were at previous time points and compared with the cryotherapy group 
at the week-12 time point. Forty individuals (41%) were happy, whereas 31 individuals (32%) 
were unhappy.
Whether or not the participants would be willing to receive the same treatment again is 
summarised in Table 12.
In total, 146 (77%) participants indicated at 12 weeks whether they would or would not have 
the same treatment again. The majority (n = 65, 71%) of cryotherapy patients reported that they 
would be willing to receive the same treatment again, whereas only 42 (43%) of salicylic acid 
patients were willing to repeat their treatment.
Pain associated with first treatment
Participants were asked to record the level of pain associated with their first treatment. This was 
reported on a 0–10 pain scale, where 0 represents no pain and 10 is the worst pain imaginable. 
The mean pain intensity associated with the first cryotherapy treatment was 3.05 (with a 
minimum score of 0 and a maximum score of 8), whereas the mean pain intensity associated with 
the first salicylic acid treatment was lower at 0.75 (with a minimum score of 0 and a maximum 
score of 7).
Pain associated with verrucae and use of painkillers
Pain associated with participants’ verrucae is summarised in Table 13. At weeks 1 and 3, 
the majority of participants in both treatment groups reported that their verrucae were not 
painful or a little painful. A minority reported a lot of pain (answering ‘quite a lot of pain’ or 
‘extremely painful’).
TABLE 11 Patient satisfaction with treatment at weeks 1, 3 and 12
Questionnaire
Satisfaction with treatment
Very unhappy Unhappy Indifferent Happy Very happy
Week 1
Cryotherapy, n (%) 6 (5.9) 1 (1.0) 26 (25.7) 43 (42.6) 25 (24.8)
Salicylic acid, n (%) 1 (0.9) 5 (4.7) 32 (29.9) 54 (50.5) 15 (14.0)
Week 3
Cryotherapy, n (%) 10 (9.6) 0 (0.0) 18 (17.3) 48 (46.2) 28 (26.9)
Salicylic acid, n (%) 3.9 (4.0) 8 (7.7) 29 (27.9) 46 (44.2) 17 (16.4)
Week 12
Cryotherapy, n (%) 7 (7.9) 5 (5.5) 23 (25.3) 30 (33.0) 26 (28.6)
Salicylic acid, n (%) 10 (10.2) 21 (21.4) 27 (27.6) 25 (25.5) 15 (15.3)
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A minority of participants found it necessary to take painkillers during the first 3 weeks of the 
study (n = 9), with more individuals taking painkillers in the cryotherapy group (n = 8) than in the 
salicylic acid group (n = 1). Those individuals who had used painkillers took them for between 1 
and 4 days.
Treatment details
Table 14 summarises the cryotherapy treatment details reported by the treating health-care 
professional. Out of the 117 patients randomised to cryotherapy, treatment details were returned 
on the podiatrist treatment assessment form for 109 (93.2%) individuals and are summarised 
here. The mean number of visits to the clinic or GP practice for cryotherapy treatment was 3.6, 
with a minimum of one and a maximum of five visits. The mean duration between visits for 
treatment was 18.3 days, with a minimum of 9.7 days and a maximum of 52.5 days. At each 
treatment visit, participants received a mean of 1.6 applications of liquid nitrogen, with each 
application lasting a mean of 10.9 seconds. In the vast majority of cases (94.2%), the health-care 
professional considered that a sufficient freeze had been achieved and for only 9% of the freezes 
did the patient request that the freeze was stopped. The main reason for stopping the freeze was 
that it was painful.
Table 15 summarises the data collected on adherence for the salicylic acid treatment group. The 
majority (76%) of individuals received one tube of salicylic acid during the trial, and a mean of 
2.8 g (SD 2.2 g) of ointment from each tube was used during the treatment period. Self-reported 
adherence was reasonably high, with participants applying salicylic acid on a mean of 6.3 days 
and 5.4 days out of 7 days at weeks 1 and 3, respectively.
Adverse events
In total, 19 participants reported 28 adverse events. Of these 28 events, one was classed as 
serious and unrelated to the treatment (salicylic acid). Of the remaining 27 events, 13 were in 
the salicylic acid group and 14 were in the cryotherapy group. The relationship between the non-
serious adverse events and treatment group is reported in Table 16. There were two treatment-
related non-serious adverse events, both of which were in the cryotherapy group. Both patients 
developed a blister that was larger in size than expected in routine practice.
TABLE 12 Participants’ willingness to receive allocated treatment again 
Response Cryotherapy (N = 91) Salicylic acid (N = 98)
Yes, n (%) 65 (71.4) 42 (42.9)
No, n (%) 9 (9.9) 30 (30.6)
Not sure, n (%) 17 (18.7) 26 (26.5)
TABLE 13 Pain associated with verrucae
Verruca painful today?
Week 1 Week 3
Cryotherapy Salicylic acid Cryotherapy Salicylic acid
Not at all, n (%) 43 (41.7) 42 (39.3) 62 (59.6) 46 (44.7)
A little bit, n (%) 35 (34.0) 34 (31.8) 25 (24.0) 34 (33.0)
Moderately, n (%) 16 (15.5) 19 (17.8) 13 (12.5) 14 (13.6)
Quite a lot, n (%) 9 (8.7) 10 (9.3) 3 (2.9) 8 (7.8)
Extremely, n (%) 0 (0.0) 2 (1.9) 1 (1.0) 1 (1.0)
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TABLE 15 Salicylic acid treatment details
Treatment details Salicylic acid
No. of tubes dispensed
N 108
One tube, n (%) 82 (75.9)
Two tubes, n (%) 26 (24.1)
Weight of salicylic acid used (g)
N 58
Mean (SD) 2.8 (2.2)
Median (minimum, maximum) 2.4 (0.06, 9.3)
No. of times salicylic acid applied in the last 7 days
Week 1
N 106
Mean (SD) 6.3 (1.5)
Median (minimum, maximum) 7.0 (0.0, 7.0)
Week 3
N 103
Mean (SD) 5.4 (2.8)
Median (minimum, maximum) 6.0 (0.0, 22.0)
TABLE 14 Cryotherapy treatment details
Treatment details Cryotherapy (N = 109)
No. of visits
Mean (SD) 3.6 (0.70)
Median (minimum, maximum) 4.0 (1.0, 5.0)
Duration between visits (days)a
Mean (SD) 18.3 (6.8)
Median (minimum, maximum) 15.5 (9.7, 52.5)
No. of times applied
Mean (SD) 1.6 (0.7)
Median (minimum, maximum) 1.5 (0.3, 4.3)
Duration of each application (seconds)
Mean (SD) 9.5 (8.6)
Median (minimum, maximum) 9.5 (2.0, 60.0)
Sufficient freezing took place (%) 94.2
Patients asked to stop the freeze (%) 9.0
a Two participants had missing data for this variable.
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Reasons for stopping treatment and any new treatments
Table 17 summarises the number of participants who found it necessary to stop their 
allocated treatment.
There was a low incidence of participants stopping their original treatment. Twenty-one 
participants (11.5%) reported stopping their original treatment. Of these, 16 participants were in 
the salicylic acid group and five in the cryotherapy group. The reasons for stopping treatment are 
summarised in Table 18.
Of the participants who reported stopping their original treatment, three (15%) reported starting 
another treatment. The cryotherapy patient started salicylic acid treatment and one of the 
salicylic acid patients continued their treatment with salicylic acid after a temporary stop. The 
other salicylic acid patient did not state which treatment they started.
TABLE 16 Relationship of the non-serious adverse events by randomised group
Relationship Salicylic acid Cryotherapy Total (%)
Unrelated 9 7 16
Unlikely to be related 4 5 9
Possibly related 0 0 0
Probably related 0 0 0
Definitely related 0 2 2
Unable to assess if related 0 0 0
Total 13 14 27
TABLE 17 Participants stopping allocated treatment
Cryotherapy Salicylic acid
Necessary to stop the original treatment?
Yes (%) 5 (5.6) 16 (17.0)
No (%) 84 (94.3) 78 (83.0)
If yes, was another treatment started?
Yes (%) 1 (25.0) 2 (12.5)
No (%) 3 (75.0) 14 (87.5)
TABLE 18 Reasons for stopping treatment
Reason Cryotherapy group Salicylic acid group
Pain 2 7
Poor condition of the participant’s skin 0 5
Blistering 2 0
Ran out of plasters 0 1
Participant believed verruca had gone 0 4a
a Participant started treatment again as found verruca had not gone.
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Chapter 5  
Economic analysis
This chapter presents the results of the economic analysis of the EVerT trial. We have undertaken several analyses to assess whether or not costing assumptions and missing data 
could have affected the results.
Summary of the resource usage
Data on resource usage were collected for the treatment visits, any additional contact with GPs or 
nurses, and emergency visits to the GP, as well as items related to the medication for both groups. 
The average resource usage on the EVerT study is reported in Table 19.
During the trial, participants in the cryotherapy arm had a mean of 3.59 visits to the GP, nurse 
or podiatrist for treatment. The salicylic acid arm participants had a mean of 1.94 visits. Only 
a small number of patients (three in each group) had extra visits to the GP, in addition to the 
planned treatment visits. Participants in the cryotherapy arm had a mean of 0.04 additional 
visits to the GP, whereas those in the salicylic acid arm had a mean of 0.01 additional visits. 
Eight patients from both groups had additional visits to a nurse. This resulted in a mean number 
of additional nurse visits of 0.05 for the patients undergoing cryotherapy and 0.08 for the 
salicylic acid group. Salicylic acid patients received a mean of 1.25 tubes of Verrugon, whereas 
cryotherapy patients received a mean of 3.49 treatments.
Two emergency visits were reported, one in each group. For the salicylic acid patient, the 
comments referred to an event that happened before the randomisation date. The cryotherapy 
patient did see the GP, but, after reviewing the trial co-ordinator’s notes for this patient, it was 
concluded that this visit was already reported as an additional visit to the GP.
Missing data on resource use and outcome
There was a significant level of missing data on resource usage relating to additional GP or 
nurse visits: 30% and 28% for the cryotherapy and salicylic acid groups, respectively. The level of 
missing data for treatment visits, number of tubes of Verrugon and cryotherapy applications was 
much lower, ranging from 2% to 7%.
The missing items were a result of either the trial participants not returning the questionnaire or 
not completing the relevant questions on the questionnaire. Missing data on number of treatment 
visits was because of missing podiatrist treatment assessment forms. The level of missing data was 
not related to the treatment allocation as demonstrated by a chi-squared test.
Table 20 presents details on the missing data for various resource usage items.
Table 20 supports the notion that the amount of missing data is not related to group allocation, 
which reduces the risk of bias. In the following analyses we adjusted for missing data through 
multiple imputation methods.
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Data analysis
Given the level of missing data for both the primary outcome and the resource use items, the 
analysis of data was based on two scenarios as will be described below.
Scenario 1: complete case analysis based on the primary outcome data
For the first scenario, only the patients who had primary outcome data were considered. Mean 
values were imputed for the missing resource usage items (i.e. treatments visits, additional visits 
to the GP or nurse, number of cryotherapy treatments, number of tubes of Verrugon). For the 
visits, the mean imputation was performed based on the outcome group (i.e. verrucae gone or not 
gone) and the treatment allocation. For the cryotherapy treatments and the number of Verrugon 
tubes, the means were imputed based on the outcome group only.
TABLE 19 Average resource usage
Item Cryotherapy Salicylic acid
Average no. of treatment visits
n 109 120
Mean (SE) 3.59 (0.072) 1.94 (0.38)
SD 0.75 0.42
Median (minimum, maximum) 4 (1, 5) 2 (1, 4)
Missing (%) 8 (7%) 3 (2%)
Average no. of additional GP visits
n 82 89
Mean (SE) 0.04 (0.03) 0.01 (0.01)
SD 0.25 0.11
Median (minimum, maximum) 0 (0, 2) 0 (0, 1)
Missing (%) 35 (30%) 34 (28%)
Average no. of additional nurse visits
n 82 89
Mean (SE) 0.05 (0.03) 0.08 (0.04)
SD 0.27 0.34
Median (minimum, maximum) 0 (0, 2) 0 (0, 2)
Missing (%) 35 (30%) 34 (28%)
Average no. of tubes of Verrugon
n NA 116
Mean (SE) NA 1.25 (0.04)
SD NA 0.44
Median (minimum, maximum) NA 1 (1, 2)
Missing (%) NA 7 (6%)
Average no. of cryotherapy treatments given to patients
n 109 NA
Mean (SE) 3.49 (0.08) NA
SD 0.80 NA
Median (minimum, maximum) 4 (1, 5) NA
Missing (%) 8 (7%) NA
NA, not applicable.
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The total costs were calculated by summing up the cost of treatment visits, additional GP or 
nurse visits and the medication costs, i.e. the cost of cryotherapy equipment and liquid nitrogen 
per patient treatment for the cryotherapy group and the cost of Verrugon, pads and plasters for 
the salicylic acid group. Table 21 presents the costs by items of resource usage. The majority of 
costs for both groups was owing to the cost of treatment visits, with the average cost per patient 
being larger in the cryotherapy group than in the salicylic acid group (£88.69 vs £39.59). The 
second largest cost for the cryotherapy group was the cost of treatment, which included the cost 
of equipment and liquid nitrogen. The average cost of the cryotherapy treatment per patient 
was £60.05.
To avoid any distributional assumptions on the cost and outcome data, the BCA 95% CIs around 
the mean difference in costs and outcomes were calculated by the bootstrapping method. The 
mean differences in costs and the proportion of patients with cleared verrucae were calculated 
based on linear regression for the former and logistic regression for the latter. Two types of 
analyses were conducted: first, based on unadjusted costs and outcomes and, second, by adjusting 
them based on the age of the participants, whether or not they had received previous treatment 
and the type of verrucae.
Unadjusted costs and outcomes
The results of the base case unadjusted analysis demonstrate that there is a significant difference 
in the total cost per patient between the two arms of the study, with cryotherapy costing on 
average £101.17 more per patient. The treatment effect for cryotherapy is smaller than that for 
salicylic acid, although statistically non-significant. The mean total costs and outcomes based 
on data after imputation are presented in Table 22, whereas the mean difference in costs and 
outcomes and the corresponding 95% CI are presented in Table 23.
Adjusted costs and outcomes
The adjusted results lead to the same conclusion as the unadjusted results, i.e. cryotherapy is 
more costly and less effective (not statistically significant) than salicylic acid treatment. Table 24 
presents the mean difference in adjusted costs and outcomes.
Cost-effectiveness and uncertainty
As demonstrated in Tables 23 and 24, cryotherapy is more costly and non-significantly less 
effective. The bootstrapped pairs of difference in costs and outcomes for both adjusted and 
unadjusted results are presented on a cost-effectiveness plane (CE plane) (see Figure 3) to 
visually demonstrate the above conclusions. As evident from the CE plane, almost 50% of 
the bootstrapped replicates falls either side of the line that goes through the zero difference 
TABLE 20 Missing data on resource use items and outcomes
Resource use or outcome data item
Missing response, n (%)
Treatment arm impact on level of 
missing data (Pearson chi-squared, 
p-value)Cryotherapy (n = 117)
Salicylic acid 
(n = 123)
Additional visits to GP or nurse 35 (30) 34 (28) (0.1511, p = 0.697)
Treatment visits 8 (7) 3 (2) (2.6528, p = 0.103)
No. of tubes of Verrugon NA 7 (6) NA
No. of cryotherapy treatments 8 (7) NA NA
Primary outcome 7 (6) 4 (3) (0.1345, p = 0.714)
NA, not applicable.
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in outcomes point (x-axis). This is indicative of high uncertainty around the difference in 
effectiveness of the two treatments. In contrast, all of the cost replicates are above the zero line 
of the y-axis, i.e. no difference in costs. Figure 3 presents the CE plane for both unadjusted and 
adjusted results.
Figure 4 presents the CEACs. This demonstrates the probability of the cryotherapy being cost-
effective given a specific willingness-to-pay value per ‘cured’ patient. The adjusted and unadjusted 
data give the same results. In both cases, the probability that cryotherapy is cost-effective is 
around 40% at a threshold value of £15,000 per cured patient.
Sensitivity analysis based on the data analysis of scenario 1 (complete case 
for primary outcome data)
The majority of costs for the cryotherapy group are owing to treatment visits (i.e. health-care 
professional’s time) and the cost of the treatment itself, i.e. the cost of the equipment and liquid 
nitrogen. A sensitivity analysis was carried out by adopting an extreme approach whereby the 
administration of the treatment was assumed to be carried out by a nurse (rather than a GP) 
in those study sites that were set up in GP practices and by excluding completely the cost of 
cryotherapy equipment and liquid nitrogen. In effect, this analysis would result in comparing 
TABLE 22 Mean total costs and outcomes based on data after imputation
Variable Treatment n Mean cost/outcome SE
Costs (£) Salicylic acid 119 49.22 3.46
Cryotherapy 110 150.39 7.48
Difference = 101.17; p < 0.001
Outcomes Salicylic acid 119 0.143 (17 patients) 0.032
Cryotherapy 110 0.136 (15 patients) 0.033
Difference = –0.006; p = 0.89
TABLE 23 Mean difference in costs and outcomes (BCA 95% CI)
Variable Mean difference 95% CI ICER
Costs (£) 101.17 85.09 to 117.26 Cryotherapy is dominated
Outcomes –0.0065 –0.10 to 0.08
TABLE 21 Costs by item of resource usage
Item Treatment group Mean cost (£) 95% CI
Treatment visits (health-care 
professional’s time)
Salicylic acid 39.59 33.26 to 45.92
Cryotherapy 88.69 74.70 to 102.68
Verrugon (including pads and plasters) Salicylic acid 8.50 7.97 to 9.03
Cryotherapy cost (liquid nitrogen and 
equipment cost)
Cryotherapy 60.05 57.57 to 62.53
Additional visit to GP Salicylic acid 0.35 –0.17 to 0.86
Cryotherapy 1.15 –0.09 to 2.38
Additional visit to nurse Salicylic acid 0.78 0.24 to 1.31
Cryotherapy 0.49 0.06 to 0.93
Total costs Salicylic acid 49.22 42.39 to 56.04
Cryotherapy 150.39 135.65 to 165.13
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both treatments based on the treatment visits only rather than including the cost of medication 
as well. Table 25 presents the results of the sensitivity analysis. Cryotherapy is again more costly 
than salicylic acid treatment. This is because of the greater number of treatment visits that 
the patients made, even though the cost of the health-care professional who administered the 
cryotherapy was lower (nurse vs GP).
TABLE 24 Mean difference in adjusted costs and outcomes (BCA 95% CI)
Variable Mean difference 95% CI ICER
Costs (£) 101.21 84.18 to 118.25 Cryotherapy is dominated
Outcomes –0.00336 –0.09 to 0.08
FIGURE 3 Cost-effectiveness plane for unadjusted and adjusted costs and outcomes.
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Figures 5 and 6 present the CE planes and CEACs for both unadjusted and adjusted results of the 
sensitivity analysis. Cryotherapy remains more costly and all of the bootstrapped replicates of 
difference in costs are above the zero line, although outcome results do not change. The smaller 
difference in costs between the two treatments (compared with the base-case analysis) results in 
cryotherapy having an approximately 40% probability of being cost-effective at a lower (than the 
base-case analysis) threshold.
Scenario 2: multiple imputation on the primary outcome data and on the 
missing total costs
Data were imputed by using multiple imputation methods for the 11 patients who had missing 
primary outcome data. The multiple imputations were performed by using age, previous 
treatment and type of verrucae as covariates. Data were imputed also for the missing total costs of 
these 11 patients.
The mean differences in costs and outcomes after multiple imputation are presented in Table 26. 
The CE plane and CEAC are presented in Figures 7 and 8. The results of the multiple imputation 
do not alter the overall conclusion of the study that cryotherapy is more costly than salicylic acid 
and that there is no evidence of it being more effective.
Summary of findings
The EVerT trial has demonstrated that there is no evidence of a difference in effectiveness 
between cryotherapy and salicylic acid at 12 weeks. In fact, cryotherapy appears to be marginally 
worse than salicylic acid, without reaching statistical significance. Cryotherapy is also more 
expensive than salicylic acid, at an average incremental cost of approximately £101 per patient. 
This evidence results in cryotherapy being dominated (i.e. more costly, less effective) by 
salicylic acid.
Two scenarios for analysing the data were developed. One was based on complete case analysis 
for patients who had primary outcome data and mean imputation of cost data for the patients 
with missing information on different cost items. The second analysis was based on multiple 
imputation of the primary outcome and missing total cost data. Both analyses resulted in the 
same conclusions, i.e. cryotherapy is more costly and less effective than salicylic acid, and, hence, 
dominated by salicylic acid.
An extreme case sensitivity analysis was conducted by replacing the provision of treatment from 
a GP with nurses, and excluding the cost of cryotherapy equipment and liquid nitrogen, the 
TABLE 25 Difference in cost and outcomes
Variable Mean difference 95% CI ICER
Unadjusted
Costs (£) 9.18 7.09 to 11.26 Cryotherapy is dominated
Outcome –0.0065 –0.10 to 0.08
Adjusted
Costs (£) 9.17 7.00 to 11.33 Cryotherapy is dominated
Outcomes –0.00336 –0.09 to 0.08
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implicit assumption being that the equipment has a dual use. However, this analysis still resulted 
in cryotherapy being more expensive than salicylic acid. By excluding the cryotherapy treatment 
costs completely and reducing the cost of the health-care professional who administers the 
treatment it is made evident that the results are strongly driven by the lack of effectiveness as well 
as the larger number of treatment visits that cryotherapy patients have. When the costs of the 
FIGURE 5 Cost-effectiveness planes for unadjusted and adjusted costs and outcomes.
FIGURE 6 Cost-effectiveness acceptability curve for the sensitivity analysis.
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TABLE 26 Mean difference in costs and outcomes after multiple imputation
Variable Mean difference 95% CI ICER
Costs (£) 101.39 86.29 to 117.29 Cryotherapy is dominated
Outcomes –0.0083 –0.10 to 0.08
40 Economic analysis
cryotherapy equipment and liquid nitrogen are included, it is found that cryotherapy is even less 
cost-effective.
In conclusion, self-treatment with salicylic acid is more cost-effective for the treatment of 
verrucae than cryotherapy administered by a health-care professional.
FIGURE 8 Cost-effectiveness acceptability curve (multiply imputed data).
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FIGURE 7 Cost-effectiveness plane (multiply imputed data).
140
120
100
80
60
40
20
0
–20
–0.3 –0.2 –0.1 0.0 0.1
D
iff
er
en
ce
 in
 c
os
ts
 (£
)
Difference in proportions
0.2 0.3
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
41 Health Technology Assessment 2011; Vol. 15: No. 32DOI: 10.3310/hta15320
Chapter 6  
Discussion
Here we report the results of a large RCT assessing the clinical effectiveness and cost-effectiveness of cryotherapy and salicylic acid for the treatment of verrucae. We were 
motivated to conduct this trial when the Cochrane systematic review into the treatment of 
cutaneous warts highlighted the lack of good-quality evidence to support the use of cryotherapy 
over simple topical treatments. This discussion summarises the key findings, compares these 
results with published studies, considers the strengths and limitations of the present study and 
summarises the clinical and research implications of the work.
Key findings
We compared the clinical effectiveness and cost-effectiveness of cryotherapy using liquid nitrogen 
and 50% salicylic acid for the treatment of verrucae and found no evidence to suggest that 
cryotherapy was more effective than salicylic acid in clearing verrucae. Overall, 32 of 229 (14.0%) 
patients had complete clearance of all verrucae at 12 weeks; 17 out of 119 (14.3%) were in the 
salicylic acid group and 15 of 110 (13.6%) in the cryotherapy group, p = 0.89. When the analysis 
was repeated, adjusting for potentially important prognostic variables (age, whether or not the 
verrucae had previously been treated and type of verruca), there was no difference in the overall 
findings (OR 0.96, 95% CI 0.44 to 2.11; p = 0.92). In addition, cryotherapy is associated with 
higher costs per cured patient. The combination of lack of difference in effectiveness between 
cryotherapy and salicylic acid, and higher costs leads to cryotherapy being dominated by salicylic 
acid. Sensitivity analysis conducted by completely excluding the cost of liquid nitrogen and the 
cost of cryotherapy equipment, and assuming that the provision of the treatment is undertaken 
by a nurse instead of a GP, did not alter the conclusions of the study, i.e. there is very small 
probability of cryotherapy being cost-effective for a wide range of willingness-to-pay values. The 
sensitivity analysis clearly demonstrates, primarily, the lack of treatment benefit of cryotherapy 
over salicylic acid and, secondly, that the larger number of treatment visits required for the 
cryotherapy drives the cost-effectiveness results.
Comparison with other studies/reviews
Our results confirm the findings of the two published studies25,26 and the results from a more 
recent Dutch primary care study,15 which compared cryotherapy with a salicylic acid or a 
combination of salicylic and lactic acid for the treatment of plantar and hand warts. These 
previous studies, like ours, showed no evidence for the effectiveness of cryotherapy compared 
with salicylic acid alone or in combination with lactic acid for the treatment of plantar warts. 
In Figure 9 we put the two studies reporting clearance rates for plantar warts15,26 (including our 
own) in a meta-analysis (the results of the Bunney et al. trial25 have not been included, as this trial 
included only participants with hand warts), which shows that the OR for cure is 1.07 (95% CI 
0.63 to 1.79). This result is not statistically significant and indicates that the odds of clearance of 
verrucae was similar in both groups.
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Our trial, however, does differ from the previous studies with respect to the cure rate. The cure 
rate in previous studies ranged from about 30%15 to 68%,26 which is at least twice the cure rate 
we observed.
This difference in cure rate could be attributed to different populations recruited to the study. 
The type of wart being treated was different between the studies. For example, Bunney and 
colleagues25 included only patients with hand warts, whereas Steele and Irwin26 excluded what 
are generally regarded as harder-to-treat mosaic warts. They also excluded patients with five or 
more lesions, lesions outside an average diameter of 3–9 mm and patients who had self-treated 
within the past month. In our study, 22% of participants had a mosaic wart, 17% had more than 
five verrucae and patients were not excluded if they had tried previous treatment. There was 
a difference in the age of the populations. Patients were younger in the Steele and Irwin25 and 
Bruggink et al.15 studies, with 59% of participants under the age of 16 in the Steele and Irwin 
study25 compared with 17.3% in our study. The median age of patients in the Bruggink et al. 
study15 was 15 [interquartile range (IQR) 7–39] for cryotherapy patients and 13 (IQR 7–31) years 
for salicylic acid patients compared with median ages of 24 years and 23 years, respectively, in 
our study.
Treatment regimen
We anticipated that a large percentage of potential participants would have received some form 
of treatment of their verruca prior to entry into the trial. In the UK the first line of treatment 
is generally an OTC salicylic acid preparation with a strength of 15–26% salicylic acid, with 
cryotherapy treatment using liquid nitrogen and higher concentrations of salicylic acid viewed 
as second-line treatments. This appeared to be the case, as 78% of our participants reported 
receiving some form of treatment and, of this 78%, 88% reported that they had self-treated and 
29% reported receiving treatment from a GP or a podiatrist. We considered it unlikely that 
patients would be willing to be randomised to a treatment that they had previously tried and 
found to be ineffective, so in order to maximise recruitment to the study we decided to use a 50% 
salicylic acid preparation for that arm of the trial.
The 50% salicylic acid preparation chosen was an OTC medication, available as a ‘pharmacy-
only’ medication, and was used within its marketing authorisation. Although we wished to 
replicate how this OTC treatment would be delivered in normal practice as far as possible, it was 
felt that in order to enhance patient safety, participants allocated to salicylic acid should be seen 
for a safety check at 2 weeks post randomisation. Using a 50% salicylic acid preparation had the 
additional benefit that this was a similar concentration to that often used by podiatrists to treat 
FIGURE 9 Forest plot of RCTs comparing salicylic acid and cryotherapy for the treatment of verrucae.
Study Odds ratio (95% Cl)
No. of events
Cryotherapy Salicylic acid
Steele 1988 26 1.97 (0.62 to 6.23) 15/26  9/22
Bruggink 2008 15 0.84 (0.33 to 2.18) 11/38 14/43
EVerT 0.95 (0.45 to 2.00) 15/110 17/119
Overall 1.07 (0.63 to 1.79) 41/174 40/184
Odds ratio
Favours salicylic acid Favours cryotherapy
0.2 0.3 0.5 1  2  4  8
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verrucae. If the results of the study demonstrated daily patient self-treatment to be more effective 
than cryotherapy then it would seem likely that podiatrists using a similar concentration of 
salicylic acid would be able to achieve similar cure rates.
A strength of this study is that it was a pragmatic trial. As far as possible we allowed clinicians to 
follow their normal practice in terms in delivering of the cryotherapy treatment. Consequently, 
we asked the clinicians to treat the verrucae as they would in normal practice, with the 
recommendation that the first freeze should be relatively gentle, in order to assess how well the 
patient could tolerate the treatment. Subsequent treatments could be more aggressive if it were 
appropriate and the patient was able to tolerate the treatment. Pooled data from Gibbs et al.’s 
systematic review8 demonstrated that higher cure rates could be achieved if a more aggressive 
cryotherapy regimen was used. However, these trials were in different populations and on 
different types of warts. They also used different definitions of ‘aggressive treatment’ ranging from 
one 10-second freeze to 2 minutes with a cryoprobe. We did originally propose that verrucae 
should be treated by applying three 10-second applications of liquid nitrogen; however, most 
health-care professionals reported that this did not reflect their normal practice and that they 
were unwilling to follow what they considered to be such an aggressive regimen.
In terms of frequency of freezing, evidence from Gibbs et al.’s systematic review8 showed no 
significant difference in long-term cure rates between applying cryotherapy treatments at 2-, 
3- or 4-weekly intervals and no significant benefit to prolonging 3-weekly cryotherapy treatments 
beyond 3 months (approximately four freezes). It was decided that cryotherapy patients should 
therefore receive a maximum of four treatments, 2–3 weeks apart. Treating at 2- to 3-week 
intervals allowed the treatment to be delivered followed by a minimum of 3 weeks before the 
outcome assessment at 12 weeks to allow the participant to heal. This would minimise the 
possibility of unblinding the outcome assessor to the treatment group.
From the limited data available on adherence to treatment, the salicylic acid patients were 
applying their salicylic acid for the first 3 weeks. However, the overall amount applied (mean 
amount applied 2.8 g) could suggest that either patients stopped self-treating after the third week 
or the amount applied during the course of the 8 weeks was relatively small. For some deep-
seated verrucae, this might not have not been sufficient to clear the verruca.
Patient satisfaction with treatment
The majority of participants in both groups were happy with their treatment at week 1 and week 
3. However, there was a difference in patient satisfaction between the two groups at week 12. The 
majority of the cryotherapy group reported that they were happy with their treatment, and only 
13% reported being unhappy. However, the salicylic acid group individuals were less happy with 
their treatment at week 12 than at previous time points. In addition to this, a larger proportion of 
salicylic acid patients (31%) were unwilling to have the same treatment again compared with only 
10% of cryotherapy patients.
Strengths and limitations of the study
This is a large pragmatic study that recruited patients with longstanding verrucae, the 
majority of which had been previously treated either by the patient themselves or by a health-
care professional. This is typical of the characteristics of patients presenting to health-care 
professionals for treatment.
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We were able to undertake a blinded outcome assessment for the primary outcome by a clinician 
present with the patient at the 12-week visit for the majority of participants and we had to rely on 
blinded assessment of photographs. However, our experience of using cameras to obtain outcome 
assessments was not without challenges. First, some sites found it difficult to find the additional 
time required to take digital photographs during busy clinics and, second, the quality of several 
photographs was such that an assessment of clearance could not be made. It was anticipated that 
as the cameras given to sites were a similar make and model to that used successfully on another 
NIHR HTA-funded trial,24 and because members of the EVerT research team owned their own 
digital cameras and used them to take photographs outside work, the quality of the photographs 
would not be too great an issue. However, members of the research team encountered difficulties, 
as they rarely took photographs of such a relatively small scale out of work, and overall a total of 
31 out of 190 (16%) photographs were uninterpretable. In an effort to improve the quality of the 
photographs taken, researchers took several photographs at the same time point and reviewed 
them on an ongoing basis, taking additional photographs if necessary. However, on several 
occasions it was noted that although the photographs appeared to be of an acceptable quality on 
the camera’s LCD screen, once uploaded/sent to the YTU the quality of the photograph meant 
that an assessment was not possible. Further issues were raised in the amount of time it took to 
send photographs to the YTU. At the time of undertaking the trial it was not possible to upload 
the photographs directly to the YTU so the photographs had to be sent via e-mail or copied 
on to a disk and put in the post, both of which were time-consuming. The delay in sending 
photographs to the YTU, which in some cases was several weeks, meant that it was not possible 
to always monitor the activity at the site, for example adherence to treatment regimen, as closely 
as we had first envisaged. Despite these problems, we were still able to achieve blinded outcome 
data from digital photographs for a total of 159 (69.4%) participants and overall for 206 (85.8%) 
of the 240 trial participants when we combined the blinded clinician assessment at 12 weeks with 
the blinded photographic assessment.
One limitation of our study is the lack of a no-treatment group, so we were unable to determine 
the spontaneous clearance rate of verrucae in this population. We did consider having a 
no-treatment arm to the study, but decided against this for several reasons. First, Gibbs and 
Harvey’s systematic review8 showed that salicylic acid was more effective than no treatment, 
while failing to find any evidence for the effectiveness of cryotherapy. Therefore, the important 
clinical question was whether or not the use of cryotherapy was superior to that of the salicylic 
acid treatment. Second, overall recruitment to the study could have been jeopardised, as patients 
might have been unwilling to be randomised to a no-treatment arm. Finally, a no-treatment arm 
might have led to bias owing to resentful demoralisation, particularly in those patients in whom 
the verrucae were painful, longstanding and resistant to previous treatment.
Generalisability of the results
The EVerT study was a pragmatic trial that recruited from 14 centres across England, Scotland 
and Ireland. The inclusion of patients recruited from podiatry clinics, from GP practices and 
from the community means that we can be confident that these results are broadly generalisable 
and that the study has external validity across the UK and Ireland. However, although the 50% 
salicylic acid preparation used in this study was an OTC treatment, it is not the most commonly 
used concentration and may be viewed as a second-line treatment. Typically, weaker preparations 
of 15–26% salicylic acid are used as the first form of treatment and so the results of this study 
may not mimic the usual clinical situation. Therefore, it is possible that cryotherapy using liquid 
nitrogen is superior to using these lower concentrations of salicylic acid. However, some GPs are 
no longer offering cryotherapy using liquid nitrogen as a form of treatment. This is because of the 
additional treatment cost incurred in order to comply with changes to the health and safety rules 
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regarding the storage of liquid nitrogen. Therefore, the availability of the treatment may be lower 
than that reported in 2002 and, in some cases, may be considered a third-line treatment.
Implications for health care
There is no evidence from this trial to suggest that cryotherapy used for the treatment of verrucae 
is more effective than patient self-treatment with 50% salicylic acid and our economic evaluation 
concludes that self-treatment with salicylic acid is the most cost-effective option. Our results are 
applicable only to verrucae or plantar warts. Warts at other sites, such as the hands, may respond 
differently to cryotherapy.
We evaluated only patient self-treatment with salicylic acid and, therefore, the results cannot 
be extrapolated to the effectiveness of salicylic acid if it had been delivered by a health-care 
professional. The freezing agent used for the cryotherapy was liquid nitrogen, so the results from 
this study cannot be extrapolated to include other freezing agents, such as nitrous oxide, frozen 
carbon dioxide (dry ice) or OTC freezing treatments, which freeze lesions at higher temperatures.
Implications for research
Health-care professionals will need to write patient information sheets in such a way to give 
patients realistic expectations in relation to the effectiveness of cryotherapy treatment.
There are other treatments available for cutaneous warts, but very little good-quality evidence 
assessing their effectiveness. Further research assessing the effectiveness of these treatments is 
required in order to inform future practice.
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Appendix 1  
Regulatory approvals
Research site Ethical site assessor
Date of favourable 
ethical opinion R&D approval
Competent 
authority approval 
School of Podiatry, Centre for 
Healthcare Education School of 
Podiatry, University of Northamptona
Leicestershire, 
Northamptonshire & Rutland 
REC 2
26 October 2004  N/A 8 February 2005
With approval to contact GPs with 
the PCT Leicestershire Primary Care 
Alliance
6 November 2006 4 January 2007
University of Brighton (Leaf Hospital) 
and Eastbourne PCT Sussex NHS 
Research Consortium
East Sussex LREC 23 September 2006 24 October 2006 10 August 2006
Southern General Hospital, South 
University Division, Greater Glasgow 
and Clyde Health Board and 
Glasgow Caledonian University
South Glasgow and Clyde REC 29 March 2007 21 December 2007 13 November 2007
Huddersfield University, Division of 
Podiatry, Department of Clinical and 
Health Sciences, Huddersfielda
Airedale REC 5 May 2007b
3 December 2008b
15 June 2007 13 November 2006
Brownlow Group Practice, Liverpool Liverpool Paediatric REC 13 May 2007 19 September 2007 26 June 2007
Springfield Surgery, Bingley Bradford REC 5 December 2007 21 November 2007 12 October 2007
Sheffield PCT North Sheffield LREC 3 April 2008 28 August 2008 23 April 2008
Claughton Medical Centre, 
Birkenhead
Cheshire REC 3 November 2008 10 March 2009 9 July 2008
Arlington Road GP Surgery, 
Eastbourne
Brighton East REC 23 December 2008 23 January 2009 4 December 2008
Harbinson House, Sedgefield Research Management & 
Governance Unit of County 
Durham & Tees Valley PCTs
6 October 2009 6 October 2009 16 October 2009
Sacriston Surgery, Sacriston Research Management & 
Governance Unit of County 
Durham & Tees Valley PCTs
7 August 2009 28 July 2009 29 July 2009
Peaseway Medical Centre, Newton 
Aycliffe
Research Management & 
Governance Unit of County 
Durham & Tees Valley PCTs
7 August 2009 28 July 2009 29 July 2009
The Haven Surgery, Burnhope Research Management & 
Governance Unit of County 
Durham & Tees Valley PCTs
7 August 2009 28 July 2009 29 July 2009
The National University of Ireland,a 
Galway
Galway REC 20 March 2009  N/A 30 January 2009
N/A, not applicable; R&D, research and development; REC, research ethics committee.
a Non-NHS site.
b Approval for change in principal investigator.
Approval was gained at two additional sites; neither was able to start recruitment.
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Appendix 2  
Details of the study sites
The following sites recruited at least one patient:
 ■ The University of Northampton Podiatry School Clinic, Northampton
 ■ The University of Huddersfield Podiatry School Clinic, Huddersfield
 ■ The University of Brighton Podiatry School Clinic at the Leaf Hospital, Eastbourne
 ■ Southern General Hospital, Glasgow/Glasgow Caledonian University Podiatry School, 
Glasgow
 ■ The National University of Ireland, Galway (NUI Galway) Podiatry School Clinic, Galway
 ■ Brownlow Group Practice, Liverpool
 ■ Springfield Surgery, Bingley
 ■ Sheffield Primary Care Trust Podiatry Clinic, Sheffield
 ■ Sacriston Surgery, Sacriston
 ■ The Haven Surgery, Burnhope
 ■ Peaseway Medical Centre, Newton Aycliffe
 ■ Arlington Road Medical Practice, Eastbourne
 ■ Claughton Medical Centre, Birkenhead
 ■ Harbinson House Surgery, Sedgefield.
Approval was gained and an initiation visit was performed at the following two sites, but neither 
recruited any patients:
 ■ Annfield Plain Surgery, Stanley, Co. Durham
 ■ Islington Primary Care Trust Services, London.
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Appendix 3  
Patient information sheets and consent form
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Patient information sheets
 1 
                                                Local headed paper  
 
 
DEPARTMENT OF HEALTH SCIENCES 
 
 
A STUDY OF DIFFERENT TYPES OF TREATMENT FOR VERRUCAE 
 
 
Information Sheet 
Version 7  16 Oct 2008 
 
You are being invited to take part in a research study, which aims to find out the best way 
to treat verrucae.  Before you decide if you would like to take part you will need to 
understand why the research is being done and what it will involve.  We would be grateful if 
you would read the following information and discuss it with your family and friends if you 
wish.  Please ask if there is anything that is unclear or if you need more information and 
take time to decide whether or not you would like to take part.     
 
What is the purpose of this study? 
Verrucae are a common, infectious and sometimes painful problem.  Most verrucae will 
disappear spontaneously after 6 to 12 months without treatment.  However, patients may 
seek treatment from a podiatrist/GP/other Health Care professional if their verruca is 
painful or because they are being prevented from doing sports. There are many different 
ways to treat verrucae but it is unclear which treatment is best.  The purpose of this study 
is to compare two of those treatments, an acid paste which you can buy over the counter 
from a pharmacist and a freezing technique, which is currently used to treat verrucae within 
the Podiatry Department/GP practice/other clinic at (insert name of specific site). We want 
to find out which is the best treatment to cure verrucae and what you thought about the 
treatment.  We are also interested to know how much the treatments costs. 
 
Who is carrying out the research? 
This is a joint research project between the Podiatry Department/GP clinic/other clinic at 
(insert name of specific site) and the York Trials Unit.  Qualified HCP at the clinic led by 
(HCP name) will treat all the patients.  Two researchers, (name of researchers) from the 
Trials Unit at York University will collect and analyse the data.  
 
Who is funding the research? 
The NHS Health Technology Assessment Programme is paying for the research.  
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Why have I been chosen? 
We are inviting all patients attending the Podiatry Department at GP practice/other clinic 
(insert name of specific site) who have a verruca to participate in this study.  We hope to 
study 266 patients in total. 
 
Do I have to take part? 
It is completely up to you if you would like to take part.  If you do decide to take part you 
will need to sign the consent form.  For patients under the age of 16 a parent or guardian 
will be asked to sign as well.  If you decide to take part you are still free to withdraw at any 
time and without giving a reason.  A decision to withdraw at any time or a decision not to 
take part, will not affect the standard of care you receive.     
 
What will happen to me if I take part? 
If you wish to take part you will need to complete the questionnaire and consent form and 
take it with you when you attend the podiatrist/GP/ practice nurse/other health care 
professional for your first appointment.  Because we do not know which of the two 
treatments is best we need to make comparisons by putting patients into two different 
groups.  Which group you are put in depends on chance and is rather like tossing a coin.  
You will have a 50:50 chance of getting either treatment.  Patients will have been sent an 
appointment by the podiatry clinic to have their verruca treated along with this information.  
All patients will be seen by the podiatrist/ GP/practice nurse/other health care professional 
at their first appointment.  Those assigned to the salicylic acid paste treatment will be 
shown how to apply it.  You will then be asked to take the treatment home with you and 
apply it daily up to a maximum of 8 weeks.  We will also ask you to attend a further 
appointment in two week’s time. Those assigned to the cryotherapy group will be required 
to attend follow-up appointments as required when the verruca will be re-treated if 
necessary depending on your verruca.  At 12 weeks after the first treatment, all patients 
will be asked to attend for a final assessment of whether their verruca has been cured, 
even if their verruca has been cured before this time.  We will take a photograph of your 
verruca at the start of the study and then regularly to see if your verruca is reducing in size.  
In this study it is important that the podiatrist carrying out this assessment remains 
unaware of the treatment you have received.  We will therefore ask you not to mention or 
talk about the treatments you have received during the trial to the person carrying out this 
assessment.  In order to help cover your travel costs to take part in this trial, we will 
reimburse you £5/£10 for each visit up to the 12 week visit you make for treatment for your 
verruca and £20 for the 12 week visit.  You will also be sent four further questionnaires by 
the University of York at 1, 3, 12 and 24 weeks after you agreed to take part in the study. 
You can choose to complete either paper or on-line versions of these questionnaires. If 
after 12 weeks your verruca has not cleared up at this stage, the podiatrist will advise you 
of the best course of action, which may include further treatment.   
 
What do the two types of treatment involve? 
The first treatment involves the application of an over the counter preparation of a salicylic 
acid paste to the verruca.  The podiatrist/GP/nurse/other healthcare professional will show 
you how to apply the paste at your first appointment.  You will then be given the treatment 
to take home with you and asked to apply it daily up to a maximum of 8 weeks.     The 
second option is the application of liquid nitrogen to the verruca tissue for ten to twenty 
seconds each treatment, and again this will be repeated every two weeks for a maximum 
of four treatments.   The area will be padded after treatment and you will be advised how to 
care for the foot after treatment.    
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What are the side effects of any treatment received when taking part? 
Occasionally, people report mild discomfort either during or after treatment.  If this happens 
then report it to the podiatrist who will advise you how best to deal with this.  If you become 
in any way concerned then contact (name of podiatrist/ GP practice nurse/other health care 
professional, Podiatrist/GP/practice nurse/other type of health care professional on tel 
(insert telephone number). 
 
What are the possible benefits of taking part? 
We hope that both the treatments will help you.  However, this cannot be guaranteed.  The 
information we get from this study may help us to treat future patients with verrucae better. 
 
What happens when the research study stops? 
You will still receive treatment after the study has stopped, if this is necessary.  The 
podiatrist will consult with you on the best course of action. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have 
grounds for a legal action but you may have to pay for it.  Regardless of this, if you wish to 
complain, or have any concerns about any aspect of the way you have been approached 
or treated during the course of this study, the University of York Trial’s Unit complaints 
mechanisms will be available to you, alternatively the normal National Health Service 
complaints mechanisms may be available to you.   
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential, both at the clinic where you receive treatment and at the University of 
York.  This will be in accordance with the Data Protection Act 1998.  Your General 
Practitioner will be notified that you are taking part in the study.  Study information must be 
made available to the Medicines and Healthcare Products Regulatory Agency, which 
supervises drug trials in the UK, and the relevant ethics committees in the UK. 
Representatives of these bodies may also examine your hospital or clinical records and, by 
signing the consent form, you are giving permission for these records to be examined. 
These organisations have strict policies regarding confidentiality.  No records bearing your 
name will leave the hospital/clinic where you take part in the study. Your study data, that 
will be transmitted to the York Trials Unit for analysis, will be identified by a Patient ID 
Number only. 
 
What will happen to the results of the research study? 
All the participants in the study will be personally informed about the results once the study 
is completed.  It is intended to publish the results in approximately Autumn 2010 in a 
suitable medical journal.  If participants wish to obtain a copy of the published results they 
should contact the podiatry clinic for details.  Individual participants will not be identified in 
any publication. 
 
What do I do if I don’t want to take part in this study? 
No problem, when you attend the clinic to see the podiatrist your treatment will not be 
affected by this.  However, even if you do not want to take part in our study we would very 
much like you to fill in the questionnaire and return it to the podiatrist when you attend for 
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treatment because we would like to know about the health of all people with verrucae.  
(You do not have to give personal details if you would prefer not to). 
 
Who has reviewed the study? 
This study has been reviewed and approved by Trent Multi Research Ethics Committee. All 
research that involves NHS patients or staff, information from NHS medical records or uses 
NHS premises or facilities must be approved by a NHS Research Ethics Committee before 
it goes ahead.  Approval does not guarantee that you will not come to any harm if you take 
part.  However, approval means that the Committee is satisfied that your rights will be 
respected, that any risks have been reduced to a minimum and balanced against possible 
benefits, and that you have been given sufficient information on which to make an informed 
decision to take part or not.   
 
What do I do if I do want to take part in this study? 
If you are interested in taking part please complete the enclosed questionnaire and sign 
the consent form, returning it to the podiatrist when you attend for your first appointment.   
 
Where can I get further information about the study? 
If you require any further help or information please do not hesitate to contact either 
(Podiatrist/GP/practice nurse/other health care professional name) the 
podiatrist/GP/practice nurse/other health care professional telephone number) or  
researcher’s contact details.  
 
What if I have any concerns?   
If you have any concerns or other questions about this study or the way it has been carried 
out, you should contact the investigator [name etc], or you may contact the hospital/PCT 
[name etc] complaints department or the trial coordinator (name of trial coordinator).   
 
 
 
THANK YOU FOR TAKING THE TIME TO READ ABOUT THIS STUDY 
 
https://www.hsytu.york.ac.uk/verruca/login.aspx 
 
https://www.verrucatrial.co.uk 
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                                                           Local headed paper  
(Information leaflet version 4 25/07/2007 for children over 12) 
Invitation 
 
The project on “treating verrucae” 
 
Hello 
 
My name is (name of researcher) and I work at the University of York looking at 
different ways of removing verrucae.  This leaflet is to invite you to take part in a 
project which is looking at two common ways of treating verrucae.  At the moment I 
am are not sure which is the best way, but doing this project should help me find out.      
 
Why am I writing to you? 
I am inviting everyone with a verruca who is going to the clinic to see if they would 
like to take part in this project.  We hope 266 people will take part.      
 
How did you get my name and address? 
If you get a leaflet from me it is because the person caring for you has given me 
permission to contact you. 
 
What is the point of the project? 
The information from the project can help in three ways:   
It will tell me which of these two ways is best at curing a verruca. 
It will give me an idea if one treatment costs more than the other. 
It will tell me what you thought about the treatment you had.    
 
What will I have to do? 
If you want to take part, you simply fill in the questionnaire and consent form and give 
it to the person who is treating your verruca.  They will arrange for you to come to 
the clinic and at the end of 12 weeks will look to see if your verruca has gone.  We will 
take a photograph of your verruca at the start of the study and then regularly to see 
if your verruca is reducing in size.   
 
I will send you four more questionnaires to fill in to find out how you felt about the 
treatment you had, how many times you had to go to the clinic and about how you got 
there.   If you like you can choose to fill these questionnaires in on-line.   
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What are the treatments being used in this study? 
 
There are lots of different ways of treating verruca, but in this study we are using 
two different treatments, a freezing method and an ointment.   
 
If your verruca is frozen, then your podiatrist/GP/nurse/ other HCP will apply a very 
cold liquid called nitrogen, to your verruca until it is frozen.  Depending on its size this 
may take up to 30 seconds to freeze.  You may be asked to come back to the clinic for 
a maximum of four treatments.  But there will be a two/ three week gap in between 
each treatment.   
 
The other treatment we are testing is an ointment.  There are several different 
ointments available but in this study we are using one called Verrugon.  Your 
podiatrist/GP/nurse/ other HCP will tell you and the person caring for you how to 
apply it safely and give you some to take home with you. You may be asked to apply it 
every day for a maximum of eight weeks.  We will ask you to come back to the clinic 
two weeks after you started in the study to make sure you are not having any 
problems and to give you some more ointment if you need it.    
 
We will ask everyone to come back to the clinic 12 weeks after they began the study 
to see if their verruca has gone and to take a photograph of it.  
 
What treatment will I get? 
Which treatment you get is a matter of chance. It is like tossing a coin to decide 
which of the treatments you will get.   This makes it a fair test.   
 
What happens to the information? 
All the information you send back to me is put into a computer where we will be able 
to see which is the best way to remove verrucae.   
 
Will anyone else be told what I say? 
No, everything in the questionnaire is confidential.  Your name will not be used in any 
articles we write about this project.   
 
Do I have to take part in the project? 
No, you do not have to take part in the project.  If you decide not to take part, I will 
accept your decision and I will not ask you to give a reason.  
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What happens next? 
If you decide you would like to take part in this project, please fill in the forms with 
this letter and take it with you and give it to the person who is treating your verruca.   
 
Thank you for reading this letter. 
 
Name of researcher 
 
 
 
 
 
 
 
  
If you want to contact me to talk about the project, telephone 
(insert telephone number) between 9:30am and 2:00pm Monday to 
Friday.  If I am not there please leave a message on the answer 
phone.   
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Consent form
Version 5  16/10/2008 
Once completed: 1 copy for the patient, 1 in the site file and 1 in the medical notes 
 
 
CONSENT FORM 
 
Title of Study:  A Study of Different Types of Treatment for 
Verrucae. 
  
Investigator’s Name:  (Podiatrist’s Name, position and name of site) 
 
Please initial the boxes. 
 
1. I confirm that I have read and understand the information        
sheet version [insert number] dated [insert date], or for children  
under the age of  16 version [insert number]  dated [insert date]  
for the above study and have had the opportunity to ask questions. 
 
 
2. I understand that my participation is voluntary and that 
I am free to withdraw at any time, without giving any 
reason, without my medical care or legal rights being affected 
 
 
3. I understand that sections of any of my medical notes may be 
looked at by responsible individuals from the podiatry   
department/GP practice at (name of centre) or other members of the NHS 
Trust, representatives of the Study’s Sponsor (university of York) and 
regulatory authorities, where it is relevant to my taking part in research.   I 
give permission for these individuals to have access to my records. 
 
4. I understand that my General Practitioner will be informed  
that I have taken part in this study. 
 
 
5. I agree to take part in the above study. 
 
6. I agree to have my verruca photographed.  
 
 
_______________________      ____________________  ___________ 
Patient name (please print)   Patient Signature              Date 
 
 
_______________________      ____________________  ___________ 
Name of *Parent/Guardian            Signature of *Parent/Guardia        Date 
(*Please delete as appropriate)    (*Please delete as appropriate) 
 
 
________________________    ____________________  ___________ 
Name of researcher taking  Signature of researcher            Date 
consent (please print)  
 
Patient’s date of birth ____/______/______ 
                                     day   month    year 
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                                      Insert trust logo 
EVerT Effective Verruca Treatments 
 
 
What is cryotherapy? 
 
Cryotherapy is used to treat various skin conditions, including warts on the 
body and verrucae on the feet (both caused by versions of the human 
papilloma virus).  
 
The treatment causes a skin irritation or a surface wound, through the 
application of liquid nitrogen which briefly freezes the skin.  This is either by 
means of a fine spray to the area, or by applying liquid nitrogen directly using 
a probe or cotton bud tip.  The treatment aims to trigger a response from your 
immune system, to this and all other warts or verrucae which you may have.  
 
Application of liquid nitrogen onto the skin can be briefly uncomfortable, due 
to the extreme cold when the area is frozen.  This is normal.  The length of 
time of freezing will depend on the depth and size of verruca being treated, 
the duration being agreed between you and your clinician beforehand.  
Usually a 10 second freeze is agreed, though often shorter for initial sessions 
in order to assess your body’s reaction to cold.  However, you can halt the 
treatment at any point, if it becomes too uncomfortable for you.   
 
What can I expect afterwards? 
 
Depending on the length of freezing time, the skin may show no reaction, or 
some reddening, or occasionally it may develop a blister or a deep bruise (as 
with a burn from heat).  This is normal.  The area may also feel a little 
uncomfortable after treatment.  Depending upon its location, your clinician 
may choose to pad the area to promote comfort, or to tape it in order to deter 
the development of a blister (making a bruise more likely). 
 
In all cases, you should keep the area as clean and dry as possible for the 
following 24 hours, in order to deter any infection at the site.  After 24 hours, 
remove the pad or dressing and inspect the area yourself.  If there appears to 
be an open wound (with a possibility of infection), then continue protecting the 
area with sticking plasters until it has healed.  If the surface of the skin 
appears intact, you may continue with your normal activities without any 
further dressings.  
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Your clinician will arrange a review appointment with you after cryotherapy to 
check the area and repeat the treatment as appropriate.  It is important that 
you attend this appointment. 
 
In the unlikely event that you experience excessive pain or a weeping 
discharge at the treatment site, or you have any concerns about the treated 
area, please contact the clinic for advice. 
 
In the first instance please contact: 
 
**************  Tel:  ***************** 
 
If unavailable please contact the podiatry clinic on: 
 
Tel:  ***************** 
 
where reception staff will be able to put you in contact with another clinician 
for advice. 
 
Insert web site details  
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EVerT Effective Verruca Treatments                                                                             Insert trust  logo 
 
 
What is acid therapy? 
 
Salicylic acid is used to treat various skin conditions, including warts on the 
body and verrucae on the feet (both caused by versions of the human 
papilloma virus).  
 
The treatment causes a skin irritation or a surface wound, through the 
application of an acid which dehydrates and damages the surface of the skin.  
The acid can be of various strengths, from 5 - 10% (Bazuka) to 50% 
(Verrugon).  The treatment aims to trigger a response from your immune 
system, to the treated wart and all other warts or verrucae which you may 
have. 
 
It is rare for application of salicylic acid to the skin to cause any pain or 
discomfort.  However, if an extreme itching, reddening, allergy reaction does 
occur, the acid can be washed away with water.  You should also wash your 
hands after applying the acid, so as to prevent its accidental rubbing into your 
eyes (very painful).  
 
Care must be taken to avoid damaging the good skin which surrounds the 
wart or verruca, since this is where the replacement skin originates from.  You 
only need to apply sufficient acid to cover the surface of the skin, particularly 
underneath feet where pressure causes any excess acid to spread onto 
surrounding areas.   
 
How do I apply Verrugon? 
 
Verrugon is suitable for application at home by adults, and can be used with 
children under adult supervision.  Please read the details on the Verrugon 
box. 
 
1. Prior to treatment, any rough skin covering the verruca which is proud of 
the surrounding skin should be removed.  Use the small personal emery 
board supplied with the Verrugon kit, or additional ones from your local 
pharmacist, to file down the surface of the verruca.  However, be careful 
not to graze surrounding skin with the file, as this could spread the verruca. 
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2. As instructed by your clinician, place the hole of the felt pad above the 
selected, treatable verruca.  It is unusual to treat verrucae which are close 
to joints or the nails.  In the case of a large or mosaic wart, centre the hole 
over an identifiable edge where the active virus is closer to the surface. 
 
3. It is not necessary, nor is it desirable to cover a large area of skin with 
salicylic acid.  You should apply acid to the verrucous skin at the bottom of 
the hole in the felt pad – only sufficient to cover the skin.  The felt is 
intended to protect the surrounding good skin.  However, if you fill the hole 
with acid, the whole pad becomes an acid reservoir and too much skin 
damage may be caused. 
 
4. Cover the felt pad and acid treatment with one of the waterproof sticking 
plasters provided with the Verrugon kit.  The dressing enhances the 
penetrative effect of the acid and helps to keep it in place. 
 
5. Now wash your hands.  
 
The Verrugon kit provides enough felt and plasters to treat your verruca for 
nine successive days.  You should treat the same wart and location, day after 
day.  Be careful not to damage the surrounding skin.   
 
What can I expect afterwards? 
 
Some reddening of the skin may result from repeated use of the salicylic acid 
treatment.  If it becomes tender, sore or inflamed, wash away the acid with 
plain water and rest the area from further treatment until the situation has 
resolved. 
 
Your clinician will arrange a review appointment with you to check the area 
and your progress.  It is important you attend this appointment.  Additional felt 
rings and waterproof plasters may be provided at this time. 
 
In the unlikely event that you experience excessive pain or a weeping 
discharge at the treatment site, or you have any concerns about the treated 
area, please contact the clinic for advice. 
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In the first instance please contact: 
 
**************  Tel:  ***************** 
 
If unavailable please contact the podiatry clinic on: 
 
Tel:  ***************** 
 
where reception staff will be able to put you in contact with another clinician 
for advice. 
 
(Insert web site address)  
 
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
69 Health Technology Assessment 2011; Vol. 15: No. 32DOI: 10.3310/hta15320
Appendix 4  
Data collection forms
70 Appendix 4
Baseline patient questionnaire
A STUDY  OF DIFFERENT TYPES OF
TREATMENT FOR VERRUCAE
BASELINE QUESTIONNAIRE
Participant Number:
(For office use only) -
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE
Thank you for agreeing to take part in this evaluation.
Please answer ALL the questions. Although it may seem that questions are asked
more than once, it is still important that you answer every one.
If you find it difficult to answer a question, do the best you can.
Please follow the instructions for each section carefully.
For each section, if you are asked to put a cross in the box, please use a cross
rather than a tick, as if you were filling out a ballot paper.
For example in the following question, if your answer to the question is yes, you
should place a cross firmly in the box next to yes.
Do you drive a car ?
If you are asked to circle a number, please use a circle rather than underlining a
number.
For example, in the following question if you are asked 'how happy are you
today?' where '1' is 'very unhappy' and '5' is 'very happy', if you feel neither happy
nor unhappy you may wish to answer 3. You do this by clearly circling the
number 3.
Yes
No
1 2 3 4 5
PLEASE USE A BLACK OR BLUE PEN.
Please do not use a pencil or any other coloured pen.
Please read all the instructions for each section.
Very
unhappy
Very
happy
72 Appendix 4
Please complete all the sections in this questionnaire.  Thank you.
Please enter the date you are completing this questionnaire:
  day                   month                        year
/ /
This section asks about your verruca
1. How long have you had your current verruca?
(Please state in months and weeks)  months   weeks
2. Have you had any previous treatment for this verruca?
(Please cross one box)
Yes No
If 'YES' please cross all that apply2a.
Self-treatment using a preparation
bought over the counter  
If Yes,
please specify
Treatment from a podiatrist/
chiropodist
If Yes,
please specify
Treatment from your GP 
Other treatment,
please specify
Participated in a trial investigating
different treatments of verrucae
If other trial, please
specify treatment
What are the reasons for seeking treatment for this verruca? (Please cross all that apply)3.
The verruca is painful
It stops me from going swimming
It stops me from doing other sports
Other If other,
please specify
0 1 2 3 4
How painful is your verruca today?  (please circle one number only)4.
Not at all A little bit Moderately Quite a lot Extremely
Other types of treatment, please
specify
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Before this verruca, have you had any others?5.
Yes No Don't know
If you had a verruca before, how many have you had?5a.
How old were you when you had your last verruca?5b.
This section asks about your preferences
If you take part in the trial, we may wish to contact you for example to remind you to fill in a
questionnaire or ask you if your verruca has gone.  Please tell us how you would like us to
contact you? (Please cross all that apply)
2.
By post
By text
If text, please write your mobile telephone number here
By email
If email, please write your email address here
This section asks about your personal details
What is your date of birth? / /
Are you? Male Female
When is your appointment with the podiatrist? (The date of your appointment will have been sent to you with
this information pack.)
/ /
IF YOU WISH TO TAKE PART IN THIS STUDY PLEASE COMPLETE THE ENCLOSED CONSENT FORM
IF YOU DO NOT WISH TO TAKE PART IN THIS STUDY WE WOULD STILL APPRECIATE YOU RETURNING THIS COMPLETED
QUESTIONNAIRE.
THANK YOU FOR TAKING THE TIME TO COMPLETE THIS QUESTIONNAIRE.
If you take part in the trial, we would like you to fill in some more questionnaires. How would you
like to fill in these questionnaires? (Please cross one box only)
1.
Please send me paper copies like this one, in the post
I would like to fill the questionnaire in on-line
https://www.hsytu.york.ac.uk/verruca/login.aspx
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Randomisation form
  
 
 
A STUDY OF DIFFERENT TYPES OF TREATMENT FOR VERRUCAE 
 
Randomisation Form 
 
Patient’s trial number     -  
                       
Trial Centre              Eastbourne Leaf Hospital    � 
(Please cross 1 box only) Glasgow Caledonian Podiatry School  � 
    Northampton Podiatry School   � 
    Huddersfield Podiatry School    � 
                                     The Arlington Road Medical Practice Eastbourne � 
    Springfield Surgery Bingley    � 
    Claughton Medical Centre    � 
    Sheffield PCT      � 
    Galway – National University of Ireland  � 
    Sacriston Surgery     � 
    Peaseway Medical Centre    � 
    The Haven Surgery     � 
    Annfield Plain Surgery    � 
    Harbinson House     � 
     
Consent criteria 
           Yes           No 
 
1.      Is the patient able to provide informed consent? 
 
 
 
          Yes             No 
2. Has the patient provided informed written consent to                         
entering the trial? i.e. have they read and understood  
the patient information sheet and signed the patient  
consent form? 
 
Date form completed 
��-��-����� 
dd/mm/yyyy 
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Inclusion criteria        Yes          No 
 
1. Is the patient aged 12 or over?   
 
 
Yes           No 
 
2. Does the patient have a verruca which can be 
 treated with both salicylic acid and cryotherapy? 
 
Exclusion criteria 
          Yes                  No 
 
1. Does the patient have impaired healing  
eg due to diabetes, peripheral vascular disease? 
 
          Yes   No  
2. Is the patient currently participating in another trial  
for the treatment of their verrucae? 
      
              Yes        No 
3. Is the patient immunosuppressed (eg has 
agammaglobulinaemia) or currently taking  
      immunosuppressant drugs such as oral corticosteroids? 
 
          Yes        No 
4. Is the patient currently on renal dialysis?  
 
 
 
Yes        No 
5. Does the patient have cold intolerance?  
(eg Raynaud’s syndrome or cold urticaria) 
 
 
Yes        No 
 
6. Does the patient have any of the following conditions: 
Blood dyscrasias of unknown origin, cryoglobulinaemia,  
cryofibrinogenaemia, collagen and auto-immune disease? 
 
          Yes        No 
7. Does the patient have neuropathy?  
 
 
 
 
If any of the responses fall into the grey boxes then the patient is 
 NOT ELIGIBLE for the trial. 
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Patient details 
 
Patient’s title:     
 
Patient’s full name:  
    
Patient’s address:    
 
 
 
 
Patient’s postcode:     
 
Patient’s date of birth     /         /   /   
 
      day                month       year   
 
 
Patient’s telephone number:  
 
Name of patient’s GP: 
 
 
GP’s address: 
 
 
 
 
 
 
Parent/guardian details for patients aged under 16 
 
 
Parent/Guardian’s title:     
 
Parent/Guardian’s full name: 
  
 
Does the parent/guardian live at the same address as the patient?    Yes                     
 
                  No 
 
If no, please give details: 
 
Parent/guardian’s address: 
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Parent/guardian’s postcode:  
 
 
Parent/guardian’s telephone number: 
  
 
The participant is due to fill in another questionnaire in one week.  It would be useful if you 
could state how they would prefer to complete this? 
 
Postal 
 
 
On-line 
 
 
 
(This information can be found on the patient’s baseline questionnaire)  
 
 
Once all of these questions are complete please call the telephone randomisation service on 
0800 056 6682 between 09:00 and 17:00 Monday to Friday, and then complete the allocation details 
on the following page according to the details given by the telephonist. 
 
Allocation details 
  
    
The patient has been assigned to:   50% salicylic acid  
(Please place a cross in the appropriate box)  
 
  Cryotherapy using liquid nitrogen  
   
 
    
Your name ………………………………………………………………. 
 
 
Your signature……………………………………………………………. 
 
 
Digital photograph reminder 
 
You will be prompted to remember to take a photo of the verruca before you treat the patient.  
 
  
Please file this form with the patient’s notes. Thank you. 
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Patient ineligible form
A STUDY  OF DIFFERENT TYPES OF
TREATMENT FOR VERRUCAE
INELIGIBLE PATIENT FORM
Please complete this form if you see a patient who would like to have taken part in the trial but who
was not eligible. (It is not necessary to give the patient's name).
Date patient considered for the trial:
  day                   month                       year
/ /
Patient's Date of Birth:
  day                   month                       year
/ /
Patient's Gender: Male Female
Type of verruca (please cross all that apply) plantar calcaneous
plantar MTPJ
mosaic
other
If other (please specify)
This patient was not eligible to take part in the trial because: (please cross all that apply)
The patient had a verruca, which could not be treated
by either treatment.
The patient was under 12 years of age.
The patient was unable to give informed consent.
The patient had impaired healing eg due to diabetes,
peripheral vascular disease or any other condition.
Patient details:
-Patient ID number:
version 2 Revised March 2007
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The patient was taking immunosuppressant drugs such as
corticosteroids.
The patient was currently taking part in another trial evaluating
other treatments for their verruca.
Other reason (Please specify)
THANK YOU FOR TAKING THE TIME TO COMPLETE THIS FORM.
PLEASE RETURN THIS FORM TO THE UNIVERSITY OF YORK IN THE PRE-PAID ENVELOPE
PROVIDED.
https://www.hsytu.york.ac.uk/verruca/login.aspx
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Patient pain questionnaire
On a scale of 0 to 10, how painful did you find your first treatment?
(where 0 is no pain and 10 is the worst pain imaginable)
Participant Number:
(For office use only) -
A STUDY OF DIFFERENT TYPES OF TREATMENT FOR VERRUCAE
PATIENT PAIN QUESTIONNAIRE
What is your date of birth? / /
Are you? Male Female
THANK YOU FOR TAKING THE TIME TO COMPLETE THIS QUESTIONNAIRE.
Please complete this form immediately after your first treatment
Day Month Year
What is the date you are filling in this form? / /
Day Month Year
Please give it to the receptionist on your way out or return it to the York Trials Unit,
University of York, Dept of Health Sciences, Area 4, Seebohm Rowntree Building, York
YO10 5DD), in the prepaid envelope provided.
Patient treatment form renamed Patient Pain Questionnaire. Version 2 7th July 2007
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Week-1 patient questionnaire
A STUDY  OF DIFFERENT TYPES OF
TREATMENT FOR VERRUCAE
FOLLOW-UP QUESTIONNAIRE WEEK 1
Participant Number:
(For office use only) -
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE
Thank you for agreeing to take part in this evaluation.
Please answer ALL the questions. Although it may seem that questions are asked
more than once, it is still important that you answer every one.
If you find it difficult to answer a question, do the best you can.
Please follow the instructions for each section carefully.
For each section, if you are asked to put a cross in the box, please use a cross
rather than a tick, as if you were filling out a ballot paper.
For example in the following question, if your answer to the question is yes, you
should place a cross firmly in the box next to yes.
Do you drive a car ?
If you are asked to circle a number, please use a circle rather than underlining a
number.
For example, in the following question if you are asked 'how happy are you
today?' where '1' is 'very unhappy' and '5' is 'very happy', if you feel neither happy
nor unhappy you may wish to answer 3. You do this by clearly circling the
number 3.
Yes
No
1 2 3 4 5
PLEASE USE A BLACK OR BLUE PEN.
Please do not use a pencil or any other coloured pen.
Please read all the instructions for each section.
Very
unhappy
Very
happy
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Please enter the date you are completing this questionnaire:
  day                   month                       year
/ /
We would like to know your views about the treatment to your verruca:
0 1 2 3 4
How painful is your verruca today?  (please circle one number only)1.
Not at all A little bit Moderately Quite a lot Extremely
If your verruca has been painful, have you found it necessary to take a pain killer?2.
Yes
No
If 'yes' how many days did you find it necessary to take the
pain killers due to your verruca treatment?     days
Have you had any other problems due to the verruca treatment? (Please specify)3.
1 2 3 4 5
How happy are you with your treatment?  (please circle one number only)4.
Very
unhappy
Unhappy Neither
happy nor
unhappy
Happy Very
happy
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5. If you have been asked to treat yourself at home with salicylic acid, how
many times in the last 7 days have you applied it?
We would like to know about any other comments you may have about the treatment you
are receiving for your verruca.
6.
PLEASE RETURN THIS FORM TO THE UNIVERSITY OF YORK IN THE PRE-PAID ENVELOPE
PROVIDED. THANK YOU FOR TAKING THE TIME TO COMPLETE THIS QUESTIONNAIRE.
https://www.hsytu.york.ac.uk/verruca/login.aspx
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Week-3 patient questionnaire
A STUDY  OF DIFFERENT TYPES OF
TREATMENT FOR VERRUCAE
FOLLOW-UP QUESTIONNAIRE WEEK 3
Participant Number:
(For office use only) -
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE
Thank you for agreeing to take part in this evaluation.
Please answer ALL the questions. Although it may seem that questions are asked
more than once, it is still important that you answer every one.
If you find it difficult to answer a question, do the best you can.
Please follow the instructions for each section carefully.
For each section, if you are asked to put a cross in the box, please use a cross
rather than a tick, as if you were filling out a ballot paper.
For example in the following question, if your answer to the question is yes, you
should place a cross firmly in the box next to yes.
Do you drive a car ?
If you are asked to circle a number, please use a circle rather than underlining a
number.
For example, in the following question if you are asked 'how happy are you
today?' where '1' is 'very unhappy' and '5' is 'very happy', if you feel neither happy
nor unhappy you may wish to answer 3. You do this by clearly circling the
number 3.
Yes
No
1 2 3 4 5
PLEASE USE A BLACK OR BLUE PEN.
Please do not use a pencil or any other coloured pen.
Please read all the instructions for each section.
Very
unhappy
Very
happy
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Please enter the date you are completing this questionnaire:
  day                   month                       year
/ /
We would like to know your views about the treatment to your verruca:
0 1 2 3 4
How painful is your verruca today?  (please circle one number only)1.
Not at all A little bit Moderately Quite a lot Extremely
If your verruca has been painful, have you found it necessary to take a pain killer?2.
Yes
No
If 'yes' how many days did you find it necessary to take the
pain killers due to your verruca treatment?     days
Have you had any other problems due to the verruca treatment? (Please specify)3.
1 2 3 4 5
How happy are you with your treatment?  (please circle one number only)4.
Very
unhappy
Unhappy Neither
happy nor
unhappy
Happy Very
happy
SECTION 1
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5. If you have been asked to treat yourself at home with salicylic acid, how
many times in the last 7 days have you applied it?
We would like to know about any other comments you may have about the treatment you
are receiving for your verruca.
6.
PLEASE RETURN THIS FORM TO THE UNIVERSITY OF YORK IN THE PRE-PAID ENVELOPE
PROVIDED. THANK YOU FOR TAKING THE TIME TO COMPLETE THIS QUESTIONNAIRE.
SECTION 2
This section asks about your verruca
Do you think your verruca has gone? (If you had more than one verrucae have they all gone?)1.
Yes
No
  day                   month                       year
/ /
If you answered 'Yes' to question 1, when did your verruca go? (If you had more than one
verruca when did the last one go?)
1a.
Please state the date
https://www.hsytu.york.ac.uk/verruca/login.aspx
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Week-12 patient questionnaire
A STUDY  OF DIFFERENT TYPES OF
TREATMENT FOR VERRUCAE
FOLLOW-UP QUESTIONNAIRE WEEK 12
-Participant Number:(For office use only)
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE
Thank you for agreeing to take part in this evaluation.
Please answer ALL the questions. Although it may seem that questions are asked
more than once, it is still important that you answer every one.
If you find it difficult to answer a question, do the best you can.
Please follow the instructions for each section carefully.
For each section, if you are asked to put a cross in the box, please use a cross
rather than a tick, as if you were filling out a ballot paper.
For example in the following question, if your answer to the question is yes, you
should place a cross firmly in the box next to yes.
Do you drive a car ?
If you are asked to circle a number, please use a circle rather than underlining a
number.
For example, in the following question if you are asked 'how happy are you
today?' where '1' is 'very unhappy' and '5' is 'very happy', if you feel neither happy
nor unhappy you may wish to answer 3. You do this by clearly circling the
number 3.
Yes
No
1 2 3 4 5
PLEASE USE A BLACK OR BLUE PEN.
Please do not use a pencil or any other coloured pen.
Please read all the instructions for each section.
Very
unhappy
Very
happy
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Please enter the date you are completing this questionnaire:
  day                   month                       year
/ /
This section asks about your verruca:
Do you think your verruca has gone? (If you had more than one verrucae have they all gone?)1.
Yes
No
If you answered 'Yes' to question 1, when did your verruca go? (If you had more than one
verruca when did the last one go?)
1a.
  day                   month                       year
/ /
This section asks about the treatment you had for your verruca:
At the beginning of this study, you will have received treatment with either the acid paste or the
freezing technique. During the study, did you find it necessary to stop the original treatment?
1.
Yes
No
If 'Yes' what was your reason(s) for stopping the treatment?
If you answered 'Yes' to question 1 in this section, did you start another treatment1a.
Yes
No
If 'Yes', please specify treatment
3
Please state the date
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Have you had any other problems due to the verruca treatment? (Please specify)2.
If you had another verruca, would you be willing to have the same treatment again?3.
Yes
No
Not sure
Please could you tell us the reasons for your answer to question 3.3a.
1 2 3 4 5
How happy are you with your treatment?  (please circle one number only)4.
Very
unhappy
Unhappy Neither
happy nor
unhappy
Happy Very
happy
This section asks about the costs related to your treatment:
How many visits in total did you make to the podiatry clinic for treatment to this
verruca? (Please include the initial assessment, and all visits for treatment and
redressings)
1.
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During this course of treatment to your verruca, have you found it necessary to visit your
General Practitioner or Practice Nurse regarding your verruca?
2.
Yes
No
2a. If 'Yes' please state number of visits and date(s) of visit(s).
General Practitioner
Number of visits Date of visit(s)
/ /
/ /
/ /
Practice Nurse
Number of visits Date of visit(s)
/ /
/ /
/ /
Have you had to see your GP for an emergency visit because of your verruca?3.
Yes
No
3a. If 'Yes' to question 3, please give details
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During this course of treatment to your verruca, have you purchased any verruca treatments
yourself? (For example, treatments purchased over the counter)
4.
Yes
No
If 'Yes' can you tell us what you bought and how much it cost?
Type of treatment purchased
Cost
Pounds Pence
.
PLEASE RETURN THIS FORM TO THE UNIVERSITY OF YORK IN THE PRE-PAID ENVELOPE
PROVIDED. THANK YOU FOR TAKING THE TIME TO COMPLETE THIS QUESTIONNAIRE.
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Verruca(e) has gone form
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Podiatrist outcome assessment form
A STUDY  OF DIFFERENT TYPES OF TREATMENT FOR
VERRUCAE
PODIATRIST OUTCOME ASSESSMENT
Participant Number:
(For office use only) -
Please enter the date you are completing this questionnaire:
  day                   month                       year
/ /
Does the verruca appear to be completely cleared/cured?1. Yes No
If 'No' how many verrucae are left?
PLEASE REMEMBER TO TAKE A DIGITAL PHOTOGRAPH.
Any other comments? (Please specify)3.
THANK YOU FOR TAKING THE TIME TO ASSESS THIS PATIENT. PLEASE RETURN THIS FORM TO THE
UNIVERSITY OF YORK IN THE PRE-PAID ENVELOPE PROVIDED.
https://www.hsytu.york.ac.uk/verruca/login.aspx
Did the patient require further treatment?2. Yes No
If 'Yes' what treatment did the patient receive?
Please specify
v3 26/02/2007
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Six-month patient questionnaire
A STUDY  OF DIFFERENT TYPES OF
TREATMENT FOR VERRUCAE
SIX MONTH FOLLOW-UP QUESTIONNAIRE
-
Participant Number:
(For office use only)
Participant's Date of Birth:
  day                   month                       year
/ /
Date Sent:
(For office use only)
  day                   month                       year
/ /
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE
Thank you for agreeing to take part in this evaluation.
Please answer ALL the questions. Although it may seem that questions are asked
more than once, it is still important that you answer every one.
If you find it difficult to answer a question, do the best you can.
Please follow the instructions for each section carefully.
For each section, if you are asked to put a cross in the box, please use a cross
rather than a tick, as if you were filling out a ballot paper.
For example in the following question, if your answer to the question is yes, you
should place a cross firmly in the box next to yes.
Do you drive a car ?
If you are asked to circle a number, please use a circle rather than underlining a
number.
For example, in the following question if you are asked 'how happy are you
today?' where '1' is 'very unhappy' and '5' is 'very happy', if you feel neither happy
nor unhappy you may wish to answer 3. You do this by clearly circling the
number 3.
Yes
No
1 2 3 4 5
PLEASE USE A BLACK OR BLUE PEN.
Please do not use a pencil or any other coloured pen.
Please read all the instructions for each section.
Very
unhappy
Very
happy
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Please enter the date you are completing this questionnaire:
  day                   month                       year
/ /
This section asks about your verruca:
Do you have any verruca(e) today? (Please cross one box only)1.
Yes
No
If you answered 'No' to Question 1, when did your verruca go? (If you had more than one
verruca when did the last one go?)
1a.
  day                   month                       year
/ /Please state the date
If you answered 'Yes' to Question 1, where are they? (Please cross all that apply)1b.
In the original place
In another place
If you still had a verruca(e) 12 weeks after you started the study, have you had any further
treatment for it? (Please cross one box only)
2.
Yes
No
If you answered 'Yes' to Question 2, was the treatment from the podiatrist/nurse/GP?2a.
Yes
No
The following questions asks whether you have had further treatment for your verruca(e),
please answer all that apply
If Yes, please specify treatment received
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Have you purchased an over the counter treatment e.g. Bazuka, Wartner?
And/OR
Yes
No
If Yes, please specify
Have you received another form of treatment for your verruca(e) e.g. homoeopathy?
And/OR
Yes
No
If Yes, please specify
2c.
2b.
We would like to know about any other comments you may have relating to your verruca3.
PLEASE RETURN THIS FORM TO THE UNIVERSITY OF YORK IN THE PRE-PAID ENVELOPE
PROVIDED. THANK YOU FOR TAKING THE TIME TO COMPLETE THIS QUESTIONNAIRE.
Thank you for taking part in this study. The trial is due to end in Spring 2009. We will write to all
participants to let them know the main results of the study.
https://www.hsytu.york.ac.uk/verruca/login.aspx
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Change of circumstances form
EVerT: A STUDY OF DIFFERENT TYPES OF TREATMENT FOR VERRUCAE
Change of Circumstances Form
Please complete this form if there are any changes in the circumstances of the EVerT participant.
Participant Trial Number: -
/ /Please enter the date you are completing this questionnaire:
Reason for change in circumstance:
Please read the following and write the number of the MAIN reason in the box at the end of this form.
1. The patient no longer wishes to have the study treatment (Please state reason and new treatment
if given)
2. The patient no longer wishes to complete postal questionnaires but agrees to follow up by
the health care professional
3. The patient wishes to leave the study (Please state reason if given)
4. The patient is being withdrawn by podiatrist/nurse/doctor/other health care professional
(Please state reason)
5. The patient has died (please also complete a 'Serious Adverse Event Form')
       dd                       mm                                 yyyy
/ /Date of death:
6. The patient is lost to follow up
7. Other reason (please state below)
The main reason for the change is option number (Please write option number in box)
Please give more details, if applicable:
Please send this form to the York Trials Unit in the pre-paid envelope provided
v1 10th July 2007
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Non-serious adverse event form
 37 
NON-SERIOUS ADVERSE EVENT FORM  
           
Patient concerned (trial number)  
 
Name & address of podiatrist reporting event. 
 
 
Date of event  
 
Details of event 
 
 
 
 
 
 
 
 
Action taken  
and outcome 
 
 
Do you think the event is related to the trial treatment (50% salicylic acid or cryotherapy using liquid 
nitrogen)?  (Please tick only ONE box)  
 
Unrelated unlikely to possibly probably definitely not able to 
 be related related related related assess if 
                 related 
 
If the adverse event/reaction has resulted in any of the following you must complete a SAE form 
instead.   
• Death 
• A life-threatening risk (that is an immediate risk of death) 
• Hospitalisation of patient or prolongation of existing hospitalisation 
• Persistent or significant disability/incapacity 
• Consists of a congenital anomaly or birth defect 
 
Possible SAEs in the Verrucae trial.  Please note that this is not an exhaustive list, if you suspect an 
event is serious, please contact the Trial co-ordinator –York Trials Unit.  We would rather you erred on 
the side of caution and reported an event to us.   
Suspected damage to underlying tissue eg tendon 
Patient has died 
Limb compromised:  
Newly diagnosed diabetic: patient diagnosed as diabetic by GP during course of trial  
Patient hospitalised 
 
Signature _________________________________ Date _________________________ 
 
  
Please include details of: site, signs, symptoms, severity, onset and duration of reaction, batch 
number medicinal product, severity of event and any other information.  
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Review of non-serious adverse event form
 38 
REVIEW OF NON-SERIOUS ADVERSE EVENT FORM 
 
                                                                                                 
REVIEW OF NON SERIOUS ADVERSE EVENT FORM 
 
Patient trial number   -            
 
                                       
 
 
 
 
 
 
 
Date of review: 
 
                                                                                   
   
 
 
 
 
 
                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
How and when notification of the event was made: 
 
Action taken:  
 
 
Signature of reviewer: 
 
 
Date reviewed by DMC and Trial Steering Committee: 
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Serious adverse event form
 39 
SERIOUS ADVERSE EVENT/REACTION FORM EVerT Trial      
 
 
STUDY DETAILS:   
EVerT Cryotherapy versus salicylic acid for the treatment of verrucae.    
 
EudraCT: 2004-000905-24   CTA: 22803/0001/001-0001  REC ref: 04/MRE04/59 
 
SUBJECT DETAILS: 
 
Patient’s ID number              Patient’s initials  
 
Patient’s date of birth   ______/_______/________                                  Male                   Female 
      day    month      year 
 
Patient’s weight if known ___________________     Patient’s height if known _________________ 
 
 
EVENT DETAILS: 
 
Date of onset of event    _____/_______/________ 
    day     month      year 
 
 
 
 
 
 
 
 
 
 
Classification of SAE: (Please tick all that apply) 
 
Death             Life or limb                            Hospitalisation 
            threatening event                     required/prolonged 
 
Persistent or significant         Other medically            Congenital anomaly 
disability/incapacity                      important condition                 or birth defect 
 
 
Maximum intensity:   
 
Mild                    Moderate                                Severe  
 
 
  PLEASE OBTAIN COPIES OF ANY AVAILABLE SUPPORTING DOCUMENTS RELATING TO 
THE EVENT FOR FORWARDING TO THE TRIAL COORDINATOR.  
Description of event/reaction and action taken : 
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OUTCOME of event at the time of this report: 
(Tick one box only) 
       Date Recovered/died 
       Day month          year  
 
Recovered fully 
 
Recovered with sequelae 
 
Died 
 
Ongoing   
 
Relationship of event to treatment (tick one box only) 
 
Not related  Unlikely to          Possibly           Probably           Definitely        Not able to assess                   
be related             related             related               related               if related               
       
 
 
 
If possibly, probably or definitely related, was the SAE unexpected?  
(Unexpected means not described in the protocol or SMPC).` 
 
            Yes 1    
 
 
                 No 2 
 
1 – The SAE is a SUSAR      2 – The SAE is not a SUSAR. 
 
 
 
 
 
 
 
 
 
 
 
MEDICINAL PRODUCT DETAILS:  
 
Name of medicinal product (MP)_______________________________________________________ 
 
Batch number ______________________________________________________________________ 
 
Indication for which suspect investigational MP was prescribed _______________________________ 
 
Dosage form and strength_____________________________________________________________ 
York Trials Unit must be notified of any serious adverse event by telephone (01904 321736) 
within 24 hours of onset of the event.   
 
Post or fax top copy of this form and any available supporting documents to Sarah Cockayne, Trial 
Coordinator, Department of Health Sciences Area 4, Seebohm Rowntree Building, University of 
York, Heslington, York, YO10 5DD, within 48 hours of onset (Fax 01904 321387).   
 
Please note that you may need to inform your Local Research Ethics Committee of this event. 
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 41 
 
Daily dose and regiment (specify units)__________________________________________________ 
 
Route of administration_______________________________________________________________ 
 
Starting date and time of day of reaction _________________________________________________ 
 
Date and time last dose given, or duration of treatment______________________________________ 
 
Date of treatments __________________________________________________________________ 
 
 
 
CONCOMITANT MEDICATION:  
(Details of administration of other medication concurrent with the IMP 
 
_______________________________________________________________________________________
_______________________________________________________________________________________
________________________________________________________________________ 
 
 
 
DETAILS OF REPORTER OF EVENT:  
 
Name position and address of reporter of event:  
 
__________________________________________________________________________________ 
 
__________________________________________________________________________________ 
 
__________________________________________________________________________________ 
 
 
Telephone number:_________________________     Email address: ________________________ 
 
 
Profession (Speciality) ______________________________________________________________ 
 
 
Signature _________________________________________________________________________ 
 
 
 
Date  _____/_______/_______ 
 day     month      year 
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    REVIEW OF SERIOUS ADVERSE 
EVENT/REACTION FORM         
 
 
Patient’s trial number:      
 
Date event reported to YTU:       _____/_________/_____ 
           Day        month    year 
 
                                       
 
 
 
 
 
 
 
YTU ASSESSMENT OF THE EVENT 
 
Date of assessment 
by YTU  
 
 
_____/_________/_____ 
day        month        year 
 
Seriousness 
(Please cross one 
box only)   
 
 
Serious 
  
 Non-serious   
Expectedness 
(Please cross one 
box only)   
 
Expected     Unexpected   Is the event listed in the reference documents, (protocol, SMPC, IB?)  
 
What is the 
relationship to the 
study drug?   
(Please cross one 
box only)   
 
Not related 
 
 
Unlikely to 
be related 
Possibly 
related            
Probably  
related                     
Definitely    
related                 
Not able 
to assess 
if  related                               
Was the event a 
SUSAR?  
(Please cross one 
box only)  
Yes   No   
Date SUSAR 
reported to MHRA  
 
 
 
_____/_________/_____ 
day        month        year      
  
How notification of the event was made: 
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Date SUSAR 
reported to Main 
REC if required 
 
 
_____/_________/_____ 
day        month        year 
Date and name of  
R&D committee  
SUSAR or SAE 
reported to, if 
required  
 
 
Name of R&D committee                        Date reported     _____/_________/_____ 
                                                                                           day        month        year 
_____________________ 
If the event was not 
assessed as a 
SUSAR, what was it 
assessed as?  
 
 
________________________________________________ 
 
Was the event 
reported to all other 
Principal 
Investigators  
 
  
Yes  No    
If yes date reported      _____/_________/_____ 
                                        day        month        year                                                                                 
 
Action taken  
 
 
 
 
 
Assessment 
undertaken by  
 
 
 
Signature of 
reviewer(s)  
 
 
Comments 
 
 
Date reviewed by 
Trial Steering 
Committee 
 
 
_____/_________/_____ 
day        month        year 
Date reviewed by 
Data Monitoring and 
Ethics Committee  
 
_____/_________/_____ 
day        month        year 
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Poster – version 1
Helping Your Podiatrist, Nurse or GP  
Treat Your Verruca 
Who can help?  
We are looking for 266 people with a verruca to take part in a 
research study.  If you have a verruca, and are aged between 
12 and 24 years of age, then you may be able to take part.   
EVERT: A multi-centre randomised trial, funded by the NHS Health Technology Assessment Programme and 
co-ordinated by the York Trials Unit at 
EudraCT No 2004-000905-24; ISRCT No (insert)  
What is the study about? 
Verrucae are a common problem.  Many will disappear without 
treatment, however, patients may seek treatment if their verruca 
is painful or if they are prevented from doing sports.  There are 
many different ways to treat verrucae, but it is unclear which 
treatment is best.   
 
The purpose of this study is to compare two commonly used 
treatments to find out which of these is the best treatment to cure 
verrucae. We are also interested in your opinion of the 
treatments.  
 
 
 
 
What will I have to do if I take part? 
The study will last for 6 months, but the treatments will last for 
a maximum of 8 weeks.  If you are treated with the acid paste 
the Podiatrist, GP or Nurse will show you how to apply it at your 
first appointment.  You will then be asked to take the treatment 
home with you and apply it daily up to a maximum of 8 weeks.  
If you are treated with the freezing technique, you will be 
treated by your Podiatrist, GP or Nurse at the clinic.   
 
If you agree to take part, your Podiatrist, GP or nurse will 
record some details about your verruca and take a digital 
photograph of it.  We will ask you to complete a brief 
questionnaire about your verrucae and during the 6 months of 
the study, we will send you a similar questionnaire after 1, 3, 
12, and 24 weeks. 
 
.   
What should I do now? 
If you are interested in taking part in the study, please 
ring  
(Insert local contact details) 
 
and they will assess you in order to see if you are eligible 
for the study.   
 
Alternatively, you can contact the Trial Manager, 
Sarah Cockayne:  
Tel 01904 321736   
or  
Email: esc5@york.ac.uk   
 
 
What are the two treatments being 
tested?   
The two treatments being tested are an acid paste called 
Verrugon which you can buy over the counter from a 
pharmacist and a freezing technique which is applied by a 
Podiatrist, GP or Nurse.   
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IF THE ANSWER IS ‘YES’ THEN WE WOULD LIKE TO HEAR 
FROM YOU! 
 
 
Treatments will be provided free of charge and set travel expenses  
will be paid.   For more information on how you could take part  
with no obligation please contact: Insert local contact details. 
Version 2 
  
 
 
ARE YOU AGED 
12 YEARS AND 
OVER? 
 
 
WOULD YOU LIKE 
  
TO BE PART OF A 
 
RESEARCH STUDY 
 
COMPARING TWO 
 
COMMONLY USED 
 
TREATMENTS? 
COULD YOU  
 
ATTEND  
 
ONE OF THE 
 
FOLLOWING 
 
CLINICS? 
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Generic press release  
                     
(Insert logo of University/Trust) 
 
Media Information 
 
 
DATE (insert date) 
REFERENCE (insert reference) 
 
University puts Verrucae on trial 
 
Podiatry lecturer/Podiatrist/health care professional (name of podiatrist/health care 
professional) at (name of site) has announced the launch of a new clinical trial that will 
investigate solutions to the irritating and painful problem of verrucae. 
 
The collaboration between (name of site) and the York Trials Unit at The University of 
York, UK will investigate which of two common treatments for verrucae - freezing with 
liquid nitrogen or an acid paste - is the most effective in terms of results and cost. 
 
Patients volunteering to take part in the trial will be treated by qualified Podiatrists at 
(name of site), while researchers at The University of York will analyse the data. 
 
Verrucae are a common viral infection and can be a painful problem. Although most 
will disappear eventually without treatment, patients often seek help if their verruca is 
painful or if they are prevented from doing sport. 
 
There are many different ways to treat verrucae but it is unclear which treatment is 
best. Since verrucae are seen as a minor condition, few clinical trials have been 
funded into the best solutions for them. 
 
(Name of podiatrist/health care professional) says: “We hope to study 266 patients in 
total and want to hear from people aged 12 years and over who have a verruca and 
are interested in taking part in the trial.”  
 
Patients will be asked to help for six months, but the treatments will only last for a 
maximum of eight weeks. Half of the patients will be asked to treat themselves daily 
with the acid paste, as directed by the (Podiatrist/health care professional), up to a 
maximum of eight weeks.  
 
The other half will be treated with the freezing technique, applied by a 
(Podiatrist/health care professional), with re-treatment at follow-up appointments if 
required. Participants will also be asked about any side effects they experience and 
their satisfaction with their treatment. 
(Name of podiatrist/health care professional) continues: “The information we get from 
this study should help us to treat future patients with verrucae more effectively.” 
 
Press releases
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If you are interested in taking part you should ring (insert clinic contact 
details and telephone number) you will be assessed in order to see if you are 
eligible for the study. The treatment provided will be free of charge. 
 
 
 
-ends- 
 
Notes for editors: 
• (Local note to editors about the university. For example for Northampton University: The 
University of Northampton is dedicated to high quality higher education at undergraduate and 
postgraduate levels, through taught courses and research. As Northamptonshire’s only dedicated 
higher education institution, it is committed to the transfer of knowledge and technology to the 
community and aims to contribute to the cultural development of the region) 
• This project is funded by the NHS R&D Programme Health Technology Assessment (HTA) 
Programme (Project No. 05/513/02), and the results will be used to inform clinical practice within 
the NHS. The study has been reviewed and approved by Trent Multi Research Ethics Committee 
(UK). The views and opinions expressed herein are those of the authors and do not necessarily 
reflect those of the Department of Health (UK). 
 
 
Details of press release officer  
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SECOND PRESS RELEASE  
 
(Insert logo of University/Trust) 
 
Press Release 
 
For immediate release  
 
Media Information: Press Office (insert Press Office telephone number) 
 
Patients wanted to put best foot forward 
 
More patients are needed to join a clinical trial in the (name of town/city) area aimed at cutting the 
£40 million a year cost to the NHS of treating warts and verrucas. 
 
Researchers at the University of York have been conducting the trial in (town/city) as part of a 
major study to establish the most effective solution for dealing with this irritating and painful 
problem. 
 
The initial trial, aimed at establishing the most effective treatment for verrucas, was restricted to 
patients aged between 12 and 24, but now the study has been extended to include any patient 
aged over 12 years old. 
 
Almost two million people see their GP about verrucas and warts each year, costing the NHS at 
least £40 million. 
 
The York Trials Unit, in the University’s Department of Health Sciences, has been working with 
health professionals in (name of town/city) to investigate which of two common treatments for 
verrucas - freezing with liquid nitrogen or an acid paste - is the most effective in terms of results 
and cost. 
 
(Name of Trial co-ordinator/Principal Investigator) said: “The response from patients in (name of 
town/city) has been great, but now our funders, the Health Technology Assessment Programme, 
have agreed that we can extend the trial to any patient over the age of 12. So we’re looking for 
about 40 more patients from the (name of town/city) area to help us with the study. People 
interested in taking part should contact (name of podiatrist/health care professional) at (name of 
site) on (site telephone number).” 
 
Patients will be asked to help for six months but the treatments will only last for a maximum of eight 
weeks. Half the patients will be asked to treat themselves daily with the acid paste, as directed, up 
to a maximum of eight weeks.  
 
The other half will be treated with the freezing technique, applied by a podiatrist or health care 
professional, with re-treatment at follow-up appointments if required. Participants will be asked to fill 
in five questionnaires to find out about any side effects they experience and their satisfaction with 
their treatment  
 
Volunteers will be assessed in order to see if they are eligible for the study and will need to attend 
the clinic for up to four additional appointments.  Set travel expenses will be paid. The treatment 
provided will be free of charge. 
 
ENDS 
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Notes for Editors: 
• This project is funded by the NHS R&D Programme Health Technology Assessment (HTA) 
Programme (Project No. 05/513/02), and the results will be used to inform clinical practice 
within the NHS. The study has been reviewed and approved by Trent Multi Research Ethics 
Committee. The views and opinions expressed herein are those of the authors and do not 
necessarily reflect those of the Department of Health. 
 
• (University of York note may be included if appropriate: The Department of Health Sciences 
at the University of York is a large multi-disciplinary department, offering a broad range of 
taught and research programmes in the health care field, including nursing. It aims to 
develop the role of scientific evidence in health and health care through high quality 
research, teaching and other forms of dissemination). 
 
• (If a recruiting site is situated in another university, an additional note about that university 
may be included. For example, for Northampton University: The University of Northampton 
is dedicated to high quality higher education at undergraduate and postgraduate levels, 
through taught courses and research. As Northamptonshire’s only dedicated higher 
education institution, it is committed to the transfer of knowledge and technology to the 
community and aims to contribute to the cultural development of the region). 
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SHORT PRESS RELEASE 
 
            (Insert 
logo of University/Trust) 
 
Media Information 
 
 
DATE (insert date) 
REFERENCE (insert reference) 
 
 
 
(Name of University/Trust) puts Verrucae on trial  
 
 
(Name of Podiatry lecturer/Podiatrist/health care professional/Principal Investigator) at (name of 
site) is seeking patients to take part in a clinical trial that will investigate solutions to the irritating 
and painful problem of verrucae.  (He/she) says “We want to hear from people aged 12 and over 
who have a verruca and are interested in taking part in the trial.”  
 
Patients will be asked to help for six months, but the treatments will only last for a maximum of 
eight weeks.  Half of the patients will be asked to treat themselves daily with an acid paste, up to a 
maximum of eight weeks.  The other half will be treated with a freezing technique, applied by a 
podiatrist/other healthcare professional, with re-treatment at follow-up appointments if required. 
 
If you are interested in taking part you should ring (name of clinic/site) on telephone number (insert 
number) and ask for (contact name).  You will be assessed in order to see if you are eligible for the 
study. The treatment provided will be free of charge. 
 
This project is funded by the NHS R&D Programme HTA Programme Project number 05/513/02. 
The views and opinions expressed therein are those of the authors and do not necessarily reflect 
those of the Department of Health. 
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                                                   Insert Trust /site logo 
(Pharmacist letter version 1  4/5/2007)                                             DEPT OF HEALTH SCIENCES 
University of York 
Area 4, Seebohm Rowntree Building 
York  YO10 5DQ 
Insert date 
Name and address of pharmacist 
 
Dear Name of pharmacist 
Re: A NHS HTA Programme funded trial of two treatments of verrucae 
 
We are writing to inform you about a research study which is currently being undertaken in your 
PCT.  This study is being funded by the NHS Health Technology Assessment Programme under 
their call for Medicines for Children  (http://www.hta.nhsweb.nhs.uk/calls/M4CUpdate.htm) and is 
a joint research project between the Podiatry Department at (insert name) and the York Trials Unit 
at the University of York.  The aim of the study is to compare the clinical effectiveness of 
cryotherapy using liquid nitrogen versus patient daily self-treatment with an over the counter 
preparation of 50% salicylic acid (Verrugon) for the treatment of verruca.  
 
This study aims to recruit 266 participants and we are writing to ask for your assistance with this 
study in two ways. First, we would like to ask you to put a poster advertising for trial participants in 
your pharmacy.  Second, we would like you to inform suitable potential participants (ie individuals 
aged 12 to 24 years with a verruca) that the trial is being conducted, and if the patient agrees give 
them the contact details of the recruiting site (insert name and contact details of recruiting site).  
Participation in the trial will not involve any commitments on your part other than putting up a 
poster and passing on recruiting site contact details to potential participants. 
 
As this study is being funded under a call for medicines for children, we currently wish to recruit 
participants aged between 12 to 24 years inclusively.  Patients will however, be ineligible if they are 
currently in a trial evaluating other treatments for their verruca, are unable to give informed consent, 
have impaired healing eg due to diabetes, peripheral vascular disease, are immunosuppressed, are on 
renal dialysis, have cold intolerance or have any of the following conditions; blood dyscrasias of 
unknown origin, cryoglobulinaemia, cryofibrinogenaemia, collagen and auto-immune disease. 
 
We have enclosed further details of the study with this letter, but if you require any additional 
information or would like to discuss the study further, please contact either (Name of 
Podiatrist/Health care professional) on (insert telephone number and email address) or (Name of 
trial coordinator and contact details). 
 
Yours sincerely 
 
Name of PI        Professor David Torgerson                              Sarah Cockayne                  
Title                                       Director of York Trials Unit                                       Trial coordinator     
                                                       
Letters to pharmacists/GPs/parents of school students
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Please contact Sarah Cockayne, telephone number 01904 321736 or email esc5@york.ac.uk if 
you are able to put up a poster in your pharmacy. Alternatively please complete the form 
below and return it to Sarah Cockayne, in the pre-paid envelope provided.  
 
 
 
Please send me a poster to put in our pharmacy:   
 
Name of Pharmacist:  _________________________________________________ 
 
Address of Pharmacy  _________________________________________________ 
 
                           _________________________________________________ 
  
    _________________________________________________ 
    
    _________________________________________________ 
 
    _________________________________________________ 
 
 
Telephone Number:  _________________________________________________ 
 
Email address:   _________________________________________________ 
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Title: Cryotherapy versus salicylic acid for the treatment of verrucae: A 
randomised controlled trial. 
 
Background 
Verrucae are a common, infectious and sometimes painful problem.  Using incidence figures from 
the 4th National Morbidity Survey (1991-92)i an unpublished economic decision model assessing the 
effectiveness and cost-effectiveness of salicylic acid and cryotherapy has estimated that almost 2 
million people see their GP per year about cutaneous warts at a cost of at least £40 million per 
annum.  Although most verrucae will spontaneously disappear without treatment many patients seek 
treatment to remove a verruca due to it being painful or because they are being prevented from 
doing sports. 
 
A recent systematic review conducted by the Cochrane Skin Group assessed the effects of different 
local treatments of cutaneous, non-genital warts in healthy peopleii.  This review highlighted the 
uncertainty with respect to the optimal treatment of verrucae.  There was however, some evidence 
from six trials to suggest that treatment with salicylic acid was more effective than placebo/no 
treatment, odds ratio 3.91 (95% confidence interval 2.40 to 6.36).  Freezing warts using cryotherapy 
is widespread.  Many patients experience unpleasant side effects such as pain and blistering during 
cryotherapy treatment, yet the same review found no evidence to suggest that it is more effective 
than treatment with topical agents such as salicylic acid.  Only two trials were identified which 
compared salicylic acid and/or lactic acid with cryotherapy, but there was no difference in the 
efficacy between the treatments (OR 1.15, 95% CI 0.72 to 1.82). However, both trials were reported 
as low quality, due to unclear allocation concealment, inadequate blinding procedures, small sample 
sizes and inappropriate follow-up and analysis.  There is a need therefore, for a high quality 
randomised controlled trial to ascertain which is the best approach for the treatment of verrucae.  
 
Primary objective  
To compare the clinical effectiveness of cryotherapy versus salicylic acid for the treatment of 
verrucae in terms of the complete clearance of all verrucae as observed on digital photographs taken 
at baseline and 12 weeks and assessed by an independent health care professional (eg podiatrist, GP, 
Practice nurse).   Blinded health care professional assessment will be used if for some reason the 
digital photograph is not interpretable.  ‘Clearance’ of verrucae will be defined as being the 
restoration of normal skin upon close inspection, as assessed by the health care professional.   
 
Secondary objectives  
To compare the cost effectiveness of cryotherapy versus salicylic acid for the treatment of plantar 
warts in terms of the complete clearance of all verrucae.  To assess the acceptability of the two 
approaches and to investigate self-reported time to clearance of verruca and recurrence/clearance of 
verrucae at six months.  
 
Design 
The proposed study is a pragmatic, multicentre, randomised controlled trial (RCT) with equal 
randomisation. Patients with a verruca will be allocated equally between the two treatment groups, 
namely:  50% salicylic acid paste and cryotherapy using liquid nitrogen.   
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Eligibility 
Inclusion criteria: 
Patients will be included if  
• The patient has a verruca that in the opinion of the health care professional is suitable for 
treatment with either salicylic acid or cryotherapy. 
• And the patient is aged 12 years and over but under 25 years of age. 
 
Exclusion Criteria: 
Patients will be excluded if any of the following criteria apply: 
• Are currently in a trial evaluating other treatments for their verruca 
• Have impaired healing eg due to diabetes, peripheral vascular disease or any other condition 
which means the patient has impaired healing 
• Patients that are immunosuppressed eg have agammaglobulinaemia, or are currently taking 
immunosuppressant drugs such as corticosteroids 
• Are unable to give informed consent 
• Are currently on renal dialysis  
• Have cold intolerance eg Raynaud's syndrome or cold urticaria  
• Have any of the following conditions - blood dyscrasias of unknown origin, 
cryoglobulinaemia, cryofibrinogenaemia, collagen and auto-immune disease 
 
Treatment details 
Participants will be randomised equally between the two arms: daily self-treatment by the patient 
with 50% salicylic acid; cryotherapy using liquid nitrogen delivered by the health care professional 
(for example podiatrist, practice nurse, General Practitioner).    
 
1. Daily self-treatment by the patient with 50% salicylic acid paste  - Verrugon as per the 
manufacturer’s instructions. 
 
• At the first appointment the health care professional will instruct the patient and/or their 
parent or guardian if appropriate, on its use.  Thereafter, it will be applied daily for a 
maximum of 8 weeks as per the manufacturer’s instructions as follows: 
• The self-adhesive ring should be fixed with the hole over the verruca. 
• Squeeze a little Verrugon ointment into the hole and directly onto the verruca.  
• Remove backing paper from plaster.   
• Cover ring completely with plaster.  Seal into position.  
• Repeat treatment daily after gently pumicing or filing off the dead part of the verruca. 
 
2. Treatment with cryotherapy using liquid nitrogen delivered by the health care professional. 
Callus surrounding the verrucae will first be debrided.  The tissue surrounding the verruca will be 
prepared according to normal practice. The area will then be sprayed with liquid nitrogen to cover 
the verruca area totally.  The health care professional should freeze the tissue until they are satisfied 
that the tissue has been frozen adequately (this will be about 10 seconds).   75% silver nitrate should 
NOT to be applied to site.  If the health care professional believes the area surrounding the verruca  
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should be padded after treatment, this will be done according to normal practice.  The patient will be 
advised to keep the area dry for 24 hours and that the area maybe uncomfortable as the treatment 
removes infected skin by causing a blister.  If the area is very painful the patient will be 
recommended to use the type of painkiller they would use for a headache, and as per the instructions 
on the packet.  The health care professional will then re book for the next treatment 14 days later.  
On the patient’s return the sequence should be repeated up to a maximum of four treatments.  
 
Primary outcome 
The primary outcome will be complete clearance of all verrucae as observed on digital photographs 
taken at baseline and 12 weeks and assessed by an independent health care professional.  Blind 
health care professional assessment will also be assessed and will be used if for some reason the 
digital photograph is not interpretable.  ‘Clearance’ of verrucae will be defined as being the 
restoration of normal skin upon close inspection, as assessed by the health care professional.    
 
Secondary outcomes 
Secondary outcomes are self-reported clearance of verrucae at six months, and self-reported time to 
clearance of verrucae. In addition to this side effects of treatment, pain intensity after treatment, use 
of painkillers, restrictions to lifestyle due to having the verruca and treatment details will be 
recorded and assessed by patient postal questionnaire.  
 
Sample size 
In this study we have decided to power the trial to show a 15% difference in effectiveness.  We 
therefore, will recruit sufficient patients to give us 80% power (5% two sided significance) to show 
a difference in cure rates of 70% versus 85% at 12 weeks after treatment.  This will require 120 
patients in each group after allowing for a 10% drop-out rate we will require 133 in each treatment 
group (i.e. 266 in total).   
 
The study has the necessary ethics, research and development and Medicines and HealthCare 
products Regulatory Agency approvals.  
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                                                   Insert Trust /site logo 
            DEPT OF HEALTH SCIENCES 
University of York 
Area 4, Seebohm Rowntree Building 
York   YO10 5DQ 
 
Name and address of doctor/practice manager 
 
Dear Name of doctor/practice manager 
Re: A NHS HTA Programme funded trial of two treatments of verrucae 
We are writing to inform you about a research study which is currently being undertaken in your 
PCT.  This study is being funded by the NHS Health Technology Assessment Programme under 
their call for medicines for Children  (http://www.hta.nhsweb.nhs.uk/calls/M4CUpdate.htm) and is a 
joint research project between the Podiatry Department at (insert name) and the York Trials Unit at 
the University of York.  The aim of the study is to compare the clinical effectiveness of cryotherapy 
using liquid nitrogen versus patient daily self-treatment with an over the counter preparation of 50% 
salicylic acid (Verrugon) for the treatment of verruca.  
 
This study aims to recruit 266 participants and we are writing to ask for your assistance with this 
study in two ways. First, we would like to ask you to consider referring suitable patients who 
present to you for treatment of a verruca, to the podiatry department for treatment.  Second to put a 
poster advertising for trial participants in the waiting room at your surgery.  Participation in the trial 
should not involve any financial or clinical commitments on your part.  The only time commitment 
involved will be in writing the referral letter to the podiatry clinic.   
 
As this study is being funded under a call for medicines for children, we currently wish to recruit 
participants aged between 12 to 24 years inclusively.  Patients will however, be ineligible if they are 
currently in a trial evaluating other treatments for their verruca, are unable to give informed consent, 
have impaired healing eg due to diabetes, peripheral vascular disease, are immunosuppressed, are on 
renal dialysis, have cold intolerance or have any of the following conditions; blood dyscrasias of 
unknown origin, cryoglobulinaemia, cryofibrinogenaemia, collagen and auto-immune disease. 
 
We have enclosed further details of the study with this letter, but if you require any additional 
information or would like to discuss the study further, please contact either (Name of 
Podiatrist/Health care professional) on (insert telephone number and email address) or insert details 
of trial coordinator. 
 
Yours sincerely 
 
Name of CI        Professor David Torgerson           Sarah Cockayne                                         
Title               Director of York Trials Unit         Trial coordinator                                                            
  
Letter to GPs (version 1 21 November 2006)
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Please contact Sarah Cockayne, telephone number 01904 321736 or email esc5@york.ac.uk if 
you are able to put up a poster in your surgery. Alternatively please complete the from below 
and return it to Sarah Cockayne, in the pre-paid envelope provided.  
 
 
Please send me a poster to put in our waiting room to:   
 
Name of GP practice:  _________________________________________________ 
 
Practice Manager:  _________________________________________________ 
 
Practice Address:  _________________________________________________ 
  
    _________________________________________________ 
    
    _________________________________________________ 
 
    _________________________________________________ 
 
 
Telephone Number:  _________________________________________________ 
 
Email address:   _________________________________________________ 
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Title: Cryotherapy versus salicylic acid for the treatment of verrucae: A 
randomised controlled trial. 
 
Background 
Verrucae are a common, infectious and sometimes painful problem.  Using incidence figures 
from the 4th National Morbidity Survey (1991-92)iii an unpublished economic decision model 
assessing the effectiveness and cost-effectiveness of salicylic acid and cryotherapy has 
estimated that almost 2 million people see their GP per year about cutaneous warts at a cost 
of at least £40 million per annum.  Although most verrucae will spontaneously disappear 
without treatment many patients seek treatment to remove a verruca due to it being painful or 
because they are being prevented from doing sports. 
 
A recent systematic review conducted by the Cochrane Skin Group assessed the effects of 
different local treatments of cutaneous, non-genital warts in healthy peopleiv.  This review 
highlighted the uncertainty with respect to the optimal treatment of verrucae.  There was 
however, some evidence from six trials to suggest that treatment with salicylic acid was more 
effective than placebo/no treatment, odds ratio 3.91 (95% confidence interval 2.40 to 6.36).  
Freezing warts using cryotherapy is widespread.  Many patients experience unpleasant side 
effects such as pain and blistering during cryotherapy treatment, yet the same review found 
no evidence to suggest that it is more effective than treatment with topical agents such as 
salicylic acid.  Only two trials were identified which compared salicylic acid and/or lactic 
acid with cryotherapy, but there was no difference in the efficacy between the treatments (OR 
1.15, 95% CI 0.72 to 1.82). However, both trials were reported as low quality, due to unclear 
allocation concealment, inadequate blinding procedures, small sample sizes and inappropriate 
follow-up and analysis.  There is a need therefore, for a high quality randomised controlled 
trial to ascertain which is the best approach for the treatment of verrucae.  
 
Primary objective  
To compare the clinical effectiveness of cryotherapy versus salicylic acid for the treatment of 
verrucae in terms of the complete clearance of all verrucae as observed on digital 
photographs taken at baseline and 12 weeks and assessed by an independent health care 
professional (eg podiatrist, GP, Practice nurse).   Blinded health care professional assessment 
will be used if for some reason the digital photograph is not interpretable.  ‘Clearance’ of 
verrucae will be defined as being the restoration of normal skin upon close inspection, as 
assessed by the health care professional.   
 
Secondary objectives  
To compare the cost effectiveness of cryotherapy versus salicylic acid for the treatment of 
plantar warts in terms of the complete clearance of all verrucae.  To assess the acceptability 
of the two approaches and to investigate self-reported time to clearance of verruca and 
recurrence/clearance of verrucae at six months.  
 
Design 
The proposed study is a pragmatic, multicentre, randomised controlled trial (RCT) with equal 
randomisation. Patients with verrucae will be allocated equally between the two treatment 
groups, namely:  50% salicylic acid paste and cryotherapy using liquid nitrogen.   
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Eligibility 
Inclusion criteria: 
Patients will be included if  
• The patient has a verruca that in the opinion of the health care professional is suitable 
for treatment with either salicylic acid or cryotherapy. 
• And the patient is aged 12 years and over but under 25 years of age. 
 
Exclusion Criteria: 
Patients will be excluded if any of the following criteria apply: 
• Are currently in a trial evaluating other treatments for their verruca 
• Have impaired healing eg due to diabetes, peripheral vascular disease or any other 
condition which means the patient has impaired healing 
• Patients that are immunosuppressed eg have agammaglobulinaemia, or are currently 
taking immunosuppressant drugs such as corticosteroids 
• Are unable to give informed consent 
• Are currently on renal dialysis  
• Have cold intolerance eg Raynaud's syndrome or cold urticaria  
• Have any of the following conditions - blood dyscrasias of unknown origin, 
cryoglobulinaemia, cryofibrinogenaemia, collagen and auto-immune disease 
 
Treatment details 
Participants will be randomised equally between the two arms: daily self-treatment by the 
patient with 50% salicylic acid; cryotherapy using liquid nitrogen delivered by the health care 
professional (for example podiatrist, practice nurse, General Practitioner).    
 
1. Daily self-treatment by the patient with 50% salicylic acid paste  - Verrugon as per 
the manufacturer’s instructions. 
 
• At the first appointment the health care professional will instruct the patient and/or 
their parent or guardian if appropriate, on its use.  Thereafter, it will be applied 
daily for a maximum of 8 weeks as per the manufacturer’s instructions as follows: 
• The self-adhesive ring should be fixed with the hole over the verruca. 
• Squeeze a little Verrugon ointment into the hole and directly onto the verruca.  
• Remove backing paper from plaster.   
• Cover ring completely with plaster.  Seal into position.  
• Repeat treatment daily after gently pumicing or filing off the dead part of the 
verruca. 
 
2. Treatment with cryotherapy using liquid nitrogen delivered by the health care 
professional. 
Callus surrounding the verrucae will first be debrided.  The tissue surrounding the verruca 
will be prepared according to normal practice. The area will then be sprayed with liquid 
nitrogen to cover the verruca area totally.  The health care professional should freeze the 
tissue until they are satisfied that the tissue has been frozen adequately (this will be about 10 
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seconds).   75% silver nitrate should NOT to be applied to site.  If the health care 
professional believes the area surrounding the verruca  
should be padded after treatment, this will be done according to normal practice.  The patient 
will be advised to keep the area dry for 24 hours and that the area maybe uncomfortable as 
the treatment removes infected skin by causing a blister.  If the area is very painful the patient 
will be recommended to use the type of painkiller they would use for a headache, and as per 
the instructions on the packet.  The health care professional will then re book for the next 
treatment 14 days later.  On the patient’s return the sequence should be repeated up to a 
maximum of four treatments.  
 
Primary outcome 
The primary outcome will be complete clearance of all verrucae as observed on digital 
photographs taken at baseline and 12 weeks and assessed by an independent health care 
professional.  Blind health care professional assessment will also be assessed and will be used 
if for some reason the digital photograph is not interpretable.  ‘Clearance’ of verrucae will be 
defined as being the restoration of normal skin upon close inspection, as assessed by the 
health care professional.    
 
Secondary outcomes 
Secondary outcomes are self-reported clearance of verrucae at six months, and self-reported 
time to clearance of verrucae. In addition to this side effects of treatment, pain intensity after 
treatment, use of painkillers, restrictions to lifestyle due to having the verruca and treatment 
details will be recorded and assessed by patient postal questionnaire.  
 
Sample size 
In this study we have decided to power the trial to show a 15% difference in effectiveness.  
We therefore, will recruit sufficient patients to give us 80% power (5% two sided 
significance) to show a difference in cure rates of 70% versus 85% at 12 weeks after 
treatment.  This will require 120 patients in each group after allowing for a 10% drop-out rate 
we will require 133 in each treatment group (i.e. 266 in total).   
 
The study has the necessary ethics, research and development and Medicines and HealthCare 
products Regulatory Agency approvals.  
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 Insert local logo       
                                                                                                                 
 
Insert contact details of local site       Department of Health Sciences 
                              University of York 
                 Area 4, Seebohm Rowntree Building 
                                          York  YO10 5DQ 
                  
 Date  
 
 
Dear Parent 
 
Re: Patients needed for a trial of treatments for verrucas  
 
We are writing to ask if you would like to help us in a research project about verrucas, which 
is being funded by the NHS. This is a joint research project between the (insert name of site) 
and the York Trials Unit at the University of York. 
 
Verrucas are a common problem and there are several different ways to treat them.  This aim 
of this study is to compare two of these treatments to find out which treatment is better.  We 
will be comparing a freezing technique, which is applied by a (podiatrist/doctor/nurse) and an 
acid paste (Verrugon), which you apply at home.   
 
If your child has a verruca then they may be able to take part and help our research. For more 
information about the study, please see the leaflet overleaf or email (Name of local PI) or 
Sarah (address below).   
 
 
Yours faithfully 
 
 
Name of PI        Professor David Torgerson            Mrs Sarah Cockayne                                         
Post       Director York Trials Unit                        Trial coordinator, York Trials Unit 
Email: (insert details)                                                                        Email: esc5@york.ac.uk 
  
Letter to parent of school children
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Appendix 6  
Flow chart for EVerT trial
Potential participants identified by the health-care professional (HCP) are sent an appointment,
patient information sheet, baseline questionnaire and consent form
Participants who wish to take part in the study give written informed
consent and complete the patient baseline questionnaire.  HCP
completes baseline data on podiatrist treatment assessment form,
randomisation form and takes digital photograph
Participants who do not wish to
take part in the trial or are
ineligible revert to normal care
HCP telephones YTU randomisation service/uses online web system to randomise the participant. HCP records
group allocation on randomisation form. HCP sends patient baseline questionnaire and photograph to YTU
What treatment has the patient been allocated to? 
Cryotherapy using liquid nitrogen
Participant given 50% salicylic acid, additional
plasters/felt pads and advice about how to apply
the ointment. Patient given advice sheet to take
home and patient pain questionnaire to
complete at home and return to YTU
by Freepost. HCP completes podiatrist
treatment assessment form and e-mails
photograph to YTU
HCP debrides surrounding callus and masks area as
per normal practice.  Applies liquid nitrogen until
lesion is adequately frozen. The surrounding area
is padded as per normal practice. Patient given advice 
sheet to take home and patient pain questionnaire 
to complete at home and return to YTU by Freepost. 
HCP completes podiatrist treatment assessment 
form and e-mails photograph to YTU
Participant’s GP is sent notification of their participation in the study.  The participant is sent follow-up
questionnaires at 1, 3 and 12 weeks and 6 months after entry into the study to return to YTU by Freepost
Participant seen 2 weeks post randomisation for
safety check.  Is given additional Verrugon tubes
and felt pads/plasters if required. HCP completes
podiatrist treatment assessment form and takes
digital photograph and e-mails to YTU
Participant receives up to three more cryotherapy
treatments at 2–3-week intervals.  HCP completes
podiatrist treatment assessment form and takes
digital photograph at each visit and e-mails them
to the YTU
All participants seen at week 12 for blinded outcome assessment.  Assessor completes podiatrist outcome
assessment form.  HCP takes a digital photograph and e-mails to YTU and sends podiatrist treatment 
assessment form and outcome assessment form to YTU by Freepost
Participant daily self-treatment with 50% salicylic acid
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Trial protocol
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PROTOCOL FOR: Cryotherapy versus salicylic acid for the 
treatment of verrucae: A randomised controlled trial. 
Protocol	  version	  10	  
16 Oct 2008 
Funded by the HTA 
 
Prof David Torgerson____________________ 
 
Prof Ian Watt __________________________ 
 
Principal Investigator____________________ 
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AMENDMENTS TO PROTOCOL  
 
A	  Protocol	  Version	  2	  29	  September	  2004	  
Change in concentration of salicylic acid from 60% to 50% Verrugon.   
 
B Protocol version 3 26th July 2006 
In light of the changes made due to obtaining funding from the HTA and after discussions 
held with the Trial Management Team the following changes were made: 
• Additional background information added 
• Clarification of primary and secondary outcomes 
• Additional exclusion criteria added 
• Clarification of treatment details for both salicylic acid and cryotherapy 
• Additional recruitment strategies included 
• Addition of web-based randomisation service added 
• Notification of participant’s GP involvement in the study included 
• Clarification of non recruitment and use of ‘Ineligible Patient Form’  
• Clarification of ethical arrangements, reporting and monitoring adverse events and 
obtaining informed consent  
• Additional section on treatment of missing data 
 
C Protocol version 4 21st November 2006 
 
In light of the advice from the Trial Steering Committee held on the 20th September 2006 and 
discussions held with the trial management team it was decided to  
• Clarify the secondary outcomes and the economic analysis 
• Add additional exclusion criteria 
• Clarify treatment details for patients presenting with more than one verrucae and the 
regimen for cryotherapy treatment 
• The influence of prognostic variables on the primary outcome will be also be 
investigated. 
D Protocol version 5 4/5/2007 
 
In light of the advice from the Trial Steering Committee held on the 22 March 2007 and 
discussions held with the trial management team it was decided to: 
• Clarify the exclusion criteria to read ‘oral’ corticosteroids, not corticosteroids 
• Further clarification to cryotherapy regimen: debridement prior to treatment now no 
longer necessary for the trial but if carried out should be done as per normal practice 
eg scalpel, file and a record kept of the method used; method of application of liquid 
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nitrogen is changed to normal practice eg spray probe or cotton bud if there is a 
choice then spray should be used; time interval between treatments to 2/3 weeks as 
there is no evidence to suggest there is a significant difference in effectiveness in 
treatments 2 or 3 weeks apart, and no further benefit from treating more than 4 times.  
• We will ask participants who did not attend their outcome assessment appointment at 
12 weeks if they would be able and willing to take a digital photo of their foot/feet 
and send it to the York Trials Unit EverT email account 
• Clarification that data on adverse events will be collected by patient self-report 
• Minor clarification to the economic analysis (patient perspective was missed out) 
• Minor clarification to the reporting of adverse events 
 
E Protocol version 6 July 2007 
• Clarification that Professor David Torgerson is the Chief Investigator and Prof Ian 
Watt is Co-Chief Investigator.  
• Additional exclusion criteria of patients with neuropathy  
• Additional information about the storage and dispensing of Verrugon and supply of 
liquid nitrogen 
• Adverse event/reaction reporting.  Additional information included about reporting 
time of adverse events/reactions, duration of reporting, out of hours contact  
 
F Protocol version 7 5th September 2007 
• Additional sites of Camden and Sefton PCT, Brownlow and Springfield 
Practice added.  
G Protocol version 8 22nd November  2007 
• Additional sites included: Islington PCT and Dr Mittal  
 
H Protocol version 9 20 February 2008  
• Additional site included: Sheffield PCT and additional recruitment strategies, 
clarification of treatment of missing data 
 
I Protocol version 10 16 Oct 2008 
• Space for signature of Principal Investigator added to front page 
• Amended to read Verrugon is to be applied ‘once’ daily rather than daily 
• A sample of the Verrugon label is included 
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• Clarification that patients should see their out of hours GP if a problem occurs 
outside of normal working hours 
• Participants who attend their 12 week outcome assessment to be sent £20 to 
cover any expenses incurred 
• Patients to be sent an unconditional £5 with the 12 week questionnaire, to 
cover expenses incurred when completing questionnaires. 
• Clarified wording to read “If a clinician feels that the potential participant is 
unable to give informed consent, then they would not be eligible to take part in 
the study.” 
• Clarified wording to read “This sample size will also enable us to show that” 
• Clarified to read “giving a total of 270 participants” 
• Camden and Sefton PCT removed from list of sites. Claughton Medical Centre 
(Birkenhead, Wirral), Woodplumpton Road Surgery (Fulwood, Preston) and 
Arlington Road Surgery (Eastbourne) added as new sites. 
• Amended Project Timetable to reflect approved extension of project 
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Key Contacts 
Professor Ian Watt, Co-Chief Investigator 
Professor of Primary & Community Care 
Department of Health Sciences 
Seebohm Rowntree Building (Area 2) 
York YO10 5DD 
Tel (01904) 321341 
Email ian.watt@york.ac.uk 
 
Professor David Torgerson, Co-Chief Investigator Health Economist 
York Trials Unit, University of York, 
Seebohm Rowntree Building (Area 4) 
York YO10 5DD  
Tel: 01904 321306 
Email david.torgerson@york.ac.uk 
 
Mrs Sarah Cockayne, and trial co-ordinator 
York Trials Unit, University of York, 
Seebohm Rowntree Building (Area 4) 
York YO10 5DD  
Tel: 01904 321736 
Email sarah.cockayne@york.ac.uk 
 
Dr Mike Curran, Podiatrist 
Senior Lecturer in Podiatry 
School of Health  
University of Northampton 
Boughton Green Road 
Northampton NN2 7AL 
Tel: 01604 892771 
Email mike.curran@northamptom.ac.uk 
 
Dr Farina Hashmi, Podiatrist 
Research Fellow 
School of Health, Sport and Rehabilitation Sciences 
Centre for School of Health, Sport and Rehabilitation Sciences Research 
Frederick Road Campus 
University of Salford 
Salford 
M6 6PU 
Tel: 0161 295 3514 
Email: F.Hashmi@salford.ac.uk 
 
Dr Kim Thomas, Associate Professor in Dermatology Clinical Trial 
Centre of Evidence Based Dermatology 
King’s Meadow Campus  
University of Nottingham, NG7 2NR  
Tel 0115 8468 632 
Email Kim.Thomas@nottingham.ac.uk 
© Queen’s Printer and Controller of HMSO 2011. This work was produced by Cockayne et al. under the terms of a commissioning contract issued by 
the Secretary of State for Health.
143 Health Technology Assessment 2011; Vol. 15: No. 32DOI: 10.3310/hta15320
 6 
 
Dr Nichola McLarnon, Podiatrist 
Lecturer in Podiatry 
Glasgow Caledonian University 
School of Health and Social Care 
70 Cowcaddens Road,  
Glasgow G4 0BA 
Tel 0141 331 3227 
Email n.mclarnon@gcal.ac.uk 
 
Ms Veronica Morton, Trial Statistician 
York Trials Unit, University of York, 
Seebohm Rowntree Building (Area 4) 
York YO10 5DD  
Tel: 01904 321365 
Email veronica.dale@york.ac.uk 
 
Mr Ben Cross, Data Manager 
York Trials Unit, University of York, 
Seebohm Rowntree Building (Area 4) 
York YO10 5DD  
Tel: 01904 321364 
Email ben.cross@york.ac.uk 
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1.  BACKGROUND 
 
Verrucae or plantar warts are a common, infectious and sometimes painful problem.  Using 
incidence figures from the 4th National Morbidity Survey (1991-92)i an unpublished 
economic decision model assessing the effectiveness and cost-effectiveness of salicylic acid 
and cryotherapy has estimated that almost 2 million people see their GP per year about 
cutaneous warts at a cost of at least £40 million per annum.  Although most verrucae will 
spontaneously disappear without treatment many patients seek treatment to remove a verruca 
due to it being painful or because they are being prevented from doing sports. 
 
A recent systematic review conducted by the Cochrane Skin Group assessed the effects of 
different local treatments of cutaneous, non-genital warts in healthy peopleii.  This review 
highlighted the uncertainty with respect to the optimal treatment of verrucae.  There was 
however, some evidence from six trials to suggest that treatment with salicylic acid was more 
effective than placebo/no treatment, odds ratio 3.91 (95% confidence interval 2.40 to 6.36).  
Freezing warts using cryotherapy is widespread (an unpublished survey of GP practices in 
Nottingham found that 71% offered cryotherapy for the treatment of warts in 2002 – Thomas, 
personal communication).  Many patients experience unpleasant side effects such as pain and 
blistering during cryotherapy treatment, yet the same review found no evidence to suggest 
that it is more effective than treatment with topical agents such as salicylic acid.  Only two 
trials were identified which compared salicylic acid and/or lactic acid with cryotherapy, but 
there was no difference in the efficacy between the treatments (OR 1.15, 95% CI 0.72 to 
1.82). However, both trials were reported as low quality, due to unclear allocation 
concealment, inadequate blinding procedures, small sample sizes and inappropriate follow-up 
and analysis.   
 
Since verrucae are seen as a ‘minor’ condition few trials have been funded in this area.  In 
addition to this of the 52 trials included in the systematic review only 3 were classed as high 
quality and 75% were classified as low quality.  There is a need therefore, for a high quality 
randomised controlled trial with a cost effectiveness analysis to ascertain which is the best 
approach for the treatment of plantar warts. 
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2. RESEARCH OBJECTIVES  
 
  Primary objective  
 
To compare the clinical effectiveness of cryotherapy versus salicylic acid for the treatment of 
plantar warts in terms of the complete clearance of all verrucae as observed on digital 
photographs taken at baseline and 12 weeks and assessed by an independent health care 
professional (eg podiatrist, GP, Practice nurse).   Blinded health care professional assessment 
will be used if for some reason the digital photograph is not interpretable.  ‘Clearance’ of 
verrucae will be defined as being the restoration of normal skin upon close inspection, as 
assessed by the health care professional.   
 
2.2    Secondary objectives  
 
To compare the cost effectiveness of cryotherapy versus salicylic acid for the treatment of 
plantar warts in terms of the complete clearance of all verrucae.  To assess the acceptability 
of the two approaches and to investigate 
- Self-reported time to clearance of verrucae 
- Recurrence/clearance of verrucae at six months 
 
In addition to this, side effects of treatment, pain intensity after treatment, use of painkillers, 
restrictions to lifestyle due to having the verruca, treatment details will be recorded.  Patient 
satisfaction with the treatment and the number of verrucae will also be recorded. 
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3.   DESIGN 
 
The proposed study is a pragmatic, multicentre, randomised controlled trial (RCT) with equal 
randomisation. Patients with a verruca will be allocated equally between the two treatment 
groups, namely:  50% salicylic acid paste and cryotherapy using liquid nitrogen.   
 
4. ELIGIBILITY 
 
4.1 Inclusion Criteria  
Patients will be eligible if all of the following criteria apply: 
• The patient has a verruca that in the opinion of the health care professional is suitable 
for treatment with both salicylic acid and cryotherapy. 
• Are aged 12 years and over  
 
4.2 Exclusion Criteria 
Patients will be excluded if any of the following criteria apply: 
• Are currently in a trial evaluating other treatments for their verruca 
• Have impaired healing eg due to diabetes, peripheral vascular disease or any other 
condition which means the patient has impaired healing 
• Patients that are immunosuppressed eg have agammaglobulinaemia, or are currently 
taking immunosuppressant drugs such as oral corticosteroids 
• Are unable to give informed consent 
• Are currently on renal dialysis  
• Have cold intolerance eg Raynaud's syndrome or cold urticaria  
• Have any of the following conditions - blood dyscrasias of unknown origin, 
cryoglobulinaemia, cryofibrinogenaemia, collagen and auto-immune disease 
• Patients with neuropathy 
 
5 TREATMENT DETAILS 
 
Participants will be randomised equally between the two arms: daily self-treatment by the 
patient with 50% salicylic acid; cryotherapy using liquid nitrogen delivered by the health care 
professional (for example podiatrist, practice nurse, General Practitioner).   If a patient 
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presents with more than one verruca, then the Health Care Professional should treat the 
verrucae as they would in normal practice.   
 
A ‘no treatment’ arm will not be included in this study.  There are a number of reasons for 
this.  Firstly, the systematic review showed that salicylic acid is more effective than ‘no 
treatment’, whilst failing to find any evidence for the effectiveness of cryotherapy.  
Therefore, the important clinical question is whether the use of cryotherapy is superior to that 
of the standard effective treatment.  Secondly, a ‘no treatment’ arm may lead to bias due to 
resentful demoralisation, particularly in those patients where the verrucae are painful, 
longstanding and resistant to previous treatment.   
 
 
5.1 Daily self-treatment by the patient with 50% salicylic acid paste  - Verrugon 
• At the first appointment the health care professional will instruct the patient and/or their 
parent or guardian if appropriate, on its use.  Thereafter, it will be applied once daily for 
a maximum of 8 weeks as per the manufacturer’s instructions as follows: 
• The self-adhesive ring should be fixed with the hole over the verruca. 
• Squeeze a little Verrugon ointment into the hole and directly onto the verruca.  
• Remove backing paper from plaster.   
• Cover ring completely with plaster.  Seal into position.  
• Repeat treatment daily after gently pumicing or filing off the dead part of the verruca  
 
Patients will be asked to return all the Verrugon tubes they have received during the duration 
of the trial to the health care professional at their 12 week appointment.  The health care 
professional will then weigh the tube to determine how much Verrugon has been used over 
the 8 week period.  
 
Only those patients enrolled in this study may receive the Verrugon.  The 50% salicylic acid 
will be provided by the sponsor and will be dispatched to the treatment centre to be dispensed 
to participants by either a podiatrist, doctor nurse prescriber, pharmacist, other qualified 
health care practitioner or under a patient group directive.  Drug accountability is a 
responsibility of study site personnel and overall drug accountability records will be kept to 
provide information on stock, dispensing and drug returns.     
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The salicylic acid should be labelled as per the labelling requirements for investigational 
medicinal products used in clinical trials which come under requirements of Directive 
2001/20/EC and the Medicines for Human Use (Clinical Trials) Regulations 2004 which 
implement the Directive and came into force on the 1 May 2004.  A sample of the labelling is 
given here: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Verrugon should be stored in a secure area, out of direct sunlight and below 25 degrees 
centigrade.    All unused study drug, including undispensed supplies and supplies returned by 
the patient will be retained until the end of the study.  
 
5.2  Treatment with cryotherapy using liquid nitrogen delivered by the health care 
professional 
 
 
Although not necessary for the trial, sometimes it is the normal practice to debride prior to 
treatment with liquid nitrogen.  If this is the case then the callus surrounding the verrucae will 
be debrided according to normal practice (eg with a scalpel, file, or not debrided at all) with 
any haemorrhages stopped by digital pressure only.  The tissue surrounding the verruca will 
be prepared according to normal practice (eg unmasked, or masked with, for example 
vaseline). Liquid nitrogen will then be applied according to normal practice (eg spray, probe 
or cotton bud).  If there is a choice in the method of application, then a spray should be used.  
The health care professional should freeze the tissue until they are satisfied that the tissue has 
Verrugon ointment 50% salicylic acid.   
Trial EUDRAct number 2004-000905-24 
Investigator: Name of investigator 
Directions for use: as directed by the instructions give by the manufacturers. 
 
Patient Name  
 
Patient ID 
 
Batch Number                   Expiry date                 Date of dispensing 
 
Name and address of podiatry school/podiatry clinic supplier 
 
Keep out of reach of children    For clinical trials use only 
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been frozen adequately (this will  be about 10 seconds if using a spray).   75% silver nitrate 
should NOT to be applied to site.  If the health care professional believes the area 
surrounding the verruca should be padded after treatment, this will be done according to 
normal practice eg padded with 7mm felt cavitied padding.   The patient will be advised to 
keep the area dry for 24 hours and that the area maybe uncomfortable as the treatment 
removes infected skin by causing a blister.  If the area is very painful the patient will be 
recommended to use the type of painkiller they would use for a headache, and as per 
instruction on the packet.  The health care professional will then re book for the next 
treatment 14 or 21 days later.  On the patient’s return the sequence should be repeated up to a 
maximum of four treatments.  
 
The recruiting site will use the equipment and liquid nitrogen used in normal practice to 
deliver cryotherapy treatment or will under prior agreement with the York trials unit be 
provided with the equipment.  Storage of liquid nitrogen should comply with the current 
health and safety guidelines.   
 
It is anticipated that some patients will request cryotherapy to be stopped.  If the health care 
professional is not satisfied sufficient freezing has taken place then Verrugon will be offered 
as the second line treatment.  Treatment details for both groups will be collected via 
questionnaire from the health care professional carrying out the treatment along with an 
assessment of how painful the treatment was (on a scale of 0 to 10) at the first visit.  All 
participants will be given a follow-up appointment at 12 weeks to assess whether the 
treatment had been successful or not.   
 
If required, patients in both groups will be able to book a ‘fast-track’ appointment to see their 
health care professional if they are concerned about adverse reactions to the treatment. If the 
patient has a problem with their verruca treatment outside of normal working hours, they will 
be advised to see their out of hours GP service. 
 
In order to standardise the study prior to commencement the health care professional will 
receive a Podiatry handbook that will include the following documentation: 
 
• Brief background and aims of the trial 
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• Inclusion/exclusion criteria 
• How to randomise using the York Trials Unit randomisation service which 
will provide a patient ID number and treatment group 
• Protocols for both treatments 
• Documentation/forms used in the trial eg randomisation forms, questionnaires, 
adverse event reporting, ineligible patient forms 
• Discuss possible ‘Frequently asked questions’ participants may ask about the 
trial 
• Give contact details of the researchers at York University 
 
We will also run a one-day training course. 
 
6 RECRUITMENT AND RANDOMISATION 
 
6.1 Recruitment 
 
Potential participants for this trial will be identified by the health care professional from either 
GP referrals or self-referrals received by the Podiatry Schools, podiatry clinics or practice 
clinic for the treatment of verrucae.  In order to facilitate recruitment, after consultation with 
the local clinics to ensure unmanageable caseloads do not arise, the following strategies may be 
adopted to increase the number of patients presenting to the clinics: 
 
• Approach GPs in the area requesting them to directly refer patients presenting 
with a verruca to the podiatry clinic for treatment.  
• We will directly advertise for participants eg within GP surgeries and local 
swimming pools.   We will also advertise for participants at local libraries; in 
local newspapers; University press releases; local radio and tv stations; in the 
following local NHS departments: dermatology clinics, outpatient 
departments, A and E and podiatry departments; staff canteens, walk-in 
centres; at local occupational health departments in large employers near 
recruiting sites; in large stores such as supermarkets near recruiting sites; at 
professional development update days run by the podiatry schools and at local 
private podiatry clinics. 
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• Approach secondary schools within the area asking them to send information 
about the trial to all students.  We will also approach local scout, guide, 
adventure scout, sea and army cadets air training corps and boy’s/girl’s 
brigades asking them to give out information about the trial to all members of 
their group.  
• We will approach the University of Bradford and ask if they will post 
information about the study on their website and noticeboards due to its close 
proximity to the University of Huddersfield recruiting site.   
• We will advertise for participants on local community websites, eg those run 
by the local Borough and County Councils, local PCT websites and on the 
EverT trial website.  
 
These patients will be sent an appointment to attend for assessment/treatment along with a 
recruitment pack and will be given a minimum of 24 hours to consider participation in the 
trial.  The recruitment pack will contain: 
 
• An invitation letter, including contact details for the local health care 
professional and trial co-ordinator so that potential participants can contact 
them to discuss any queries they may have regarding the trial.  
• An appropriate patient information leaflet(s), an 'adult' information sheet will 
be sent to participants aged 16 and over.  Participants under the age of 16 will 
receive two information sheets, one designed for children under the age of 16, 
the second for their parent/guardian. 
• Baseline questionnaire   
• Consent form  
 
6.2 Randomisation  
 
Those patients that return the baseline questionnaire and indicate that they are willing to take 
part will be assessed for inclusion in the study by the health care professional when they 
attend for their appointment.  The health care professional will obtain written consent from 
all patients/and their parent if required, who are willing to participate prior to the patient 
being randomised.  The York Trials Unit will notify the patient’s GP of their involvement in 
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the study.    After consent and before randomisation the health care professional will collect a 
digital photograph of the verruca. 
 
The health care professional will randomise the patient by either phoning the York Trials 
Unit remote telephone randomisation service (free phone number) or using the web-based 
programme.  Patients will be allocated to either of the two treatment arms in a 1:1 ratio.   
Participants will then receive the allocated treatment at that appointment.  If at the end of the 
study the verruca is still present and the participants requires further treatment, the health care 
professional will consult with the patient as to the best course of action. 
 
Patients who do not wish to take part in the trial or those who wish to opt out will revert to 
usual care.  The health care professional will discuss alternative methods of treatment used 
within the department with the patient and once a course of treatment has been agreed on, the 
health care professional will treat and organise further appointments as required.  
 
6.3 Non recruitment 
The Health care professional will be asked to complete an “Ineligible Patient Form” for those 
patients who wished to take part in the trial but were ineligible to do so.  These forms will be 
returned to the York Trials Unit.  Information collected will be all reasons patients not 
eligible, DOB, gender, type of wart and date of consideration for trial entry. 
 
7. OUTCOMES 
7.1 Primary outcome 
The primary outcome will be complete clearance of all verrucae as observed on digital 
photographs taken at baseline and 12 weeks and assessed by an independent health care 
professional.  Blind health care professional assessment will also be assessed and will be used 
if for some reason the digital photograph is not interpretable.  ‘Clearance’ of verrucae will be 
defined as being the restoration of normal skin upon close inspection, as assessed by the 
health care professional. 
 
Participants who attend their 12-week outcome assessment will be sent £20 to cover any 
expenses incurred when attending this appointment. 
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Participants who do not attend their 12-week outcome assessment appointment will be 
written to, to determine whether they have a digital camera and if they would be willing to 
take a photograph of their foot.  Those participants who agree to take a photograph will be 
asked to complete a colour card, which has the participant’s ID number on it and the date the 
photo was taken.  The photo will then be sent by email to the York Trials Unit’s EverT email 
account. 
 
Participants may be sent the following reminders 
• To attend their final follow up appointment at 12 weeks approximately one week 
before hand  
• To complete follow-up questionnaires, two weeks after the initial questionnaire sent 
• At week 7, to stop treatment at week 8 for those assigned to the salicylic acid group  
• Weekly to return their tear-off slip when their verruca has gone.  
 
The format of this reminder will either by post, email or text as per the participant’s 
preference.  
 
7.2 Secondary outcomes 
 
• Self-reported clearance of verrucae at six months will be assessed by either patient 
postal or web-based questionnaire according to the participant’s preference. 
 
• Self-reported time to clearance of verrucae will be assessed by either patient postal or 
web-based questionnaire according to the participant’s preference. 
 
In addition to this side effects of treatment, pain intensity after treatment, use of painkillers, 
restrictions to lifestyle due to having the verruca and treatment details will be recorded and 
assessed by patient postal questionnaire, which will be sent at 1 and 3 weeks after 
randomisation.   The questionnaire will also include a section for the patient to complete and 
return to the York Trials Unit once the patient believes their verruca has been cured.    The 
format of this questionnaire will be either paper or web based according to the participant’s 
preference.    
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Patient satisfaction with the treatment will be recorded by either patient postal or web based 
questionnaire at 1, 3 and 12 weeks according to the participant’s preference. All participants 
will be sent an unconditional £5 with the 12 week questionnaire in recognition of their 
commitment to the study and to cover any expenses incurred in completing the 
questionnaires. 
 
The influence of prognostic variables on the primary outcome (clearance at 12 weeks) will be 
investigated. Such variables will include age, type of wart, gender and duration of current 
wart. The variables to be included will be finalised before any analyses are performed. 
 
Economic evaluation:  The Economic evaluation will be carried out from the perspective  of 
the UK health care provider, the National Health Service over a time horizon of 12 weeks and 
the patient.     
 
Resource data: Data will be collected on the volume of participant access to NHS staff and 
cost of treatments used during the trial.  The  number of visits each participant makes to the 
podiatrist or the health care professional for wart treatment, will be assessed using a 
participant-completed questionnaires sent at 12 weeks.  The use of over the counter verrucae 
treatments, will be assessed by patient postal questionnaire at 12 weeks. 
 
Health outcomes:  We will assess the number of verruca free days for each participant using 
patient self-reported time to clearance of verrucae.   
 
Cost effectiveness analysis:  We will carry out a cost effectiveness analysis as detailed in 
section 10.4 
  
Data on adverse events will be assessed by the number of visits the participants makes to a 
doctor or health care professional, and notification of adverse events by the health care 
professional treating the patient or self-report by the participant 
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8 ETHICAL ARRANGEMENTS 
 
We are aware that children are considered a vulnerable group.   However, we do not 
anticipate any major ethical issues with the proposed study since both treatments under 
investigation are currently used within normal practice to treat children with verrucae and 
Verrugon is licensed as an over the counter treatment. 
 
8.1 Adverse events/adverse reactions  
 
The health care professional will routinely record any serious and non-serious adverse 
events/reactions, which occur during the course of the trial on a serious or non-serious 
adverse event/reaction form.  An assessment of the seriousness, causality and expectedness of 
the event/reaction will be undertaken.  Participants should be asked at each trial visit about 
hospitalisations, consultations with other medical practitioners, disability or incapacity or 
whether other relevant adverse events have occurred.  The adverse event/adverse reaction 
reporting period for this trial begins when the patient is randomised into the study and ends 6  
months after the date of randomisation.  All adverse events and reactions should be followed 
up until they are resolved or the patient’s participation in the trial ends.  In addition serious 
adverse reactions assessed by the investigator as possibly related to the investigational 
product should continue to be followed even after the patient’s participation in the trial is 
over.  Such reactions should be followed until they resolve or until the investigator assesses 
them as ‘chronic’ or ‘stable’.  Appropriate on-going care will be arranged through the 
appropriate services.    Resolution of such events is to be documented on the serious adverse 
event/reaction form.  
 
Fatal or life-threatening Suspected Unexpected Serious Adverse Reactions (SUSARs) will be 
recorded and reported to the MHRA, Ethics Committee and Data Monitoring Committee 
within 7 days of knowledge of such cases. In each case relevant follow-up information should 
be sought and a report completed as soon as possible. This should be sent to the CA and the 
Ethics Committee within an additional eight days.  All other suspected unexpected serious 
adverse reactions will be reported to the DMEC, MHRA, and trial sponsor and ethics 
committee within 15 days of first knowledge.  
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Once a year a list of all suspected serious adverse reactions, which have occurred over the 
period, and a report of the subject’ safety will be provided to the MHRA.    
 
The known side effects of treatment associated with treatment with salicylic acid and 
cryotherapy are: pain, blistering, irritation to the skin, burning sensation, bleeding, scarring, 
infection and in some cases allergic contact rash may occur in some people. 
 
8.2 Informing trial participants of possible benefits and risks of intervention 
 
All trial participants will be provided with a patient information sheet prior to their giving 
informed consent.  The information sheet will outline fully the potential benefits and risks of 
being involved in the trial.  The health care professional will inform the participant if new 
information comes to light that may affect the participant’s willingness to participate in the 
trial.  
 
8.3 Informed consent 
Participation in the study will be entirely voluntary and written consent will be sought.  All 
data will be treated with the strictest confidence.   
 
For those participants under the age of 16, the parent/guardian will be asked to give written 
consent along with assent of the child. The researcher will at all times consider the explicit 
wish of the minor if they are capable of forming an opinion and assessing the information 
provided.    This will apply not only to the wish of a minor to refuse to take part, but also to 
withdraw from the trial at any time.  Where the parent is competent to decide for their child 
but unable to read or write, an impartial witness will sign the consent form to say that the 
information sheet has been read to the parent and verbal consent has been given.  
 
If a clinician feels that the potential participant is unable to give informed consent, then they 
would not be eligible to take part in the study.  
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8.4 Proposed time period for retention of trial documents 
Paper copies of the relevant trial documentation from the study will be held in a locked room 
for a period of 9 years at the University of York (i.e, until the youngest participant is aged 21 
years), whilst electronic copies will be held indefinitely.   
 
9 STATISTICAL CONSIDERATONS  
 
9.1 SAMPLE SIZE 
 
The Cochrane systematic review found only one small trial directly comparing the 
effectiveness of a chemical treatment, salicylic acid, with cryotherapy in patients with warts 
on their feet alone.  This poor quality study found a 58% cure rate among the patients 
allocated to cryotherapy compared with 41% among those treated with salicylic acid.  This 
difference of 17% was not statistically significant.  The overall cure rates from this study are 
smaller than those observed in two placebo controlled trials of salicylic acid, both of which 
reported cure rates of 85% for active treatment, possibly because more resistant verrucae 
were included in the study comparing cryotherapy with salicylic acid.   
 
In this study we have decided to power the trial to show a 15% difference in effectiveness.  
We therefore, will recruit sufficient patients to give us 80% power (5% two sided 
significance) to show a difference in cure rates of 70% versus 85% at 12 weeks after 
treatment.  This will require 120 patients in each group after allowing for a 10% drop-out rate 
we will require 133 in each treatment group (i.e. 266 in total).  This sample size will also 
enable us to show that cryotherapy increases the cure rate from 85% to 97% (i.e. a 12% 
increased cure) for a similar power and significance level.  
 
9.2 Recruitment 
It is expected that five centres will recruit 3 patients per month, over a recruitment period of 
18 months, giving a total of 270 participants.  Northampton and Eastbourne Podiatry schools 
have already agreed to participate in the trial and we have approached Glasgow and 
Huddersfield Podiatry Schools.  We will recruit other podiatry clinics by: 
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• Contacting the Heads of the remaining Podiatry Schools  
• Networking using the Podiatry Research Forum  
• Advertising in “Podiatry Now” for new centres 
• Running workshops at the Podiatry Conference  
 
The following sites have agreed to recruit participants: Huddersfield Podiatry School, 
Brownlow Practice Liverpool, Glasgow Podiatry School/Southern General Hospital, 
Springfield Surgery Bradford, Islington PCT Dr Mittal Balham London Sheffield PCT, Dr 
Arthur at Claughton Medical Centre (Birkenhead, Wirral), Dr Ghori at Woodplumpton Road 
Surgery (Fulwood, Preston) and Dr Rajap at Arlington Road Surgery (Eastbourne).  
 
10 STATISTICAL ANALYSIS 
 
10.1 Primary analysis  
 
There will be a single principal analysis at the end of the study using 5% two sided 
significance tests. We will use ‘intention to treat’ analysis.  All patients will be included in 
their initially randomised groups whether or not they received their allocated treatment. The 
primary outcome is complete clearance of all verrucae at 12 weeks. The two treatment groups 
will be compared using simple proportions of cure or not cured using the Chi squared test.  
The analysis will be conducted blind to group.   
 
10.2   Secondary analysis 
 
As in the primary analysis, all secondary analysis will be by ‘intention to treat’.  For these 
secondary outcomes stricter statistical levels of significance will be adopted (i.e. p = 0.01) to 
reduce the chance of type I error.  All analysis will be conducted blind to group.   
 
Data on baseline demographics such as gender, age, type and duration of verrucae, previous 
treatments will be summarised and descriptive summary statistics provided. For variables 
with continuous measures we will report the mean and standard deviation, for categorical 
data we will report numbers and percent.    
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The primary analysis will be repeated, but controlling for age, whether or not the wart has 
been previously treated and type of wart. Should numbers be sufficient, in order to examine 
whether mosaic warts respond less well to treatment than simple warts, the primary analysis 
will be repeated, but the type of wart mosaic/simple will be included as a covariate and also 
an interaction term wart type*treatment will be included.iii  
 
Survival analysis of patient self-reported time to clearance of verrucae, censoring for loss to 
follow up, will be tested for using Cox regression adjusting for relevant co-variates to be 
defined before the analysis.    
 
As patients and practitioner are not blinded to treatment, we will carryout a second, sub group 
analysis, assessing the influence of participant’s treatment preference on treatment outcomes 
and the results of the cost effectiveness analysis.  
 
Data on side effects of and pain intensity during and after treatment, use of painkillers, 
restrictions to lifestyle due to having a verruca, treatment details, patient satisfaction with 
treatment, number of warts, will be summarised and descriptive summary statistics provided. 
For variables with continuous measures we will report the mean and standard deviation, for 
categorical data we will report numbers and percent.    
 
The number of patients discontinuing treatment prematurely for any reason will be 
summarised by treatment group and by reasons for discontinuation.   
 
The recurrence/clearance of verrucae at 6 months will be analysed in the same way as the 
primary outcome measure.  
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10.3 Missing data 
 
We will try and minimise any missing data with respect to the primary outcome of verrucae 
clearance within 12 weeks. However if we are unable to ascertain the status of any patients 
then they will be treated as not having a cleared verrucae in the primary analysis. Sensitivity 
analyses will be performed considering missing primary outcome data as positive or negative 
in the different treatment groups. Any missing baseline data will be imputed using 
appropriate methods before being used in any adjusted analyses. 
 
The incidence of all suspected adverse treatment reactions will be summarised by treatment 
group.  
 
10.4  Economic analysis 
We will undertake a cost effectiveness analysis of the treatments.  The costs of the two 
approaches will be collected as part of the study.   Costs will be collected by using a patient 
questionnaire and from clinic records of attendances. For instance we will record the number 
of attendances to the health care professional both groups have (excluding the final 
attendance as this a research review).  We will then calculate an incremental cost per cured 
patient at 12 weeks.   
 
The primary economic evaluation will be a cost effectiveness analysis of the trial treatments. 
The cost of resource use will be calculated for each trial participant using data collected (as 
described in section 7.2). Staff costs will be calculated using standard NHS costs (Netten A 
Dennett J, Knight J. Unit costs of Health and Social Care. Caterbury: PSSRU, University of 
Kent at Canterbury, 2005.  Topical treatments will be costed using the BNF (British National 
Formulary. Number 52 and manufacturer’s costs where required.  Patient outcome will be 
measured as verrucae-free days. 
 
 The incremental mean difference in costs between the two trial arms and incremental 
difference in patient outcome will be calculated. There are four potential scenarios:  
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1. Cryotherapy is less costly than salicylic acid treatment and leads to better patient 
outcomes  
2. Cryotherapy is more costly than salicylic acid and has worse outcomes 
3. Cryotherapy is more costly then salicylic acid but has better (worse) patient outcomes 
4. Cryotherapy is less costly than salicylic acid treatment and leads to worse patient 
outcomes 
 
If we are faced with situation 1 or 2 one treatment clearly dominates the other. That is there is 
a clear choice about the treatment that is cost-effective. However, if we are faced situation 3 
we must weigh up the potential cost implications versus patient benefit to make a decision 
regarding cost effectiveness. We will do this by relating the incremental mean costs between 
the two trial arms to the incremental mean outcome as a ratio, the incremental cost 
effectiveness ratio (ICER). The ICER represents the additional cost per additional verruca 
free day.  A treatment strategy can then be considered cost-effective if the decision maker’s 
willingness to pay for an additional verruca-free day is equal to, or greater, than the ICER 
Uncertainty regarding the cost effectiveness analysis will be assessed using cost effectiveness 
acceptability curves.  
 
10.5 Monitoring of  safety  
Data presented to the DMEC will be blind to group allocation at 6 monthly intervals once 
recruitment has started.  The number and type of adverse reaction/event will be reported and 
compared between the two groups. 
 
11.0   OTHER CONSIDERATIONS 
 
A Trial Steering Committee (TSC) will be set up to oversee the conduct of the trial.  This will 
include an independent chair and at least two other independent members, along with the lead 
investigator and the other study collaborators.  They will meet twice a year.   
 
An independent Data Monitoring and Ethics Committee (DMEC) will be set up and will 
comprise of an independent statistician and podiatrist.  The role of the DMEC is to 
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immediately see all serious adverse events thought to be treatment related and look at 
outcome data at six monthly intervals. 
 
12 PROJECT TIMETABLE 
1st September 2006:  Apply for ethics, research and development (R & D) and MHRA 
approval for all sites as required. 
Approach other podiatry schools to take part in the trial, apply for 
ethics and R & D as appropriate.  
 
October 2006 to Start patient recruitment at Northampton, Eastbourne and new              
   sites as soon as protocol approval/ethics/ R & D approval are received 
Sept 2009 Approach GP practices to refer patients to the podiatry schools and         
advertise for participants eg at GP surgeries, swimming pools and local   
secondary schools. 
 
March 2010   Final (6 month) follow up questionnaire sent to last participant.   
 
April 2010    Data cleaning, statistical analysis and writing up study findings. Final  
to June 2010    report.  
 
 
July 2010   Apply to ethics for approval of letter to be sent to trial participants 
informing them of the study’s results.  
 Send out results of study once approval has been received.  
 
13 STUDY ORGANISATIONAL STRUCTURE 
 
13.1    The York Trials Support Unit (TSU) and trial co-ordination 
 
The York Trials Support Unit will run the trial, monitor and verify the data and analyse the 
results.  A data coordinator, statistician, data-processing clerk and database programmer for 
the project will be based in the TSU.  
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14 PUBLICATION POLICY  
 
The main trial will form the basis of an academic paper in a peer-reviewed journal on its 
completion.  The trial team will also ensure that the results are published in a professional 
journal in order to ensure access by podiatrists and other health care professionals. The 
results of the study will be submitted for consideration at the Podiatry Conference.  
 
Dr Mike Curran and Dr Farina Hashmi are members of the Podiatric Research Forum and 
they will ensure that the results of the trial are disseminated amongst health care 
professionals.   
 
Participants will receive a summary of the study’s findings after obtaining ethical and R & D 
approval.  
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